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Summary 
 
Chronic hypoxia, in animals and man, results in remodelling of the pulmonary 
vasculature with consequent pulmonary hypertension.  The pulmonary artery 
fibroblast (PAF) has been shown to play an early and important role in hypoxia-
induced pulmonary vascular remodelling.  In acute and chronic hypoxia there is 
excess proliferation of PAFs.  Morevoer, it is likely that cell-cell interactions 
between hypoxia-stimulated PAFs and other vascular cells – particularly smooth 
muscle cells - initiates and progresses the changes that occur in pulmonary vascular 
remodelling in the other vessel compartments.  Although hypoxic proliferation of 
PAFs has been shown to be circulation specific and dependant on phosphorylation of 
p38 mitogen-activated protein (MAP) kinase, the cell signalling pathway(s) 
underlying this are incompletely characterised.  Hypoxic activation of PAFs is a 
potential therapeutic target but, as p38 MAP kinase inhibitors are not established for 
clinical use, work was proposed to better characterise this pathway and identify 
agent(s) which may inhibit p38 MAPK indirectly.   
 
The HMG-CoA reductase inhibitor simvastatin was recently shown to inhibit 
hypoxic pulmonary vascular remodelling in rats, but the applicability of this finding 
to clinical practice is incompletely established and the mechanism of action of the 
statin is unclear.  Statins have been shown to influence MAP kinase pathways in 
other cell types and, as their modes of action are well established, they can be used to 
interrogate uncharacterised upstream cell signalling pathways.  On this basis, the 
aims of this study were firstly to determine whether statins had a therapeutically 
useful inhibitory effect on hypoxia-induced, p38 MAP kinase-mediated PAF 
proliferation.    A second aim was to exploit the known effects of statins to better 
characterise hypoxic cell signalling upstream of p38 MAP kinase in PAFs.  Lastly, 
comparison of the effects of statins with established pulmonary hypertension 
therapeutics and a preliminary assessment – also using statins as an experimental tool 
- of cell-cell interactions between PAFs and pulmonary artery smooth muscle cells 
(PASMCs) was proposed. 
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1µM of fluvastatin was found to selectively inhibit acute and chronic hypoxia-
induced p38 MAP kinase phosphorylation and proliferation in rat PAFs.   At this 
dose, fluvastatin had no effect on serum-induced proliferation in PAFs, no effect on 
systemic adventitial fibroblast proliferation, and no effect on the phosphorylation 
status of other MAP kinases.  Selective use of mediators and inhibitors related to the 
HMG-CoA pathway indicated that a geranylgeranylated protein, probably Rac1, had 
an obligatory role upstream of p38 MAPK, in this signalling pathway.  Co-culture 
and conditioned media experiments with bovine PAFs and PASMCs demonstrated 
the release of PASMC mitogens from hypoxic PAFs.  1µM fluvastatin and the p38 
MAP kinase inhibitor SB203580 selectively blocked the hypoxic PAF-PASMC 
interaction.  Results with hypoxic PAF proliferation with the prostacyclin analogue 
treprostinil, the phosphodiesterase-5 inhibitor sildenafil and the endothelin-1 
antagonist bosentan were negative.  Bosentan, however, inhibited the hypoxic PAF-
PASMC interaction, suggesting endothelin-1 release by hypoxic PAFs, with pro-
proliferative effects on PASMCs.   
 
The results reported in this thesis provide new information on hypoxic signalling, 
PAF proliferation and PAF cell-cell interactions in hypoxic states.  A circulation and 
stimulus specific anti-proliferative effect of fluvastatin on PAFs was identified and 
this may be of clinical relevance in hypoxia-associated pulmonary hypertension. 
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Chapter 1 
 
 
Introduction  
 
 21
1.1 General Introduction 
Pulmonary hypertension is now recognised to be a common and important condition 
in humans.  The last 10 years has seen significant progress in our understanding of 
the pathophysiology and epidemiology of the different forms of pulmonary 
hypertension.  These advances have allowed an appropriate classification of the 
spectrum of disorders causing pulmonary hypertension, recognition and validation of 
specific treatments for selected forms of pulmonary hypertension, and a resultant 
improvement in the prognosis for patients, in parts of the world where these new 
drugs are available.  In addition, it is now appreciated that pulmonary hypertension is 
an important complication of common hypoxic lung diseases1.  If we can improve 
our understanding of the pathophysiology of pulmonary hypertension, in particular 
hypoxia-related pulmonary hypertension, and identify agents which can tackle this 
selectively, inexpensively and without major side effects, then we would have 
therapies which could potentially improve the quality of life and survival prospects 
of the millions of people worldwide suffering from this disorder2.   
 
Despite progress, our understanding of the pathophysiology of pulmonary 
hypertension is incomplete.  What we do know now is that, regardless of the 
aetiology, the pathology of the disease at the time symptoms develop is similar.  
Structural remodelling of the pulmonary vascular bed leads to an increase in 
pulmonary vascular resistance which causes respiratory and right heart failure.  Data 
from animal models indicates that an acceleration of pulmonary adventitial fibroblast 
(PAF) proliferation is a primary event in the development of pulmonary vascular 
remodelling and pulmonary hypertension, when hypoxia is the initial stimulus3.  
Although hypoxia is only one of the causes of pulmonary hypertension, it is a useful 
model, particularly when considering the behaviours of pulmonary adventitial 
fibroblasts.  Assessment of the cell signalling processes, proliferation and other 
behaviours of PAFs, in hypoxic conditions may provide important insights into the 
early events in the pathogenesis of hypoxic pulmonary hypertension, and potentially 
other forms of the disease.  Also, use of this established model system allows for the 
assessment of the potential new pulmonary vascular therapies.  
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Recently, statin drugs have been shown to significantly attenuate the development of 
pulmonary hypertension (PH) in rats exposed to chronic hypoxia4 and these findings 
have subsequently been replicated in other experimental pulmonary hypertension 
models5-10.  Using statin drugs to treat human pulmonary hypertension is an attractive 
prospect: there is considerable clinical experience in the use of these drugs for 
hyperlipidaemia and cardiovascular disease, they are relatively inexpensive and 
major side effects are rare11-17.  There are, however, large gaps in our knowledge in 
relation to the potential utility of statins for pulmonary hypertension, which need 
addressed before large clinical trials.  Notably, we do not know the mechanism(s) of 
the statin effect, we have no information to help us judge how to combine or 
compare statins with other established or proposed pulmonary hypertension 
therapies, and we do not know which statin, at which dose, to select for clinical 
studies.   
 
Though the specific mechanism(s) of action of statins in the animal models of 
pulmonary hypertension are incompletely explored, the effects of statins on cell 
signalling pathways, in general, are well known18.  It was considered possible that 
the effects of the statin may be mediated via an effect on pulmonary artery 
fibroblasts.   Also, it is notable that whilst hypoxic signalling in PAFs is 
incompletely understood, lipid raft structures and membrane GTPase systems – both 
of which are sensitive to statin inhibition – are signalling systems which might 
potentially be involved.  Based on these possibilities, it was concluded that if positive 
effects of statins on hypoxic PAFs were identified, it might present an opportunity to 
better characterise hypoxic signalling in this important cell type and add to the body 
of preclinical knowledge of statin therapy for pulmonary hypertension.  Accordingly 
a body of work on statins and hypoxic PAFs, to address three specific issues was 
proposed.  Firstly we sought to determine whether early signalling events in hypoxic 
PAFs were statin sensitive, and to exploit any positive findings, in relation to the 
known mechanism of action of statins, in order to better characterise the nature of 
these signalling events.  Secondly we wished to evaluate whether PAF inhibition was 
a potential mechanism(s) of action of statins in hypoxic pulmonary hypertension and 
use this as an approach to provide relevant insights for future potential clinical use of 
statins in human pulmonary hypertension.  Lastly, there is an increasing awareness 
that fibroblast-smooth muscle cell interactions are important in the pathogenesis of 
 23
hypoxic PH and we sought to extend our established PAF cell model and develop a 
PAF-pulmonary artery smooth muscle cell (PASMC) experimental model, and study 
the effects of statins on this. 
 
1.2 Pulmonary Hypertension: Definitions and Classification  
Pulmonary hypertension is, by definition, a condition of abnormally high pressure 
within the pulmonary circulation.  It can develop in many species, including humans, 
either as a de novo condition, as a complication of common heart, lung and systemic 
diseases, or as a complication of prolonged residence at high altitude.   
 
Haemodynamic definitions of pulmonary hypertension have some deficiencies, as 
information on normal and abnormal pulmonary haemodynamics at all situations of 
rest and exercise is limited: invasive measurement of pulmonary haemodynamics 
carries small but notable risks.  A definition consisting of a persistent elevation in 
mean pulmonary artery pressure >25mmHg at rest, or >30mmHg on exercise is, 
however, widely accepted, and the recent 4th World Symposium on Pulmonary 
Hypertension (see below) will hopefully provide further consensus on this.  
Pulmonary arterial hypertension (where the pathology originates in the pulmonary 
circulation, rather than being a consequence of high flow state or passive pressure 
elevation due to left atrial hypertension and venous backpressure) additionally 
requires the exclusion of elevated left heart pressures by identification of a normal 
left atrial pressure (<15mmHg; estimated either from pulmonary capillary wedge 
pressure or left ventricular end-diastolic pressure).  Also, demonstration of an 
elevated pulmonary vascular resistance is required (resistance = pressure/flow, where 
flow is the cardiac output), to exclude passive rise in pulmonary artery pressure 
simply due to a high flow state19. 
 
Dramatic rises in the incidence of pulmonary arterial hypertension (PAH) were noted 
in relation to the introduction of the appetite suppressant drugs aminorex20 and 
dexfenfluramine/fenfluramine21, 22.  In response to these, the World Health 
Organisation (WHO) convened international symposia first in 1973 (following the 
aminorex outbreak) and 1998 (following the dexfenfluramine outbreak).  These 
summarised the state of knowledge in relation to pulmonary hypertension, 
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standardised disease classification and considered future research priorities23.  In the 
face of considerable scientific and clinical developments further WHO supported 
world symposia were convened in 2003 (Venice) and 2008 (Dana Point, California; 
symposia summary not yet published).  The 2003 meeting in Venice provided a state 
of the art overview of the current knowledge of disease pathology24, pathogenesis25, 
genetics26, treatment27 and consensus statements on clinical assessment of patients 
with suspected PH28 and clinical trial design29.  Also, the conference revised the 
clinical classification of pulmonary hypertension which had originally been made at 
the Evian symposium in 199830.  The current comprehensive clinical classification, 
shown in Table 1.1, is useful both as a clinical standard and as a summary of the 
principle aetiological factors from which pulmonary hypertension may arise.   
 
1.3 Pulmonary Hypertension: Epidemiology 
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary 
hypertension (CTEPH) are the forms of pulmonary hypertension for which disease 
specific medical or surgical treatment (rather than general supportive measures) are 
now validated31, and it is for these that the most robust epidemiological data, in the 
developed world, is available.  PAH and CTEPH are rare disorders, though probably 
not as rare as previously thought.  Epidemiological studies in this area are 
challenging as these are difficult diseases to recognise and classify and non-expert 
care can lead to both under and overdiagnosis.  With these reservations, recent 
reports suggest that pulmonary arterial hypertension has a prevalence between 26 and 
52 / million32.  This may still be an underestimate as it is likely that PAH is under-
recognised in patients with HIV infection, portal hypertension and other associated 
conditions.  Considering CTEPH, it has recently been reported that significant 
pulmonary hypertension may develop in as many as 4% of patients following an 
acute, symptomatic pulmonary thromboembolism33.  Symptomatic pulmonary 
thromboembolism is common and, additionally, a substantial number of patients 
develop CTEPH in the absence of antecedent acute thromboembolism34.  
Accordingly, CTEPH may be a relatively common condition.  Even taking our 
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1. Pulmonary arterial hypertension (PAH) 
 1.1 Idiopathic (IPAH) 
 1.2 Familial (FPAH) 
 1.3 Associated with (APAH) 
  1.3.1 Collagen vascular disease 
  1.3.2 Congenital systemic-to-pulmonary shunts 
  1.3.3 Portal hypertension 
  1.3.4 HIV infection 
  1.3.5 Drugs and toxins 
  1.3.6 Other (thyroid disorders, glycogen storage disease, Gaucher  
   disease, hereditary haemorrhagic telangiectasia,  
   haemoglobinopathies, myeloproliferative disorders, splenectomy) 
 1.4 Associated with significant venous or capillary involvement 
  1.4.1 Pulmonary veno-occlusive disease (PVOD) 
  1.4.2 Pulmonary capillary haemangiomatosis (PCH) 
 
2. Pulmonary hypertension with left heart disease 
 2.1 Left-sided atrial or ventricular heart disease 
 2.2 Left-sided valvular heart disease 
 
3. Pulmonary hypertension associated with lung diseases and/or hypoxaemia 
 3.1 Chronic obstructive pulmonary disease 
 3.2 Interstitial lung disease 
 3.3 Sleep-disordered breathing 
 3.4 Alveolar hypoventilation disorders 
 3.5 Chronic exposure to high altitude 
 3.6 Developmental abnormalities 
 
4. Pulmonary hypertension due to chronic thrombotic and/or embolic disease 
 4.1 Thromboembolic obstruction of proximal pulmonary arteries 
 4.2 Thromboembolic obstruction of distal pulmonary arteries 
 4.3 Non-thrombotic pulmonary embolism (tumor, parasites, foreign material) 
 
5. Miscellaneous 
 Sarcoidosis, histiocytosis X, lymphangioleiomyomatosis, compression of  
 pulmonary vessels (adenopathy, tumour, fibrosing mediastinitis) 
 
 
 
Table 1.1 Revised Clinical Classification of Pulmonary Hypertension30 
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current understanding of prevalence, the number of patients suffering from PAH and 
CTEPH justifies continued research and development in this field. 
 
The true public health burden of pulmonary hypertension is likely to be much 
greater1.  In particular, the number of patients with pulmonary hypertension related 
to respiratory disease and/or hypoxaemia is likely to be substantial.  Three points 
seem relevant when considering this.  Firstly, the number of individuals worldwide 
who live chronically at high altitude is substantial, and severe pulmonary 
hypertension develops in a significant proportion of these35.  Secondly, the 
prevalence of the commonest respiratory disorder associated with pulmonary 
hypertension - chronic obstructive pulmonary disease (COPD) - has increased 
significantly in recent years, and is projected to continue to do so36.  It is likely that 
the number of patients with pulmonary hypertension related to this will increase 
similarly.  The number of patients with COPD who develop complicating severe PH 
is uncertain, but one recent study found that, in patients with severe COPD, PH 
develops in 50% of patients, with severe resting PH in 7% of patients37.  Even if only 
the patients with severe COPD and severe resting PH experience morbidity or 
mortality related to their pulmonary hypertension, given how common COPD is, this 
still represents a substantial burden of PH in the worldwide community.  Thirdly, 
although most patients with PH related to underlying lung disease have only mild-
moderate resting PH38, this may be a significant underestimate of the impact of PH 
on their health and on their symptoms.  Pulmonary hypertension in these patients - 
measured as mild-moderate at rest -  may worsen significantly with exercise, sleep 
and during exacerbations and therefore if we consider only their resting 
haemodynamics (whether they are invasive or non-invasive) we may be significantly 
underestimating the contribution of the pulmonary vascular component of these 
patient’s conditions to the overall morbidity and mortality39. 
 
Taking all of this together it seems clear that severe pulmonary hypertension - 
including pulmonary hypertension related to lung disease and/or hypoxaemia - is an 
important human disease, worthy of further research.   
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1.4 The Normal and Diseased Pulmonary Artery 
1.4.1 Structure of Normal Pulmonary Arteries40, 41 
The normal pulmonary circulation is a high-flow, low pressure system and, by design 
or by consequence, the pulmonary arteries are thin-walled and compliant.  There is 
also, in health, a substantial reservoir vascular bed which is relatively unperfused, at 
rest.  These properties give the pulmonary circulation the capacity to passively cope 
with large changes in volume (when cardiac output rises), without the requirement 
for high filling pressures (which the normal right ventricle cannot generate).   
 
A normal artery consists of circumferential layers.  From the lumen outwards these 
are the intima (comprising endothelial cells and their basement membrane), the 
internal elastic lamina (a thin layer of elastin fibres), the media (consisting of smooth 
muscle cells and their associated extracellular matrix, an external elastic lamina and 
the adventitia (containing fibroblasts, extracellular matrix and connective tissue).  In 
the proximal elastic arteries the medial smooth muscle layer is thinner, may partly be 
arranged longitudinally and the adventitia contains small blood vessels (vaso 
vasorum) from the systemic (bronchial) circulation.  Progressing distally, the 
muscular (resistance) arteries have a relatively thicker media, with the smooth 
muscle cells arranged spirally.  Further out, the smaller arteries have an incomplete 
media, and lose their elastic laminae.  At the most distal arteries and arterioles there 
is no laminae or smooth muscle cell layer: media consists solely of undifferentiated 
pericyte cells. 
 
1.4.2 Pathology of Pulmonary Hypertension 
The primary pathological processes which can cause pulmonary arterial hypertension 
are vasoconstriction, constrictive pulmonary vascular remodelling (consisting of 
thickening / hypertrophy of the vessel wall layers), distortion or loss of the 
pulmonary vascular bed and pulmonary vascular thrombosis24.  Additionally, in 
idiopathic pulmonary arterial hypertension (and rarely in other forms of PH) complex 
pathological lesions, in particular so-called plexiform lesions, develop in the pre-
acinar and intra-acinar pulmonary arteries.  Plexiform lesions consist of endothelial 
channels lined by myofibroblasts, extending out from destroyed arterial walls, often 
associated with intravascular thrombus.  It is hypothesised that these lesions may 
 28
relate to a monoclonal proliferation of an abnormal endothelial cell clone, and that 
this may be the primary / initiating pathological defect in idiopathic PAH 42, 43. 
 
The relative contribution and the exact pathological features of each of these 
processes vary in the different forms of pulmonary hypertension.  For example, 
certain individuals with IPAH have long term symptomatic responses to calcium 
channel blocker therapy44, and it is assumed that vasoconstriction plays a dominant 
role in these patients.  In contrast, extensive arterial thrombosis, in proximal and 
distal vessels is typical in CTEPH, whilst it is an inconsistent feature, typically 
present only in the small arterioles, in PAH45.  In most instances, however, it is now 
considered that the pathological process responsible for the clinical manifestations in 
severe PAH is pulmonary vascular remodelling.    In severe pulmonary hypertension, 
remodelling of the pulmonary arteries causes luminal restriction and loss of vessel 
compliance, leading to a rise in pulmonary vascular resistance, an increase in right 
ventricular afterload and, consequently, respiratory and right heart failure. 
 
1.4.3 Pulmonary Vascular Remodelling 
Pulmonary vascular remodelling is a complex and incompletely understood process.  
There is some heterogeneity in the features, when the different forms of severe 
pulmonary hypertension in humans are compared, and also in the different forms of 
experimental pulmonary hypertension.  However, it appears to be the common 
endpoint to the diverse genetic errors or injurious stimuli which the pulmonary 
circulation is susceptible.  Medial hypertrophy / increased muscularisation of 
muscular arteries and distal extension of smooth muscle into normally non-muscular 
arterioles are often considered to be the morphological changes responsible for most 
of the haemodynamic upset in severe PH.  All vessel wall compartments are however 
involved and intimal thickening, neointima formation, thickening and distal 
extension of elastic laminae and adventitial thickening (+/- complex lesions) are also 
hallmarks46.  A schematic representation of some of the pathological features of 
pulmonary hypertension is shown in figure 1.1.   
 
As discussed in Chapter 1.2, chronic hypoxia is one of the main causes of pulmonary 
vascular remodelling and severe pulmonary hypertension in humans.  The nature of 
the pulmonary vascular remodelling in hypoxic pulmonary hypertension has been  
 29
 
 
Figure 1.1: Schematic Representation of Key Aspects of Pulmonary Vascular Remodelling
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described in humans, with some differences in the remodelling - notably longitudinal 
intimal neomusclarisation of small pulmonary arteries – compared with other forms 
of severe PH47.  Remodelling in hypoxic animal models has been extensively studied 
and summarised48.  In animal models it is notable that the earliest changes are seen in 
the adventitia, where the resident adventitial fibroblast is seen to proliferate before 
other cell types49.   
 
The view that luminal narrowing and vessel loss consequent on pulmonary vascular 
remodelling are the key pathological features of pulmonary hypertension in chronic 
hypoxia has recently been challenged.  Emerging experimental data indicates that 
rather than a reduction in the vascular bed, there may actually be angiogenesis and an 
expansion of the pulmonary circulation50.  The subsequent identification by this 
group of acute reversal of chronic hypoxic pulmonary hypertension with a Rho 
kinase inhibitor, led to the conclusion that sustained and relatively intractable 
pulmonary vasoconstriction, arising on a background of structurally altered 
pulmonary vessels, may be much more important than remodelling in causing the 
haemodynamic upset in chronic hypoxic pulmonary hypertension51.  With the 
multiple failures of vasodilator therapies in clinical practice (other than calcium 
channel blockers for a small subset of patients with idiopathic PAH) it had been 
concluded that reversible vasoconstriction was an unimportant aspect of established 
severe PH52.  It is intriguing to speculate that vasoconstriction, potentially reversible 
by novel vasodilators acting via new mechanisms, may be relevant in hypoxia-
associated PH in humans, or other forms of severe PH53.    
 
Regardless of whether the nature of the vessel remodelling is luminal narrowing 
consequent on inward remodelling, reduction of the pulmonary vascular bed 
consequent on proximal remodelling or sustained vasoconstriction arising in 
structurally abnormal vessels, pulmonary vascular remodelling seems to be the 
primary pathological process which leads to severe pulmonary hypertension.   This 
makes it an important area for ongoing research and an important target for new 
treatments, for all forms of pulmonary hypertension. 
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1.5  Pulmonary Vascular Remodelling: Components &  
 Mechanisms 
Despite advances, our understanding of the pathophysiology of pulmonary vascular 
remodelling remains limited: in particular the sequence of events in human disease is 
far from clear.  There have, however, been numerous experimental advances in 
recent years, with considerable insights into the cellular and molecular factors which 
contribute to the process.  The specific components of pulmonary vascular 
remodelling and the cellular and molecular mechanisms thought to be involved are 
considered individually. 
 
1.5.1 Cellular and Extracellular Matrix Changes in Pulmonary Hypertension 
1.5.1.1 Endothelial Cells   
The normal pulmonary endothelium acts a semipermeable barrier (between the 
vascular and extracellular spaces) and importantly functions to maintain normal 
vessel homeostasis, vascular tone, proliferation and the coagulation system.  It is the 
vessel component most readily exposed to injury (eg shear stress, drugs or toxins) 
and the origins of many of the hallmark features of pulmonary vascular remodelling 
have been related to alterations in normal endothelial cell (EC) function. 
 
Increased endothelial cell proliferation is seen as an early feature in experimental 
models49, 54, and endothelial cells from pulmonary hypertensive lungs have a 
hyperproliferative phenotype55.  This endothelial proliferation is thought to 
contribute to intimal thickening, and is the primary constituent driving the formation 
of plexiform lesions.  Though plexiform lesions are not thought to contribute 
significantly to vascular obstruction, and are only rarely seen in forms of PAH other 
than IPAH, the recognition that the endothelial cells in IPAH plexiform lesions are 
monoclonal42 – suggesting a semi-malignant process – provides interesting insights 
into possible disease mechanisms.  In addition, specific mutations in a TGF-β 
receptor protein in ECs from plexiform lesions43, and infection of ECs with the 
angioproliferative agent human herpes virus 856 have been reported (though this 
secondt finding is contentious and unreplicated)57, 58.  Taken together, however, these 
findings suggest the possibility that various events (somatic mutations, viral 
infection) may trigger clonal proliferation of endothelial cells as an early event in 
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idiopathic PAH pathogenesis, with subsequent cell-cell and cell-matrix interactions 
driven by these phenotypically abnormal, proliferative ECs causing the development 
of the other features of pulmonary vascular remodelling25.   
 
Endothelial cell proliferation and dysfunction may be the initiating factor in some 
forms of PAH, and a secondary – but eminent - factor in others.   Regardless, it is 
likely that the EC contributes significantly to the propogation and maintenance of 
pulmonary vascular remodelling in most forms of the condtion.  Endothelial 
dysfunction, leading to reduced production of vasodilators / antiproliferative 
mediators (eg nitric oxide and prostacyclin) and increased production of 
vasoconstrictors / pro-proliferative mediators (eg endothelin-1, angiotension II), 
seems to be a ubiquitous feature in severe PH59.  Lastly, loss of the endothelial 
barrier (either as a consequence of endothelial cell dysfunction or disruption of the 
elastic lamina) may contribute to vessel oedema, disruption of the extracellular 
matrix and allow influx of disruptive mediators from the circulation to the media and 
adventitia60.  
 
1.5.1.2 Smooth muscle cells 
Under normal laboratory or in vivo conditions the smooth muscle cell (SMC) 
population in general demonstrates minimal proliferation and synthetic activity.  
There are, however, different subpopulations of SMCs identifiable within the medial 
layer and these have been shown to have different proliferative and synthetic 
properties and responses to injury or growth factors61.  During the development of 
severe PH, SMCs hypertrophy, proliferate, migrate and synthesise matrix proteins, 
contributing significantly to pulmonary vascular remodelling59.  In some situations 
these changes in SMC behaviour may be intrinsic to the SMC (eg due to changes in 
potassium channel activity62-64) but there is significant evidence that the SMC is a 
relatively passive player, responding to paracrine signals from endothelial cells65 or 
fibroblasts66.  Also, the apparent SMC population in the neointima and media of 
remodelled arteries may originate from differentiation of other vascular cells, rather 
than expansion of the native SMC population59.   
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1.5.1.3 Fibroblasts 
The adventitia was previously considered to be a relatively inert structure and many 
observers fail to comment on it, when describing pulmonary hypertension.  It is now 
considered likely that the adventitial fibroblast acts as a ‘concert leader’, particularly 
in hypoxia-associated pulmonary hypertension, where it is the first cell to respond to 
the injury67.   Also, there is an evolving understanding that generalised excessive 
fibroblast proliferation is a primary pathogenic step in the development of 
complications in connective tissue disease68.  Based on this it is speculated that the 
pulmonary adventitial fibroblast (PAF) is affected along with dermal and systemic 
vascular fibroblasts in connective tissue diseases and that this may be an important 
and early pathogenic feature of pulmonary vascular remodelling in connective tissue 
disease-associated PAH.   It seems increasing likely that the fibroblast is a major 
contributor in all forms of pulmonary vascular remodelling.  Adventitial thickening 
is generally difficult to assess histologically and is not consistently commented on24 
but, where it is assessed it is found to be a prominent feature in forms of severe PH 
other than hypoxia-associated PH69.  Migrated and differentiated adventitial 
fibroblasts likely also contribute significantly to the population of myofibroblasts 
which are found in the neointima and plexiform lesions in these other forms of PAH.  
PAFs may also be the origin of mitogenic factors and facilitated changes in the 
extracellular matrix, which may contribute to the intiation / progression / persistence 
of the other cellular changes in pulmonary vascular remodelling59.   
 
The evidence for the role of the PAF in pulmonary vascular remodelling is most 
established in hypoxic rat and bovine models.  In these models, in addition to 
increased proliferation, hypoxic PAFs synthesise matrix proteins, demonstrate 
increased migration and secrete paracrine factors which cause SMC proliferation48.  
Pro-angiogenic factors (eg endothelin-1) secreted by hypoxic PAFs may also 
contribute to the vasa vasorum neovascularisation which is seen in remodelled 
vessels70 and which may serve as a conduit via which circulating leukocytes and 
progenitor cells (potentially attracted by the inflammatory mediators also released by 
adventitial fibroblasts) enter the vessel wall71. 
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1.5.1.4 Circulating progenitor cells  
Various circulating cells seem to have an important role in the normal maintenance 
and repair of the pulmonary vasculature, and dysregulation of this function (leading 
either to deficiency or excess activity) may be an initiating or contributing factor in 
PAH pathogenesis72.  There is strong evidence for an important role of circulating 
progenitor cells, particularly fibrocytes, in hypoxic pulmonary vascular 
remodelling71.  In hypoxic animal models, there is an increase in bone-marrow 
derived circulating cells, and these cells, particularly the circulating fibrocytes, are 
recruited into, and become resident in, the pulmonary arteries.  These may contribute 
directly (eg increase resident cell population, proliferate, transform to 
myofibroblasts, modify extracellular matrix) or indirectly (eg via paracrine effects on 
resident vascular cells) to pulmonary vascular remodelling. 
 
1.5.1.5 Inflammatory cells 
Inflammatory cells may be more important contributors to pulmonary vascular 
remodelling than previously thought.  PAH does not appear to be a typical 
inflammatory disorder however a small, selected group of patients with SLE-related 
PAH respond well to immunosuppressant therapies73.  Systemic activation of 
inflammatory pathways in PAH patients and local production of inflammatory 
mediators by pulmonary vascular cells has been identified.  Also, inflammatory 
infiltrates can be seen in plexiform lesions.  These changes may be secondary 
phenomena and there is certainly not evidence of a widespread arteritis in pulmonary 
vascular remodelling.  It is notable, however, that significant numbers of 
macrophages and neutrophils are seen transiently in the pulmonary circulation in the 
early stages of hypoxic PH in animal models (a model not conventionally seen as 
inflammation-related) and pursuing the role of inflammatory cells and inflammatory 
signalling pathways in pulmonary vascular remodelling seems likely to be an 
important future research direction74.   
 
1.5.1.6 Extracellular matrix 
Though the extracellular matrix in the normal vessel appears relatively static, there 
is, in fact, important dynamic turnover of matrix.  Matrix protein synthesis (by ECs, 
SMCs and fibroblasts) and breakdown (by metalloproteinases, regulated by tissue 
inhibitors of metalloproteinases) is usually balanced.  Interactions with the normal 
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extracellular matrix – eg sequestration of growth factors by matrix proteins and 
facilitation of cell migration – are likely important for normal vascular cell 
function75.   
 
Changes in the extracellular matrix (increased collagen deposition, disruption of 
elastic lamina) in remodeled pulmonary arteries are notable and the importance of 
these changes is underscored by observations that agents which enhance or disrupt 
matrix protein degradation significantly modify experimental pulmonary vascular 
remodeling76. 
 
1.5.2 Cell Signaling and Molecular Events in Pulmonary Vascular  
 Remodelling 
Regardless of the cause of PAH, the vascular pathology seen is stereotyped.  This 
suggests that the different forms of the disease may have similar cellular and 
molecular mechanisms.  Diverse initiating cellular or molecular events may result in 
stereotyped upsets in normal vasodilator / vasoconstrictor, pro/anti-proliferative and 
anticoagulant / procoagulant balances in the pulmonary vasculature.   
 
It is difficult to see that we will ever be fully confident about the early pathogenesis 
of all forms of PH, given our inability to recognise the disease clinically until it is 
most advanced, and given the deficiencies of our animal models.  The discovery, 
however, that mutations in the bone morphogenetic protein (BMP) type II receptor 
(BMPR-II) gene were responsible for most forms of familial PAH was a major 
breakthrough77, 78.  Familial PAH is a rare form of PAH, sporadic mutations in 
BMPR-II do not appear to be common in other forms of PAH and also it is observed 
that only a minority of individuals carrying BMPR-II mutations develop PAH and 
accordingly the importance of this, at first glance, seems limited26.  Recognition of 
the gene for familial PAH has, however, led to considerable insights.  Broadly 
speaking, normal BMP-BMPR2 signalling has an antiproliferative and pro-
differentiation effect on pulmonary vascular cells79.  Deficient and/or dysfunctional 
BMP-BMPR2, or other TGF-β family signaling systems, is apparent in other forms 
of PAH, and it seems likely that disruption of these systems is an early and important 
contributor to the pathogenesis of forms of PH other than familial PAH80. 
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Study of the molecular nature of the underlying defect in the underlying primary 
disorder has also led to observations about potential molecular mechanisms 
implicated in the early pathogenesis in specific forms of associated-PAH eg HIV 
infection81, HHT82, portal hypertension83, anorexigen-induced PAH84, 
myeloproliferative disease85. 
 
The majority of molecular signaling pathways implicated in PH pathogenesis have 
been initially characterized in animal models and/or patients with established IPAH, 
anorexigen associated PAH or CTEPH.  It is not completely clear which of these are 
disease initiating mechanisms and which are secondary mechanisms contributing to 
disease propogation.  A summary of some of molecular mechanisms currently 
considered important are illustrated in figure 1.2.   
 
When considering the aims of this thesis, the most relevant pathways for further 
elaboration are those which currently seem to be fundamental to the disease process 
and for which modifying therapies have had clinical success (ie the prostacyclin, 
endothelin-1 and nitric oxide-cGMP pathway).  These can be considered as 
‘benchmarks’ when considering any potential new therapy (such as statins) and are 
considered in specific detail below.  Also relevant to this thesis are those pathways 
potentially involved in hypoxia / MAPK signaling.  These are considered in detail in 
Chapters 1.6 and 1.7. 
 
 1.5.2.1 Prostacyclin 
Prostacyclin is an arachidonic acid metabolite, produced by the vascular 
endothelium.  It is a potent pulmonary and systemic vasodilator and inhibitor of 
vascular cell proliferation.  It also has antiplatelet and positive inotropic effects.  
Prostacyclin acts via a G-protein / adenyl cyclase coupled cell membrane receptor, 
causing an increase in intracellular cyclic AMP which, in pulmonary vascular 
smooth muscle cells, leads to relaxation and decreased proliferation.  Studies in the 
late 1980’s and early 1990’s led to a recognition of a relative imbalance of 
arachidonic acid metabolites (reduced prostacyclin and excess of thromboxane A2, 
which has opposing effects) in humans and PH animal models86.  Pulmonary 
endothelial cells from PAH patients have subsequently been shown to have reduced 
levels of prostacyclin synthase87.  It was considered likely that there was relative
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Figure 1.2 Molecular Signaling Pathways & Potential Therapies in Pulmonary Arterial Hypertension 
Selected extracellular factors (yellow), cell membrane receptors (purple), membrane channels (green) and intracellular pathways (white boxes) implicated in PAH 
pathogenesis are shown on a generic cell diagram.  Specific factors and receptors have been implicated in different vascular cells (eg ET1 principally originates from 
endothelial cells but may act primarily on smooth muscle cells).  Potential disease modifying / therapeutic interventions (red boxes) are also shown.
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prostacyclin deficiency in PAH, and that prostacyclin supplementation may have 
therapeutic benefit.  Initial observations of benefit from continous intravenous 
infusion of prostacyclin (epoprostenol) in individual patients were striking, and this 
led to randomised control trials of these agents for PAH, and the subsequent 
development and validation in further clinical trials of novel prostanoids / delivery 
mechanisms88.  Currently, intravenous prostacyclin remains the ‘gold standard’ drug 
treatment for PAH with considerable evidence demonstrating survival benefit.  
Inhaled and subcutaneous prostacyclin is also effective, but oral analogues have been 
less successful.  Though prostacyclin therapies significantly benefit large numbers of 
patients, treatment is very expensive, has substantial side effects and risks (making it 
inapplicable to a large number of patients, even in resource rich countries) and it only 
retards disease progress: it doesn’t cure the disease.   
 
There is also evidence for a role for the prostacyclin pathway in the pathogenesis of 
hypoxia-associated pulmonary hypertension.  Hypoxia inhibits the production of 
prostacyclin by pulmonary endothelial cells89.  Also, the development of hypoxic PH 
is accentuated in mice lacking prostacyclin receptors90 and diminished in transgenic 
mice overexpressing prostacyclin synthase91.   Lack of benefit of prostacyclin 
monotherapy in the chronic hypoxic rat model might suggest that prostacyclin is not 
a major contributor in hypoxic PH92 but, in contrast, other observers have seen 
reduction in experimental hypoxia-induced pulmonary vascular remodeling with 
prostacyclin therapy93 and some success with prostacyclin treatment of hypoxic lung 
disease related PH in humans has been seen94.   
 
1.5.2.2 Endothelin-1 
Endothelin-1 (ET-1) is a peptide hormone / paracrine molecule.  In the lung, it is 
principally considered to be synthesised and released by endothelial cells and act, via 
G-protein coupled receptors, on adjacent smooth muscle cells with vasoconstrictive 
and pro-proliferative effects.  As shown in figure 1.3, ET-1 is also known to have 
effects on fibroblasts, platelets and inflammatory cells and interact with nitric oxide 
and prostacyclin pathways.  From this it can be seen that excess of ET-1 would 
potentially cause the development and / or progression of pulmonary hypertension.   
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Increase in production and reduced clearance of ET-1 is evident in PH models95 and 
patients96, and endothelin blockade has substantial positive effects on experimental 
PH97, 98.  The importance of ET-1 in PH pathogenesis is underscored by the success 
of endothelin antagonist therapy in PAH99 and chronic thromboembolic pulmonary 
hypertension100: oral endothelin antagnosists have variously but consistently been 
shown to improve symptoms and survival in PAH101.  Many patients, however, 
benefit from these drugs for only a short period and effects on pulmonary 
haemodynamics are minimal: as with prostacylin, these drugs do not cure PAH and 
additional therapies are required. 
 
In the normal pulmonary artery, vasoconstrictor and proliferative actions of ET-1 
seem to be mediated via the endothelin A and B receptor on smooth muscle cells, 
whilst on endothelial cells the ET-B receptor facilitates a negative feedback loop on 
ET-1 synthesis, triggers release of vasodilator molecules and mediates clearance of 
endothelin-1 from the vascular interstitium and the circulation.  The situation appears 
more complex in the diseased state, as there is more extensive expression of the B 
receptor in smooth muscle cells from the distal arteries and activation of both the A 
& B receptor may contribute to adverse effects of ET-1 in the diseased pulmonary 
artery102.   
 
Both selective endothelin A receptor antagonists and dual A/B receptor antagonists 
have shown benefit in PH treatment, but whether selective or dual inhibition is better 
in clinical practice remains uncertain102, 106.   
 
ET-1 release, endothelin receptor blockade and endothelin receptor deficient mice 
have been studied in hypoxic conditions and, ET-1 release, and its effects, likely 
contribute to vasoconstriction and vascular remodeling107, 108, although there is 
conflicting data109, 110.  Hypoxia triggers release of endothelin-1 from bovine PAFs 
and this may act as an autocrine fibroblast growth factor and chemoattractant111.   
Hypoxic bovine PAF derived ET-1 has also been shown to promote growth of vasa 
vasorum endothelial cells105, and this ET-1 release may contribute to adventitial 
neovascularisation and consequent influx of circulating mesenchymal cells in 
hypoxic pulmonary vascular remodeling in these animals71.  Lastly, differences in 
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Figure 1.3 Endothelin-1 Signalling in Pulmonary Vascular Remodelling 
Endothelin-1 (ET-1) synthesised and released by endothelial cells (green) acts on 
smooth muscle cells (blue), fibroblasts (brown) and enters the circulation102.  ET-1 
mediates diverse effects which promote pulmonary vasoconstriction and pulmonary 
vascular remodeling, via the endothelin A & B receptors103, as shown.  Smooth 
muscle cells104 and fibroblasts105 may also produce ET-1 and ET-1 derived from 
these cells may also contribute to the initiation and propogation of pulmonary 
vascular remodelling.   
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upregulation of ET-1 release, in response to hypoxia have been suggested as a 
contributory factor explaining the differential susceptibility of different rat strains to 
chronic hypoxic pulmonary hypertension112.  This last observation raises the 
possibility that species differences in ET-1 responses may explain some of the 
contradictory results seen with ET-1 studies in hypoxic pulmonary vascular cell 
interactions.  Overall, it is concluded that ET-1 is likely to be a hypoxia-responsive 
paracrine mediator, contributing to pulmonary vascular remodeling, but that 
additional work is required to clarify its role in different cell-cell interactions, in 
different animals.   
 
1.5.2.3 Nitric oxide 
In pulmonary artery smooth muscle cells, via activation of guanylate cyclase and 
increase in intracellular cyclic GMP, endothelial cell-derived nitric oxide acts as a 
vasodilator and antiproliferative agent.  Disruption of endothelial nitric oxide 
synthase (eNOS) is seen in PAH blood vessels113 and deficiency of nitric oxide is 
seen in experimental chronic hypoxic PH114.  Supplemental, inhaled nitric oxide 
(NO) is used clinically in the acute assessment of vasoreactivity as part of the 
diagnostic evaluation of patients with severe pulmonary hypertension and prolonged 
inhalation is also used in neonatal intensive care units for the treatment of respiratory 
failure of prematurity and pulmonary hypertension.  Chronic ambulatory nitric oxide 
inhalation systems have been developed and trialed in PAH115 and PH-associated 
with COPD116 with some success but the high cost and very cumbersome nature of 
this makes it an unattractive prospect for further development.   
 
More successful has been an indirect approach to amplify the residual nitric oxide 
signal in PAH, by inhibiting the degradation of the intracellular 2nd messenger, 
downstream of nitric oxide.  In the pulmonary circulation, cGMP is principally 
degraded by phosphodiesterase - PDE-5.  Selective inhibition of PDE-5 – an enzyme 
which has relatively restricted expression in other tissues of the body - would 
potentially allow relatively lung specific amplification / persistence of any residual 
NO-cGMP signal in the pulmonary arteries117.  Therapy with sildenafil – a PDE-5 
inhibitor - has proven successful in clinical trials in the treatment of PAH118.   
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Disturbance of NO-cGMP signaling likely contributes to chronic hypoxic PH.  
Chronic hypoxia leads to a decrease in nitric oxide production119 and treatment with 
sildenafil attenuates chronic hypoxic PH in rats120 and mice121.  In human trials, 
PDE-5 inhibition with sildenafil improves haemodynamics in acute hypoxic states121, 
122
 and chronic therapy has been shown to improve chronic hypoxic PH123, 124.  
 
1.5.2.4 Other molecular signaling pathways in PAH 
Disturbances of a variety of other signaling pathways – including serotonin, 
potassium channel, angiopoietin, vasoactive intestinal polypeptide, adrenomedullin 
and tyrosine kinase growth factor/receptors – have been implicated in PAH 
pathogenesis and/or, based on experimental observations, highlighted as pathways of 
interest for potential therapeutic manipulation in PAH.  These are not expanded on 
here – they are outwith the focus of this thesis – but they are described in detail in 
recent reviews125, 126. 
 
1.5.2.5 Summary 
Disturbances of a variety of molecular pathways are seen in pulmonary hypertensive 
blood vessels.  Establishing whether these pathways are restricted to established 
disease, to subtypes of the disease, to restricted cells within the vessel and the 
interactions / relative contributions of these pathways is work in progress. The work 
in the BMPR-2 field seems most promising and it may be that it will lead to novel 
pathogenetic insights and therapeutic breakthroughs. 
 
At the current time, however, the pathways best characterised are the three 
elaborated on in the preceding sections (prostayclin, endothelin-1 and nitric oxide).  
Though the established therapeutics for PAH are imperfect, any potential new 
therapy needs to be considered in relation to these and any effects additional or 
alternative to these should be sought.  For example, an agent found initially to be 
beneficial in an experimental PH model but subsequently shown to simply duplicate 
the molecular/cellular effects of sildenafil would be of limited value.  Work to 
explore how these signaling pathways may complement one another in experimental 
models, and in clinical scenarios, is ongoing93, 127.  With regards to the work in this 
thesis, comparison of statins (the focus of this thesis) with a drug from each of the 
established therapeutic classes, acting on these three key pathways seems relevant.   
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1.6 Hypoxia 
1.6.1 Definition  
Hypoxia is a physiological term for the condition in which the oxygen supply to 
tissue, organs or whole animals is insufficient to maintain a normal function. 
Hypoxia is a relative condition: eg exercising skeletal muscle (where blood supply is 
reduced and oxygen consumption is increased) is ‘used’ to much lower oxygen 
tensions in comparison to the brain or kidneys.  The response of a given organ or cell 
type to a specific oxygen tension, and whether this constitutes ‘hypoxia’ or not, 
depends on the usual oxygen tension (under resting or active conditions) that the 
tissue under study is exposed to.   In response to relative hypoxia, mammals exhibit 
systemic responses that decrease cellular oxygen requirements and dependence and 
increase tissue oxygen supply.  Alterations in oxygen tension also elicit important 
stereotyped responses at the organ, tissue and cellular level, which are site specific.   
 
Hypoxia, either generalised to the animal (caused by reduction in inspired oxygen, 
cardiopulmonary disease or other disturbance of oxygen transport) or occurring in a 
specific organ (localised vascular insufficiency), results in what are now relatively 
well characterised changes in molecular, cellular and organ status.  For the purpose 
of this thesis, the most relevant effect of hypoxia in the body is its effect on the lungs 
where hypoxia leads to pulmonary vasoconstriction and pulmonary vascular 
remodelling 
 
1.6.2 Hypoxic Lung Disease and Pulmonary Hypertension 
Exposure to chronic hypoxia causes pulmonary hypertension in most mammalian 
species. Hypoxic pulmonary hypertension is associated with changes in vascular tone 
and is nearly always associated with significant structural changes within the 
pulmonary vascular bed (pulmonary vascular remodelling)128. There are also marked 
changes in the phenotype of endothelial, smooth muscle and fibroblast cell 
populations. Over the last few years it has become clear that the vascular responses 
to hypoxia involve extremely complicated cell-cell interactions mediated by growth 
factors, cytokines and other biological messengers48.  
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The first recognition of hypoxia-induced pulmonary hypertension in mammals was 
brisket disease.  This entity arose in cattle taken to new high pastures in Colorado 
and was subsequently shown to reflect right heart failure, secondary to pulmonary 
hypertension, at this altitude (10,000 feet)129.  Pulmonary hypertension secondary to 
chronic hypoxia, consequent on residence at high altitude is thought to be one of the 
commonest forms of the disease worldwide2.   
 
Diverse respiratory diseases can be associated with pulmonary hypertension.  These 
include COPD, cystic fibrosis, restrictive lung diseases (eg kyphoscoliosis), 
parenchymal lung diseases (eg idiopathic pulmonary fibrosis, sarcoidosis) and sleep-
disordered breathing30.  The pulmonary vascular component of these conditions has 
proven difficult to characterise: it is difficult to determine how much is due to effects 
of hypoxia on the pulmonary vasculature (vasoconstriction and vascular remodelling) 
vs non-specifc destruction of the pulmonary vascular bed due to progressive lung 
disease vs direct effects of the primary disorder on the pulmonary vasculature130.  
Also, there seems to be individual susceptibility factors which modify the effects of 
hypoxia: some individuals develop severe pulmonary hypertension despite only 
modest lung disease and/or hypoxia whilst some individuals seem relatively 
‘immune’ to pulmonary hypertension, despite severe lung disease or prolonged 
residence at very high altitude35.  Different animal species exhibit different 
susceptibilities to chronic hypoxic PH112 and also ethnic origin seems to modify 
human susceptibility to altitude-related pulmonary hypertension131.  These 
observations suggest genetic factors which modify susceptibility to hypoxic 
pulmonary hypertension and recently, polymorphisms in the serotonin transporter 
gene have been suggested to modify the severity of PH in COPD patients132.  Also, 
polymorphisms in the angiotensin converting enzyme gene seem to be associated 
with the varying susceptibility to high altitude pulmonary hypertension in Kyrgyz 
highlanders35. 
 
The importance of pulmonary hypertension in chronic hypoxic diseases has been 
disputed but there is now a substantial body of data indicating that PH is a common 
complication of chronic hypoxic disorders and that, when it occurs, it carries a very 
adverse prognosis.  Altitude-related pulmonary hypertension is definitely and COPD-
related pulmonary hypertension is probably a major public health problem.  
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Pulmonary hypertension does not necessarily regress when hypoxia is corrected (eg 
by providing supplemental oxygen in COPD or moving residence to lower altitude) 
and correction of hypoxia in these conditions is often impossible.  A better 
understanding of the pathogenesis of hypoxic pulmonary hypertension is therefore 
required, and seeking therapeutic strategies to manipulate the pulmonary vascular 
response to hypoxia seems very relevant for human disease. 
 
1.6.3 Hypoxic Pulmonary Vasoconstriction and Pulmonary Vascular  
 Remodelling 
The ability of the pulmonary resistance arteries to constrict in response to alveolar 
hypoxia – hypoxic pulmonary vasoconstriction (HPV) - is of fundamental 
importance to normal pulmonary vascular physiology: a generalised but reversible 
constriction of the mammalian pulmonary circulation facilitates the change from 
fetal to infant circulation when the lungs are first ventilated, at birth, in utero133.  
Also, the maintained ability of the pulmonary arteries to constrict in response to lung 
pathology (eg consolidation or atelectasis) allows for the maintenance of 
ventilation/perfusion matching and systemic circulation oxygen tensions in the face 
of acute lung illnesses.  This response - constriction of the pulmonary arteries to 
alveolar hypoxia – is circulation specific (systemic arteries dilate to hypoxia) and is 
conserved across species.   
 
Whilst essential for normal health, HPV is also important in human disease.  
Generalised alveolar hypoxia (eg shift from sea level to high altitude) results in 
generalised constriction of the pulmonary arteries, with consequent rise in pulmonary 
vascular resistance and development of pulmonary hypertension134.  Dysfunctions or 
maladaptions of the molecular and cellular mechanisms of HPV have also long been 
considered potential pathogenetic factors in PAH. 
 
Although the hypoxia sensing mechanism at a cellular level remains controversial, 
the effector mechanism of HPV, at both molecular and cellular level has been well 
characterised.  PASMCs (either in endothelium-denuded vascular rings or isolated in 
cell culture) contract in hypoxia.  This is dependant on influx of extracellular calcium 
through L-type calcium channels and, to a lesser extent, release of intracellular 
calcium from the sarcoplasmic reticulum.  Hypoxia also activates smooth muscle cell 
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RhoA & Rho-kinase (ROCK) and this acts to sensitise myosin to the effects of 
intracellular calcium, facilitating and enhancing acute hypoxic vasoconstriction.  
Persistence of Rho-ROCK activation may be an important contributor to the 
sustained vasoconstriction which occurs in chronic hypoxia.   The secondary, 
sustained phase of HPV is also dependant on extracellular calcium but also requires 
an intact endothelium, with both reduction in eNOS activity (leading to decreased 
nitric oxide signal to SMCs with consequent decreased intracellular cGMP causing 
cellular contraction) and endothelial cell release of ET-1 (causing SMC contraction 
via G protein coupled receptor), in response to acute hypoxia, implicated134.  
 
As previously outlined, chronic hypoxia leads to changes in the behaviour of 
pulmonary vascular cells and structural changes in all vessel compartments: 
pulmonary vascular remodelling (Chapter 1.4.3).  Also previously discussed is the 
ongoing debate as to which aspect – remodelling per se, sustained vasoconstriction 
consequent on remodelling etc – is responsible for persistent pulmonary hypertension 
in animal and human chronic hypoxia.   
 
The link between acute hypoxic vascoconstriction and pulmonary vascular 
remodelling (and the newly emerging concept of chronic hypoxic vascoconstriction) 
in chronic hypoxic PH, and also a connection between HPV mechanisms and other 
forms of PAH has been speculated on for some time.  It is recognised that 
constriction and remodelling share common mechanisms – so called cell growth-
vasomotor coupling – and these continue to be added to.  Paracrine agents such as 
prostacyclin, nitric oxide and ET-1 are now readily recognised for their effects both 
on SMC contraction, and proliferation.  Inhibition of Kv1.5 (a cell membrane 
potassium channel) activity is an important early event in acute hypoxia in SMCs, 
mediating cellular depolarisation with consequent opening of Ca++ channels133.  
Chronic hypoxia has been shown to downregulate the Kv1.5 and Kv2.1 potassium 
channels in rat pulmonary arteries135.  Also, modification of potassium channel 
activity has been implicated in the pathogenesis of pulmonary vascular remodelling 
secondary to anorexigen drugs, suggesting a more generalisable link between 
mechanisms of acute HPV and non-hypoxia related forms of PH136.  More recent 
studies using inhibitors of Rho kinase have shown inhibition of both HPV and 
chronic hypoxia-induced vascular remodelling, implicating the RhoA-Rho kinase 
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signalling pathway in both processes.  Taken together, these findings significantly 
support the concept of cell growth-vasomotor coupling and suggest that the field of 
acute hypoxia and HPV remains important, offering the potential for improvements 
in our understanding of human PH, in general.   
 
The specific mechanisms which may be involved in oxygen sensing in HPV are 
considered in more detail below (chapter 1.6.5). 
 
1.6.4 Effects of Hypoxia on Pulmonary Vascular Cells 
The contributions of the different resident vascular cells to pulmonary vascular 
remodelling have previously been considered (Chapter 1.5.1).  The responses of each 
individual cell to acute or chronic hypoxia, in cell culture, have been extensively 
studied.  The focus of this thesis is the adventitial fibroblast and, to a lesser extent, 
the pulmonary artery smooth muscle cell and the effect of hypoxia on these are 
considered in more detail.   
 
There is some controversy in this field and contrasting / contradictory results have 
been published.  Important aspects to consider are the different origins (species, size 
of vessel derived from, cell harvest technique used) of the cells studied by different 
investigators and what constitutes hypoxia to different investigators, and to different 
cell types.  For example, smooth muscle cells from the central media of a proximal 
vessel, being distant from both the alveoli and the vessel lumen, are likely routinely 
exposed to low oxygen tensions in vivo and therefore may be relatively hypoxia 
‘resistant’.  Smooth muscle cells from the distal vessel (where all vessel layers are 
thinner) may be more hypoxia sensitive – either because of a fundamental difference 
in their nature or because they are ‘used’ to higher oxygen tensions in vivo.  As 
adventitial fibroblasts reside closer to the alveoli than medial smooth muscle cells, 
they may be ‘used’ to higher oxygen tensions and therefore appear more sensitive to 
a specific level of cell culture hypoxia vs proximal vessel medial SMCs137.   
 
Smooth muscle cells proliferate in vivo in the chronic hypoxic animal models but this 
is inconsistently replicated with explanted cells in vitro.  Hypoxic proliferation of 
PASMCs may be a function of an isolated, specific subset of PASMCs, it may be 
that it is dependant on cell-cell or cell-matrix interactions, it may be that PASMC 
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proliferation is not consequent on hypoxia directly, but a function of release of 
mitogens by other hypoxic cells or it may simply be that we are inadequately 
modelling the media of pulmonary arteries with PASMCs in hypoxic cell culture.  
There is, however, significant evidence of crosstalk between hypoxic PAFs and 
PASMCs, and it seems likely that PAF activity is a major contributor to PASMC 
proliferation3, 66. 
 
The effects of hypoxia on pulmonary artery fibroblasts are considered in more detail 
in a following section (chapter 1.8). 
 
1.6.5 Hypoxia as an Experimental Model of Pulmonary Hypertension 
There are numerous animal models of pulmonary hypertension but the two most 
commonly used and best characterised are chronic hypoxia and monocrotaline (a 
direct pulmonary endothelial cell toxin, used alone or in conjuction with 
pneumonectomy)59.  Whilst the monocrotaline-pneumonectomy model and other, 
newer animal models recapitulate some of the histological features of PAH not seen 
with other models, the initiating factors are not seen in human disease.138  In contrast, 
the chronic hypoxic model seems to have advantages:- 
• The haemodynamic, compensatory and pathological changes seen in this 
model have been extensively described and are reliably achieved with 
standard experimental conditions (maintenance of adult animals in hypobaric 
hypoxia for 2 weeks)139.   
• The model directly reflects one of the commonest initiating factors in 
pulmonary hypertension worldwide (pulmonary hypertension associated with 
chronic exposure to high altitude)140.  Although imperfect (the pathological 
changes seen in the hypoxic rat model incompletely reflect those seen in 
human pulmonary arterial hypertension and the pathogenesis of the 
pulmonary vascular remodelling may be different) this model is the one 
where the initiating insult most closely reflects a human condition.    
• The success of new pulmonary hypertension treatments has significantly 
reduced the number of patients with pulmonary hypertension requiring lung 
transplant.  This limits the ability to perform work on pulmonary vascular 
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cells derived from remodelled human vessels.  Given this restriction, work on 
animal models is essential.   The relevance of work on animal cells to human 
disease remains uncertain and speculative but, for the experiments in this 
thesis, the recognition that pulmonary artery fibroblast responses to hypoxia 
are conserved between species (see Chapter 1.8) offers some reassurance 
about the relevance of the model.  In addition, although this is not considered 
in the experimental work of this thesis, animal models allows study of the 
early stages of pulmonary vascular remodelling whereas work on explanted 
or post-mortem diseased human lung only allows assessment of end-stage 
remodelling.   
 
Experimentally, the effects of acute and chronic hypoxia can be studied separately, 
or in tandem.  When we consider the cell proliferation models under consideration in 
this thesis, work with acute and chronic hypoxia is related, but complementary.  An 
acute hypoxic cell model has the advantage of allowing ‘screening’ studies of a 
battery of different drugs / drug concentrations on readily available tissue from 
normal animals.  Studying cells from chronic hypoxic animals has the advantage of 
allowing study of disease tissue in comparison to normal ‘control’ tissue and 
allowing conclusions to be reached about mechanisms common to acute and chronic 
hypoxic signalling (helping to unify our understanding of the pathogenic links 
between acute hypoxic signalling and cellular changes in chronic hypoxic pulmonary 
vascular remodelling).   
 
Experimentally, hypoxia can be induced by two mechanisms:-  
• Normobaric hypoxia.  Hypoxia is induced by reducing the fraction of oxygen 
(from 21%) in normal pressure air.  This is the mechanism utilised in the 
acute hypoxic cell model in this thesis. 
• Hypobaric hypoxia.   The fraction of oxygen in air is maintained but the 
pressure is reduced.  This directly reflects the aetiology of high altitude 
pulmonary hypertension in humans and is the mechanism utilised to generate 
the chronic hypoxic rat model in this thesis. 
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1.6.6 Hypoxia-Sensing Mechanisms  
Our understanding of the fundamental mechanism(s) by which cells recognise and 
respond to low oxygen have progressed significantly in the last 15 years.  In relation 
to pulmonary hypertension and chronic hypoxic pulmonary vascular remodeling the 
most relevant and most studied pathways are the HIF (hypoxia inducible factor) 
pathway and the sensing mechanism(s) of acute hypoxic vasoconstriction. 
 
1.6.6.1 HIF-1 signalling  
First recognised in relation to the hypoxia responsive element in the erythropoietin 
gene141, the HIF-1 pathway is now known to function as a ubiquitous mediator of 
cellular responses to hypoxia, being present in all nucleated cell types.  HIF-1 is a 
heterodimeric protein consisting of 2 constitutively transcribed proteins HIF-1α and 
HIF-1β142.  In the presence of oxygen, proline residues on HIF-1 α are hydroxylated.  
Hyrdoxylated HIF-1α binds to the Von-Hippel Lindau protein which leads to 
recognition by cellular ubiquitination mechanisms with consequent proteasomal 
protein degradation.  In hypoxia, prolyl hydroxylase activity is reduced leading to 
reduced degradation of HIF-1α with consequent stabilisation of the HIF-1 protein 
complex143.  HIF-2α and 3α subtypes of the protein, expressed in a more restricted 
panel of cell types, are now being characterised144. 
 
Stabilised HIF-1 protein complexes (whose existence is promoted by hypoxia) 
translocate to the cell nucleus where they are associated with coactivator proteins (eg 
CREB or p300) and this association is also facilitated by hypoxia145.   The HIF 
protein-coactivator complex promotes transcription of genes containing a hypoxia 
responsive element in the gene promoter.  The ultimate effect of this modified gene 
transcription is cell specific but can involve increased cellular proliferation, increased 
production of mitogens etc.   
 
The HIF protein system is likely important in the pathogenesis of pulmonary 
vascular remodeling.  Proteins whose transcription is mediated by HIF-1 include 
VEGF, ET-1 and voltage dependant calcium channels146 and these are mediators 
implicated in pulmonary vascular remodeling.  Studies with knockout / transgenic 
mice suggests activity of HIF-1α in PASMCs and HIF-2α in PAECs contributes to 
hypoxic pulmonary vascular remodeling147.   
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1.6.6.2  Oxygen Sensing in Acute Hypoxic Pulmonary Vasoconstriction133  
The connection between acute HPV and vascular remodeling is underscored by the 
observation that the cellular processes mediating PASMC constriction (Kv channel 
closure, increase in intracellular Ca++, activation of Rho-ROCK) can also influence 
PASMC proliferation.   
 
Consideration of the ongoing debate about oxygen sensing mechanisms in acute 
HPV allows for an elaboration of the experimental difficulties which exist in this 
field.  There currently exist two contradictory models of oxygen sensing in HPV and 
there is good experimental evidence for both.  In both these models, reduction in 
cellular oxygen is ‘sensed’ both at the inner plasma membrane and in the 
mitochondria.  This leads to alterations in activity of NAD(P)H oxidases (either in 
the cell membrane or the mitochondria) and/or in the mitochondrial electron 
transport chain and/or in heme oxygenase-1 activity.  What is contentious is whether 
alterations in these leads to an increase or decrease in cellular reactive oxygen 
species (ROS) and where the connection between these processes (eg is the NADPH 
oxidase activation a cause or a consequence of changes in ROS) and the downstream 
processes lies148.   
 
1.6.6.3  Summary 
Difficulties with the experimental definition and application of hypoxia to different 
cell types and the deficiencies of the current knowledge base and contentions which 
exist in relation to oxygen sensing mechanisms have been noted.  When results of the 
experimental work – using ‘hypoxia’ as a very generic term - in this thesis are 
considered, all of these problems are acknowledged. 
 
1.7 Mitogen Activated and Other Protein Kinases in Cell  
 Proliferation 
1.7.1 Mitogen activated protein kinases 
Cell activities (growth, differentiation, apoptosis, gene activation, cytoskeletal 
conformation, mediator synthesis and secretion, etc) are regulated and influenced by 
diverse extracellular signals.  Extracellular signals are integrated and amplified with 
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signal-specific responses generated (eg gene activation) by complexes of signalling 
cascades.  The mitogen-activated protein kinases (MAPK) process various 
extracellular signals and constitute a key intracellular signalling complex.   
 
Extracellular stimuli (mitogens149, hypoxia150, UV light151) activate diverse cell 
receptor complexes with consequent activation (eg by phosphorylation or GTP-
loading) of upstream kinase proteins in the MAPK cascade.  The signal is amplified 
at two preceding kinase steps, leading to phosphorylation (at tyrosine and threonine 
residues) of the MAPK protein (figure 1.4).  MAPK exists in the cytoplasm and 
phosphorylated MAPK can act directly, phosphorylating and activating substrate 
cytosolic proteins152.  Also, once phosphorylated, MAPKs can translocate to the cell 
nucleus and act on cell type specific transcription factors153.  The MAPK pathway 
therefore acts as a physical link and also a signal amplification step from 
extracellular signals to cell nuclear responses. 
 
Three distinct MAPK subfamilies are recognised in mammalian cells154.  The 
classical MAPK pathway, consisting of ERK1 & ERK2 (extracellular regulated 
kinases) and their associated upstream kinases and downstream substrates, is 
typically implicated in mediation of conventional, constitutive signalling by growth 
factors.  The stress activated protein kinase pathway (SAPK) is recognised as a key 
mediator of cellular responses to stress signals (eg hypoxia, UV light).  p38α MAPK 
and c-Jun N-terminal kinase 1 (JNK-1) are the prototype SAPKs.  Along with ERK 
these constitute the three MAPK subfamilies.  Within each subfamily there exist 
various isoforms which seem to have tissue-specific functions155.  Aspects of the p38 
MAPK signalling cascade are represented in figure 1.5. 
 
1.7.2 Upstream Signalling Events in MAP kinase activation 
As illustrated in figure 1.5, phosphorylation of MAPKs is dependant on initial 
processing of the extracellular signal by receptor or other cell membrane-associated 
proteins with consequent activation of MEKK proteins.  The small GTP binding 
proteins comprising the Ras superfamily have attracted considerable experimental 
attention in recent years, firstly based on their apparent involvement in the 
pathophysiology of diverse conditions and secondly based on the recognition of these 
as potential therapeutic targets156.  A schematic of potential interactions between cell 
 53
 
 
Figure 1.4 Mitogen-Activated Protein Kinase Signalling Pathways 
Mitogen-activated protein kinases (MAPKs) integrate & process various 
extracellular signals.  The MAPK cascade consists of 3 protein kinases: a MAPK and 
2 upstream kinases a MAPK kinase (MAPK or MEKK) and MAPKK kinase 
(MAPKKK eg raf or rho kinase)  
ERK: extracellular signal-related kinase.  JNK: c-Jun-N-terminal kinase. 
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Figure 1.5 Overview of the p38 MAP Kinase Signalling Cascade 
Extracellular signals activate MAPKKKs via variety of signalling mechanisms.  MAPKKKs activate MAPKKs, which in turn phosphorylate and activate MAPKs.  
Activated MAPKs then phosphorylate downstream substrates, leading to altered cellular activity.   
STK39: serine threonine kinase.   PAK: p21-activated kinase. MAPKAP: MAPK-activated protein kinase.   
TRAF: Tumour-necrosis factor receptor-associated factor ATF: activating transciption factor.  
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membrane receptors, extracellular signals, Ras family proteins and MAPKs is shown 
in Figure 1.6.   
 
Signalling from extracellular growth factors via Ras-Raf1-ERK is well 
characterised157.  More recently a connection between Rho family proteins and the 
SAPKs has been shown in various cell types158, 159.  Experimental evidence linking 
the individual involvement of these proteins (Ras, ERK, RhoA, Rac1, p38 and JNK) 
to the cellular processes of interest in this thesis (ie hypoxia sensing, adventitial 
fibroblast proliferation, pulmonary vascular remodeling) is notable.  Also notable is 
the emerging evidence that other processes extracellular / cell membrane systems 
potentially disrupted in PAH pathogenesis may mediate their effects via SAPK 
pathways: eg certain mutations in the BMPR-2 gene have been shown to disrupt 
normal antiproliferative downstream signaling (via phosphorylation of SMAD 
proteins) and result in activation of p38 MAPK (presumably with resultant 
dysregulated cellular proliferation)160.  It is considered likely that Ras superfamily – 
MAPK signaling pathways are ‘final common pathways’ in PH pathogenesis and 
further investigation of these should provide further insights into fundamental 
disease mechanisms and potential therapeutic strategies161. 
 
Individual signaling systems that we are speculating may be involved in hypoxia-
induced p38 MAP kinase activation in PAFs have been implicated in hypoxic 
pulmonary vascular remodeling.  There is significant interest in the RhoA-Rho 
kinase signaling pathway.  Rho kinase inhibition (eg with fasudil) inhibits hypoxic 
pulmonary vasoconstriction, reverses experimental pulmonary hypertension, inhibits 
pulmonary vascular remodeling and is likely to be safe for human use51, 162-164.  
Clinical trials of Rho kinase inhibitors for PAH are proposed.  There is, however, 
some evidence that activation of RhoA-ROCK may be a secondary phenomeon, 
rather than an initiating factor in PH pathogenesis165.  Knockout of a specific subunit 
protein of the NADPH oxidase complex (NOX2 / gp91phox) inhibits the production of 
reactive oxygen species and prevents pulmonary vascular remodeling in chronic 
hypoxic mice166.  The Rho GTPase family proteins Rac1 and Rac2 are involved in 
signal transduction from extracellular signals, leading to the activation of NOX (and 
subsequent reactive oxygen species generation) in most cell types, including 
fibroblasts167.  The recent observation that specific inhibition of the NOX4 protein 
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reduced hypoxic proliferation and p38 activation in PAFs is particularly intriguing 
and NOX4 has been specifically implicated in the pathogenesis of both experimental 
hypoxic PH and IPAH168.  This last point also supports the relevance of continuing to 
study experimental hypoxic PH, and relating findings to PAH in humans.   
 
This converging evidence suggests a fundamental role for the RhoA-ROCK and Rac-
NOX signaling pathways in hypoxia sensing and the pathogenesis of hypoxic 
pulmonary vascular remodeling.  When we were speculating about pathways 
potentially upstream of p38 MAPK in hypoxic PAFs, we considered that these two 
pathways would likely be of specific interest for further study (if the initial 
experiments conducted supported the involvement of a GTPase protein).   
 
Other signaling proteins are likely involved upstream of MAPKs in hypoxia, in other 
cell types and situations.  In acute hypoxia in PAFs from neonatal calves, 
phosphatidylinositol-3-kinase, Akt and mTOR have been shown to be upstream 
activators of ERK MAP kinase, and this signaling pathway is necessary for acute 
hypoxic proliferation of this cell type169. 
 
In addition to the downstream substrates of MAPKs illustrated in Figure 1.4, 
activation of MAPKs has been linked to increased HIF-1α stabilisation and HIF-1α 
phosphorylation (phosphorylation promotes nuclear translocation of the HIF 
complex, see Figure 1.6)170.  In particular, inhibition of p38 MAP kinase in acutely 
hypoxic PAFs has been shown to reduce HIF-1α stabilization and consequent 
cellular proliferation, indicating a link between these fundamental hypoxia-
responsive signaling systems, in a cellular process important in pulmonary vascular 
remodeling155, 171, 172.   
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Figure 1.6 Pivotal Role of Ras Superfamily Proteins in Cell Signal Transduction 
Via G-protein coupled receptors, tyrosine or serine-threonine kinase receptors or other mechanisms, Ras family guanine exchange factors (not 
shown) are activated, resulting in conversion of a Ras protein-GDP complex to Ras-GTP170.  This active complex then activates specific kinases 
(eg in the case of Ras, this can be Raf-1 which is activated by translocation from the cytoplasm to the inner plasma membrane) which in turn 
phosphorylate downstream kinases (eg MKK3) with consequent MAPK phosphorylation.  Hypoxia and/or changes in reactive oxygen species 
have been implicated in the activation of RhoA and Rac1 (members of the Ras superfamily) and this may be important in the molecular 
pathogenesis of hypoxic pulmonary vascular remodelling. 
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1.8 Fibroblasts in Pulmonary Vascular Remodelling and Effects 
of Hypoxia on Fibroblast Proliferation and MAP Kinase Pathways 
In comparison to other resident vascular cells, adventitial fibroblasts seem to have a 
very notable capacity to proliferate, migrate and transdifferentiate in response to 
hypoxia.  They play an important role in the initiation and evolution of pulmonary 
vascular remodeling in chronic hypoxic pulmonary hypertension.  Some of the 
experimental evidence to support this has been discussed previously (chapter 1.5.1) 
but is summarised here:- 
• Adventitial thickening (with increased cell numbers and matrix deposition) is 
the earliest and most prominent change in hypoxic pulmonary vascular 
remodelling.  Increased proliferation and matrix deposition by pulmonary 
artery fibroblasts contribute to this adventitial thickening173. 
• Pulmonary artery fibroblasts proliferate faster in hypoxia than other vascular 
cells174 
• In response to hypoxia, growth factors or injury PAFs synthesise collagen 
precursors.  Collagen subsequently accumulates in the adventitia, 
contributing to loss of vessel distensibility.  PAFs also migrate to the medial 
and intimal layers of the vessel and lay down collagen here, further 
contributing to reduction in vessel lumen and loss of vessel distensibility48   
• In response to pulmonary artery injury and hypoxia PAFs transform and 
contribute to the population of subintimal, medial and adventitial 
“myofibroblasts.”175  These myofibroblasts seem to have a key role in the 
generation of the typical histological lesions seen in pulmonary 
hypertension.  
• Signals generated by PAFs influence endothelial and smooth muscle cell 
activities eg pulmonary artery smooth muscle cells have been found to 
proliferate in hypoxic conditions only when cultured in association with 
PAFs (or in PAF conditioned media)66. 
• The adventitial fibroblasts in the remodelled vessel may be heterogenous.  
Different subsets may have different proliferative, synthetic and migratory 
phenotypes176.  Some subsets of PAFs in the diseased vessel may be derived 
from a hypoxia-induced influx of vascular mesenchymal stem cells, rather 
than from resident adventitial fibroblasts71. 
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Previous work in the Scottish Pulmonary Vascular Unit (SPVU) laboratory150, 155, 
171, 177-181
 has characterised the effects of acute and chronic hypoxia on MAPK 
phosphorylation and proliferation of PAFs.  Notable findings are:-  
• Bovine, rat and human PAFs (from normal subjects) proliferate excessively 
when exposed to acute hypoxia. 
• PAFs from chronic hypoxic rats are constitutively hyperproliferative: they 
demonstrate increased proliferation in comparison to PAFs from normal 
animals, even when cultured and passaged in normoxia. 
• Acute hypoxic proliferation in PAFs is associated with a biphasic increase (at 4 
and 16 hours) in phosphorylation of the α and γ isoforms of p38 mitogen-
activated protein kinase.  p38 MAPK is constitutively phosphorylated 
(abnormally) in PAFs from chronic hypoxic rats. 
• ERK is always, and JNK may be, phosphorylated (dependant on species 
studied) in hypoxic PAFs, but as hypoxic proliferation is not affected by 
ERK or JNK inhibition these do not seem important in this hypoxia-induced 
proliferative signalling pathway. 
• p38 MAPK inhibition completely and selectively blocks acute hypoxic 
proliferation and reverses the hyperproliferative phenotype of PAFs from 
chronic hypoxic rats.   
• No changes are seen in proliferation or p38 MAPK phosphorylation in 
systemic artery fibroblasts in acute hypoxia or when derived from 
chronically hypoxic animals: the p38 MAPK pathway would seem to be a 
mechanism responsible for the circulation specific response to hypoxia. 
• p38 MAPK phosphorylation was found to be partially responsible for HIF-1α 
stabilisation in acutely hypoxic rat and human PAFs. 
 
There is some data in the literature which contradicts these findings.  In particular, 
Stenmark’s group typically report that PAF proliferation is dependant on ERK 
phosphorylation, rather than p38 MAPK169.  This may be a function of different cells 
studied by this group (eg derived from neonatal calves) or study of the cells at 
different time points (eg p38 MAPK phosphorylation is only present at 2 time peaks 
and is absent at other times during a 24 hour acute hypoxic period).  The 
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reproducibility of the SPVU lab findings throughout publications is notable and 
similar findings (p38 MAPK dependant hypoxic proliferation of fibroblasts) have 
been reported by others172.  The experiments subsequently conducted in this thesis, 
however, sought to examine this controversy again. 
 
Based on the SPVU’s previous experimental results, p38 MAPK inhibition would 
seem an attractive therapeutic strategy, potentially achieving a circulation specific 
inhibitory effect on one of the fundamental cellular processes in chronic hypoxic 
pulmonary hypertension.  This possibility is supported by the positive effects 
(attenuation of pulmonary hypertension) seen with p38 MAPK inhibitors in 
experimental pulmonary hypertension182, and also the recognitions that p38 MAPK 
mediates sustained hypoxic pulmonary vasoconstriction183 and pulmonary artery 
endothelial dysfunction in chronic hypoxic rats184 (adding yet further support to the 
concept of cell growth-vasomotor coupling- see chapter 1.6.3) .  A significant 
concern, however, is potential toxicity of p38 MAP kinase inhibitors in humans.  
Although there have been clinical trials (for other diseases) with p38 MAPK 
inhibiting agents, therapeutic development of p38 MAPK inhibitors is at an early 
stage and safety has not been absolutely demonstrated185-188. 
 
The signaling pathway upstream of p38 MAPK in PAFs is incompletely explored but 
an intriguing observation - that mitochondrial ROS activation was necessary for p38 
MAPK phosphorylation - has been made.  This raises the possibility that signaling 
protein(s) under scrutiny in hypoxic pulmonary vasoconstriction eg Rho kinase 
(ROCK) or NADPH oxidase (NOX) may be involved in hypoxic signal transduction 
and p38 MAPK phosphorylation in PAFs.  This seems plausible in the context of 
MAPK in general: MAPKs have been linked to Ras superfamily proteins in 
pulmonary vascular cell proliferation189.  Also specific proteins from this family 
(RhoA,  Rac1 & CDC-42) have been linked to ROCK190 , NOX167 and p38 MAP 
kinase158, 159.   
 
Based on this, we considered the literature further, in order to determine an 
experimental strategy which would allow us to clarify hypoxic cellular signaling 
upstream of p38 MAPK in PAFs.  Also we sought a potential indirect inhibitor of 
this p38 MAPK pathway which might be more immediately therapeutically 
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applicable to our patients than the direct p38 inhibitors currently only in early drug 
development.  Given their known effect on small protein GTPase (ie Ras 
superfamily) dependant signaling191 we considered the possibility that statin drugs 
may fit these requirements, and that they would be a potential tool to interrogate 
hypoxic signaling upstream of p38 MAPK, in PAFs.   
 
1.9 Statins 
1.9.1 Clinical Effects of Statins: Lipid Lowering and Cardiovascular Disease 
Statin drugs are one of the great successes of modern pharmacology.  Based on the 
(now considered relatively simplistic) observations that elevated blood LDL-
cholesterol levels were associated with atherosclerosis and cardiovascular disease 
and that statin drugs could inhibit hepatic cholesterol synthesis and thus reduce blood 
cholesterol, clinical trials to determine the effect of statins on the primary and 
secondary prevention of cardiovascular disease were initiated and reported in the 
mid-1990’s11, 12, 15.  With their beneficial effects and good tolerability (side effects 
are usually minor, the major side effect of rhabdomyolosis is very rare)192 statins 
have revolutionised the management of atherosclerotic disease and are now 
prescribed almost ubiquitously for patients with established cardiovascular disease or 
who are at high risk of developing cardiovascular disease. 
 
Statins are competitive inhibitors of the rate limiting step in cholesterol biosynthesis: 
they inhibit the enzyme 3-hydroxy-3methylglutaryl (HMG) CoA reductase.  
Inhibition of this in hepatocytes leads to a decrease in LDL-cholesterol (ie ‘bad 
cholesterol) synthesis by the liver and also an upregulation in hepatocyte LDL 
receptor expression, with resulting clearance of LDL complexes from the 
bloodstream.  This results in a reduction in total blood cholesterol, LDL-cholesterol 
and an improvement in the blood lipid profile.  Clinical trials have latterly compared 
the differential clinical efficacy of the different statins, clarifying that the different 
pharmacology of these drugs is clinically relevant and that larger doses of statins 
have additional benefits193.  Also, these large clinical trials and the widespread 
experience with statins in routine clinical practice has provided substantial 
reassurance about the safety and tolerability of these drugs, even at higher doses194, 
195
. 
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1.9.2 Clinical Effects of Statins: Pleiotropic Effects and Cardiovascular 
Disease 
Following on from the initial positive clinical reports there have been innumerable 
experimental studies of the effects of statins in cell culture and animal models, in 
order to elucidate their mechanism(s) of action in cardiovascular disease.  From these 
experiments it has been realised that statins, in addition to their lipid lowering 
effects, have diverse other effects on molecular and cellular processes implicated in 
atherosclerosis pathophysiology, which may contribute to their clinical utility196.  In 
the systemic circulation, statins have been shown to increase production of 
endothelial nitric oxide synthase, reduce production of endothelin-1 and reactive 
oxygen species and inhibit smooth muscle cell and macrophage proliferation18.  It is 
observed that, if these effects were duplicated in the pulmonary circulation, statins 
would potentially inhibit pathogenic processes in pulmonary vascular remodeling. 
 
Whether these so called ‘pleiotropic effects’ of statins contributes partly or wholly to 
their clinical benefits, is unclear and much debated197.  It is argued that, as their 
benefit is on a par with their effects on lowering serum LDL-cholesterol, additional 
mechanisms of effect are not present.  The evidence supporting the existence of 
pleiotropic effects is, however, currently considered to be stronger.  In particular, 
hydrophilic statins (which have effects limited to hepatocytes, rather than other cells 
in the body) are generally less clinically potent for a given effect on serum 
cholesterol.  Beneficial effects on systemic vascular reactivity, thrombotic and 
inflammatory profiles are seen early after statin initiation, before effects on serum 
cholesterol are apparent198.   
 
1.9.3 Clinical Effects of Statins: Pleiotropic Effects and Other Diseases 
Experimental observations about the ‘broad spectrum’ positive effect of statins on 
disease-implicated cellular signaling systems and their putative pleiotropic benefits 
in cardiovascular disease led to the exploration of the benefits of statin therapy for 
non-cardiovascular disease199.  Retrospective analysis of database/registry data  and 
substantial laboratory research suggests that statin use  may be beneficial in other 
diseases (notably cancers, sepsis, neurodegenerative diseases, osteoporosis and 
respiratory diseases)200-205.  Based on more specific positive experimental 
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observations, small clinical trials of statin therapy in various ‘non-cardiovascular’ 
diseases have been reported.  Some of these have been negative but in each it is 
acknowledged by the investigators that it is unclear if this is a true negative result or 
a function of the trial design206.  It seems, however, that our knowledge about disease 
mechanisms, statin pharmacology and choice of specific statin and dose needs to be 
refined for any future trials of this nature207.  That this is likely to be worthwhile is 
supported by the two notable positive prospective trials of statin therapy for 
rheumatoid arthritis208 and multiple sclerosis209.   
 
1.9.4 Clinical Pharmacology of Statins 
Mevastatin and lovastatin were first isolated from aspergillus species and their 
effects (potent inhibition of the HMG-CoA reductase enzyme) were characterised in 
the 1970’s.  Concerns about animal toxicity with mevastatin delayed clinical 
application until safety data for lovastatin was established.  Initial trials, however, 
with this drug showed substantial reductions in LDL-cholesterol levels, much greater 
than that seen with agents acting on serum cholesterol via other mechanisms210.  This 
led to the recognition of naturally occurring similar compounds (pravastatin and 
simvastatin) and synthesis of related compounds (including atorvastatin and 
rosuvastatin) and their subsequent clinical validation.  The different statins differ in 
their pharmacology and cholesterol lowering potency.  The lipophilic compound 
atorvastatin is currently considered by most observers to be the benchmark for 
clinical applications.  The chemical structures and pharmacological characteristics of 
the statins in current clinical use are shown in figure 1.7 and table 1.2. 
 
The different pharmacological properties of the different statins provides theoretical 
reasons why they may differ in their clinical utility for non-cardiovascular 
diseases211.  When considering lipid lowering, the target organ for statin action is the 
liver and it would seem to matter little if they act only on hepatocytes (as pravastatin 
and rosuvastatin are thought to do) or whether they are extensively first pass 
metabolised, achieving only very small drug levels in the pulmonary or systemic 
circulations (as simvastatin and atorvastatin do).  This last point is difficult as 
metabolites of simvastastin and atorvastatin (which reach the pulmonary and   
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Figure 1.7: Chemical Structure of HMG-CoA Reductase Inhibitors 
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Parameter Atorvastatin Fluvastatin Simvastatin Lovastatin Pravastatin Rosuvastatin 
Cmax (µM/L) 0.02 – 0.05 1.035 0.024 – 0.082 0.024–0.048 0.1 – 0.123 0.045 
Solubility  Lipophilic Lipophilic Lipophilic Lipophilic Hydrophilic Hydrophilic 
Metabolism CYP3A4 CYP2C9 CYP3A4 CYP3A4 Sulfation CYP2C9 / C19 
 
 
Table 1.2 Clinical Pharmacokinetics of HMG-CoA Reductase Inhibitors 
Relevant properties of statins in clinical use are summarized.  Maximum serum 
concentrations are following a 40mg oral dose of statin.  Lipophilic statins have 
effects on non-hepatic cells whereas hydrophilic statins (ie rosuvastatin and 
pravastatin) typically do not.  Statins metabolised via the cytochrome P (CYP) 3A4 
enzyme have an increased potential for drug interactions.  Adapted from Bellosta et 
al192 
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systemic circulation) may be active, but this is unconfirmed.  Nevertheless, it seems 
relevant to consider that a drug which doesn’t exhibit these problems, and also has 
reduced drug-drug interactions (eg fluvastatin) may be most relevant to consider for 
non-cardiovascular disease studies.   
 
1.9.5 HMG-CoA Reductase: The Cholesterol Biosynthesis Pathway and  
 Mechanisms of Action of Statins 
At a cellular level, statins mediate their effects via competitive inhibition of HMG-
CoA reductase, inhibiting the intracellular synthesis of cholesterol and intermediates 
of the cholesterol pathway.  Importantly, the production of the intermediate 
compounds farnesyl pyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP) 
are also inhibited (figure 1.8).  FPP is the substrate for many important intracellular 
molecules including ubiquinone, dolichol and transfer RNA but cells tend to have a 
stable pool of these molecules present and statin therapy, at clinical doses, has not 
been shown to impact on cellular functions requiring these molecules.  In contrast, 
the membrane GTPases of the Ras superfamily require a ready supply of either FPP 
(Ras family212) or GGPP (RhoA family213) for normal function.  The GTPase 
proteins undergo post-translational modification (prenylation) with addition of a FPP 
or GGPP molecule.  This prenylation step (which may be dynamic) is necessary for 
normal association of these GTPases with the cell membrane (Figure 1.9).  Inhibition 
of the prenylation step - either indirectly via HMG-CoA reductase inhibition, or via 
inhibition of a specific prenyltransferase enzyme (which catalyses the addition of the 
prenyl molecule to the protein) - prevents their function.  The majority of the 
pleiotropic effects of statins have been associated with effects on protein 
prenylation18. 
 
The plasma cell membrane is not a homogenous structure: specific channels and 
receptor proteins are maintained in relative association by substructures in the plasma 
membrane, such as lipid rafts (Figure 1.10).  Inhibition of intracellular cholesterol 
synthesis results in a failure of normal plasma membrane lipid raft maintenance.  
Statins have been shown to disrupt plasma membrane lipid rafts in vitro and in vivo 
and it is speculated that some of their pleiotropic effects may be mediated via this 
mechanism214.
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Figure 1.8 Cholesterol Biosynthesis Pathway  
The conversion of HMG-CoA (derived from Kreb’s cycle intermediates) to cholesterol involves a number of intermediate enzymes, but HMG-CoA reductase (which 
catalyses the conversion of HMG-CoA to mevalonate) is the rate limiting step.  Cholesterol can subsequently be converted on to other steroid molecules but a ready 
intracellular supply is required for the maintenance of cellular lipid raft structures (see Figure 1.10).  Specific cholesterol pathway intermediates - the prenyl 
compounds (aka isoprenoids) farnesyl pyrophosphate and geranylgeranyl pyrophosphate (purple boxes) - are required for diverse cellular functions, including transfer 
RNA and ubiquinone synthesis.  These prenyl compounds are also required for the normal post-translational modification of proteins involved in centromere 
assembly and also GTPase proteins of the Ras and Rho superfamilies, which couple extracellular-intracellular signaling (see Figure 1.9).  Adapted from Liao18.
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Figure 1.9 Prenylated GTPase Signalling Systems 
Normal post-translational modification of Ras and Rho superfamily GTPase proteins (RhoA shown here as an example) involves the addition of a prenyl moiety, 
either farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate (GGPP), depending on the specific GTPase involved.  Specific transferase enzymes catalyse the 
addition of FPP or GGPP to the protein.   
 
The molecular structure of the prenyl compounds (see figure 1.8) involves a long lipophilic portion and it is thought that the attachment of this, to the protein, 
facilitates association with the inner aspect of the plasma membrane, where GTPases couple signalings from extracellular receptors via guanine exchange factors 
(GEF).  Removal of GDP and attachment of GTP by the GEF activates the GTPase protein causing downstream phosphorylation and activation of target proteins (eg 
Rho Kinase).  Constitutive activation is prevented by the rapid intrinsic phosphodiesterase activity of the GTPase, whereby GTP is rapidly broken back down to GDP.  
Prenylation of GTPase proteins appears to be a high-turnover protein system and reduction in supply of prenyl compounds, or inhibition of prenyltransferase enzymes 
rapidly disrupts the normal function of GTPase dependant signaling systems, by blocking their normal association with the plasma membrane. 
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Figure 1.10 Cell Membrane Lipid Rafts 
Plasma membrane lipid raft structures and associated signaling pathways (the EGF-
Ras-Raf pathway is shown as an example).  Cell membrane cholesterol, in 
conjunction with structural proteins such as Caveolin-1, localises in islands or 
invaginations (caveolae) in the plasma membrane.  A ready supply of intracellular 
cholesterol seems required for the normal maintenance of these structures.  These 
islands facilitate the normal association of cell membrane receptors / intracellular 
signaling proteins and, if disrupted, the associated signaling systems may be 
disconnected. 
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Lastly, simvastatin and lovastatin have been shown to bind directly and inhibit the 
integrin LFA-1 (a lymphocyte adhesion/activation molecule), independent of their 
effects on HMG-CoA reductase215.  This property is not shared by all statins and this 
emphasises that a need exists to ensure that any positive experimental observations 
realised with an individual statin need to be fully explored with other statins and the 
mechanism of action interrogated, before clinical application. 
 
Given the potential effects of statins on cell signaling systems (ie inhibition of 
protein prenylation and disruption of cell membrane lipid rafts), if statins are shown 
to have an effect on a cellular process (eg growth factor-induced proliferation) the 
mechanism of action of the statin can be deduced.  If a subsequent, complementary 
experiment is conducted and a specific compound from the cholesterol pathway is 
added along with the inhibitory dose of the statin the experimental results achieved 
will allow conclusion about which ‘arm’ of the cholesterol pathway is implicated in 
the cell signaling system under consideration.   Previous investigators have used this 
approach to determine the mechanism of action of statin on a specific cellular 
process216: we expanded on the experiments in this report to design the experimental 
protocol used in Chapter 4 of this thesis. 
 
1.9.6 Statins in Experimental Models of Pulmonary Hypertension 
Statins demonstrate notable antiproliferative effects on smooth muscle cells217, 
including pulmonary artery smooth muscle cells218, in vitro.  It was also observed 
that all of the noted pleiotropic effects of statins in the systemic circulation (eg 
increase in eNOS activity, reduction in ET-1 synthesis219) would be potentially 
beneficial in PH.  Based on this, investigators studied the effects of simvastatin on 
the chronic hypoxic rat model.  Simvastatin given intraperitonealy or orally at a dose 
of 80mg/kg/day before or subsequent to 2 weeks of chronic hypoxia resulted in 
normalization of pulmonary artery pressures and reductions in medial hypertrophy, 
right ventricular hypertrophy and secondary polycythaemia.  These effects were 
negated by co-administration of mevalonate (implicating an HMG-CoA reductase 
dependant mode of action of the statin) and were associated with reductions in 
ROCK activity (which may have been via a direct or indirect effect of the statin)4, 220.  
Similar results were reported - prevention and reversal of pulmonary vascular 
remodeling, pulmonary hypertension and compensatory right ventricular hypertrophy 
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– along with improved animal survival, in the monocrotaline rat model5, 6   
Subsequent to this, these effects have been confirmed in other PH models8, and 
extended to other statins221.  There has, however, been some conflicting data.  Some 
of this may relate to problems with preparation of the statin drug9 (verbal 
communication from authors).  The negative results of McMurtry et al with 
simvastatin and atorvastatin in the monocrotaline-PAH model are however, not 
explained, in comparison to the many other positive reports222.  The conclusion of the 
authors and specific correspondence is that further pre-clinical study of statins for 
pulmonary hypertension is required, a statement which supports the experimental 
work of this thesis.   
 
When considering statin benefits and potential mechanisms of action in pulmonary 
vascular remodeling, other notable experimental findings include the recognition that 
simvastatin can inhibit growth factor release and proliferation of lung fibroblasts223, 
and that lovastatin can stimulate release of BMP-2 (which is an agonist for the 
BMPR-2 receptor, which has a primary role in the pathogenesis of familial PAH) 
from vascular smooth muscle cells224.  Mevastatin has been shown to inhibit serum-
induced rat PASMC proliferation218 and atorvastatin inhibits serotonin-induced MAP 
kinase nuclear translocation and proliferation of bovine PASMCs225.  Statins have 
also recently been shown to indirectly increase the activity of the nuclear peroxisome 
proliferators activated receptor γ (PPARγ)226.  There is an evolving body of research 
relating insulin resistance (and consequent PPAR dysfunction) to PAH 
pathogenesis227, 228.  PPARy is downregulated in human and experimental PAH and 
PPARy agonists are beneficial in animal models229, 230.  It can be speculated that 
interactions with PPAR may partly explain statin’s mechanism of action in PH 
animal models and, more importantly, that statin’s positive effects on PPARγ may be 
clinically useful in PAH.  One notable problem, however, with the experimental 
approaches in the above cited papers is the dose of statin used in the cell culture.  
This is typically in the range of 10-80µM of statin, which is many orders above the 
circulating dose of statin achieved after standard oral dosage (Cmax ranging from 
0.082-1µM, see table 1.2).  Accordingly, the relevance of any of these experimental 
studies to clinical application has to be questioned, and it is again considered by us 
that further experimental work, as we propose for this thesis, is required. 
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Whilst positive results have been reported in a small, observational case series of 
simvastatin treatment of PAH patients231, it is our group’s view that the currently 
running clinical trials of statin therapy for PAH (1 using simvastatin and 1 
atorvastatin) are problematic.  Firstly, there are important considerations in relation 
to statin choice for clinical use and dosage.  For example, the CH rat experiments 
used 80mg/kg/day of simvastatin, whereas 80mg total is the current maximum dose 
of simvastatin used in humans.  The problems with statin dosing in the reported cell 
culture experiments have been discussed in the previous paragraph.  Drug 
interactions with currently used PAH therapies (warfarin, bosetan, sildenafil) are 
notable for both atorvastatin and simvastatin and it is not clear how these – eg 
simvastatin concentrations will typically be halved in patients taking bosentan -   will 
be controlled for in these clinical trial protocols. 
 
In conclusion, whilst there exists promising experimental data for statins in relation 
to pulmonary hypertension, a number of questions need resolved if we are to judge 
how best to exploit them in clinical practice.  Based on the available knowledge 
about the effects of statins, and the cell signaling processes (ie p38 MAPK 
phosphorylation) involved in hypoxia-induced PAF proliferation it seemed plausible 
that statins would have an inhibitory effect on this.  If an inhibitory effect were 
identitifed, it would allow further interrogation of the hypoxic-proliferative cell 
signaling pathway in these cells (in particular to determine if prenylated protein or 
membrane lipid rafts were involved).  Also, our established cellular models would 
potentially allow experimental comparison of different statins, assessment of dose 
responses and comparison with other established pulmonary hypertension 
therapeutics.  Given these conclusions, the experiments which form this body of 
work were conceived and undertaken.   
 
1.10 Hypothesis 
Review of the literature provided the following key points:- 
• Hypoxia induces proliferation of PAFs and this is, either directly, or via 
interaction with other cells (eg PASMCs) an important aspect of hypoxic 
pulmonary vascular remodelling.  Further study of the cellular and molecular 
mechanisms involved in this should provide important insights into the 
pathogenesis of chronic hypoxic pulmonary hypertension. 
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• Hypoxia-induced p38 MAPK phosphorylation in PAFs is a circulation and 
stimulus selective proliferative signaling mechanism.  Consideration of 
signaling mechanisms upstream of MAPKs in other cell types and of hypoxic 
signaling in other contexts strongly suggests a role for Rho family GTPases.  
As direct inhibitors of p38 MAPK are not yet clinically available, inhibitors 
of upstream pathways may have important therapeutic potential. 
• Statin drugs have promising effects on cellular and animal models of 
pulmonary hypertension but the pre-clinical knowledge is incomplete.  As 
statins are now known to inhibit chronic hypoxic pulmonary vascular 
remodeling and have well established inhibitory effects on cell signaling 
processes including prenylated Rho family GTPases, it is plausible that they 
may have inhibitory effects on hypoxia-induced p38 MAPK phosphorylation 
and proliferation in PAFs. 
• If an effect of statins on hypoxic PAFs were identified, further elaboration on 
this should provide answers to key questions about hypoxic signaling in these 
cells, and about the potential clinical utility of statins in hypoxic pulmonary 
hypertension.   
• Whether the cellular effects of statins complement, duplicate or contradict the 
effects of established pulmonary hypertension therapeutics is unknown, and 
this cannot be adequately addressed in the available animal models.  
Experimental cell models of pathogenic processes in pulmonary hypertension 
provide an opportunity to compare different potential PH therapies.   
 
The hypothesis was that statins would inhibit hypoxia-induced PAF proliferation and 
that exploration of this would allow interrogation of hypoxic cell signaling in PAFs 
and provide useful insights into the therapeutic potential of statin therapy for human 
pulmonary hypertension. 
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1.11 Aims 
The aims of this thesis are:- 
• To establish competency with a cell model of fibroblast proliferation in acute 
and chronic hypoxia. 
• To establish the effects of statins on mitogen,  acute hypoxia and chronic 
hypoxia induced proliferation and MAP kinase phosphorylation in pulmonary 
and systemic artery fibroblasts. 
• To exploit the known effects of statins to interrogate hypoxic cell signaling 
upstream of p38 MAP kinase in pulmonary artery fibroblasts. 
• To further explore the potential of statins as a new pulmonary hypertension 
treatment by studying dose responses, comparing different statins and 
differentiating any effects of statins from those of established pulmonary 
hypertension therapeutics. 
 
Cell-cell interactions and release of PASMC mitogens by hypoxic PAFs is likely an 
important factor in chronic hypoxic pulmonary hypertension.  A preliminary 
assessment of this was also proposed by:- 
• Establishing a PAF-PASMC co-culture and conditioned media cell model. 
• Assessing the effects of acute hypoxia on PAF-PASMC interactions / 
PASMC proliferation and establishing whether statins, p38 MAPK inhibitors 
or established PH therapeutics have any effect on these. 
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Chapter 2 
 
 
Materials and Methods 
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2.1 Materials 
All general chemicals were of analar grade and supplied by Sigma (Poole, Dorset 
UK).  All tissue culture plastics were from Greiner Labortechnick Ltd 
(Gloucestershire.UK).  All components of tissue culture medium were purchased 
from Gibco Life Technologies (Paisley, Scotland). Galaxy-R incubators were 
supplied by Wolf Laboratories (York, UK).  [methyl-3H]thymidine was from 
Amersham (Little Chalfont, Bucks).  Mevalonate, squalene, farnesyl pyrophosphate 
(FPP) and geranylgeranyl pyrophosphate (GGPP) were from Sigma (Poole, Dorset 
UK).  Simvastatin, pravastatin, cholesterol pathway intermediates and inhibitors, Rho 
kinase inhibitor (hydroxyfasudil) and Rac1 GEF exchange inhibitor (NSC23766) 
were from Calbiochem (Nottingham, UK).   
 
I am grateful to Professor A Jardine (Glasgow University) for the gift of fluvastatin.  
I am also grateful to Drs G Boutros (Pfizer, UK) for atorvastatin and sildenafil, J Jepf 
(Actelion, Switzerland) for bosentan and C Sterrit (United Therapeutics, USA) for 
treprostinil diethanolamine.  All of these were donated by the manufacturing 
pharmaceutical company without restriction.   
 
Antibodies used for Western Blot analysis were from New England Biolabs 
(Hertfordshire, UK).  Gel electrophoresis equipment was purchased from Bio-Rad 
Laboratories (Herts, UK).  Immobilon-P transfer membrane was from Millipore 
(Massachusets, USA).  ECL Western blotting detection reagent was from Amersham 
(Buckinghamshire, UK). 
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2.2 Animal models 
2.2.1 Rat model 
Cells derived from the pulmonary artery and aorta of adult Sprague-Dawley rats 
from the “In House” breeding stock of the University of Glasgow’s Central Animal 
Facility were used. Thirty to thirty-three day old rats were maintained in normoxic 
conditions on a 12 hour (h) light/dark cycle and allowed free access to standard diet 
and water. 
 
2.2.2 Chronic hypoxic rat model 
The chronic hypoxic rat model was established and maintained in the laboratory of 
Professor R Wadsworth (University of Strathclyde). 
 
2.2.2.1 Chamber design 
The chamber is designed to hold two standard rat cages, with up to four rats in each 
cage. The structure of the chamber is made from transparent high resistance 
Plexiglas. Air is continually removed from the chamber by the pump. Air constantly 
flows through the chamber at 45L/minute, ensuring that moisture and CO2 do not 
build up. Temperatures are similar both inside and outside of the chamber. 
 
2.2.2.2 Maintenance of animals 
The chamber was housed in a specially designed environmental room which 
maintains temperature at approximately 21oC, humidity at 55%, gives 20 changes of 
filtered air per hour and maintains a 12h on 12h off light cycle. Animals used in the 
experiments were obtained from credited commercial suppliers (Harlan UK Ltd, 
Nottingham). The Wistar rats supplied were male specific, pathogen-free and ordered 
in at age 28-30 days (approximately 60g weight). Animals were allowed to 
acclimatise within the environmental chamber for five days before being established 
in chronic hypoxia. 
 
2.2.2.3 Maintenance of rats in hypobaric hypoxia 
The chamber door was removed and the rat cage placed in the chamber with the food 
and water dispensers at the rear, thus allowing observation of the rats. The chamber 
door was replaced and the pump switched on. The chamber was taken down to the 
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desired pressure (55mbar – 418mmHg) in small steps by slowly closing the inlet 
valve and observing the pressure reading on the gauge. Once the stable experimental 
pressure was reached, rats were checked every 15min for the following hour to 
ensure that the pressure remained stable and the animals were not in distress. The 
chamber could then be left to run for the experimental time required. Checks were 
made 5 times a day to ensure that pressure readings were not fluctuating beyond 
desired levels, temperature inside and outside the chamber remained between 20 and 
23oC, animals were not showing signs of distress and that the pump was in good 
operating condition.  When the animals required fresh food and water, usually every 
three days, the chamber was taken down to atmospheric pressure over 2h by opening 
the inlet valve. Once atmospheric pressure was reached, the pump was switched off 
and allowed to cool for half an hour while the rat cages were cleaned and animals 
given fresh food and water. Following this, the animals were placed back in the 
chamber, the pump switched on and the chamber taken back to 55mbar over a period 
of two hours. After 14 days in the chamber, the rats were removed and sacrificed. 
 
2.2.3 Bovine model 
Cells derived from bovine pulmonary and mesenteric arteries were used. Tissue was 
obtained fresh on the day of experimentation from a local abattoir (Sandyford, 
Paisley). Lungs and small intestine/mesentery were removed from healthy, freshly 
slaughtered cattle and transported to the laboratory in a container filled with chilled 
Krebs-Henseleit Solution (NaCl 118mM, NaHCO3 25mM, KCl 4.7mM, KH2PO4 
1.2mM, MgSO4 1.2mM, CaCl2 2.5mM, and Glucose 11mM).  
 
2.3 Primary cell culture 
Fibroblasts and smooth muscle cells used throughout these studies were obtained 
from primary culture by explant using tissues derived either from bovine or rat.  The 
explant techniques and cell lines have been established in the Scottish Pulmonary 
Vascular Unit laboratory for many years.  That the techniques achieve pure fibroblast 
and smooth muscle cell lines has been previously clarified by staining for α-actin150.   
 
To prevent fungal and bacterial contamination of cell lines, all steps such as making 
up solutions, changing media or preparing experimental reagents were conducted 
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under sterile conditions, within a clean Microflow laminar flow hood (model number 
M25121/1) (Figure 2.1). The flow hood was dismantled and cleaned regularly and 
before use each day was sprayed liberally with 70% (v/v) ethanol. Anything taken 
inside the flow hood (i.e. pipettes and reagent bottles) was also sprayed with ethanol 
and sterile gloves were worn throughout.  Non-sterile consumables and reagents 
were sterilised using a Prestige Medical “Classic 210” autoclave or sterile-filtered 
(0.2µM pore filter). 
 
2.3.1 Primary adventitial fibroblast culture 
Lobar pulmonary artery was dissected free from the lung of either a freshly dissected 
cow or rat (Figure 2.2). A section of artery located towards the apex (Figure 2.3) of 
the lobe was cut longitudinally and opened into a flat sheet (Figure 2.4). Pulmonary 
artery fibroblasts were prepared using the technique of Freshney232, with some 
modifications178. Muscular tissue and endothelial cell layers were removed by gentle 
abrasion of the vessel using a sterile razor blade (Figure 2.5). The remaining tissue 
(adventitia) was then dissected into 5mm2 portions and approximately 25 portions of 
this size were evenly distributed over the base of a 25cm2 culture flask containing 
2ml of Dulbeccos modification of Eagles medium (DMEM) with 20% fetal calf 
serum (FCS), supplemented with penicillin/streptomycin (400iu/ml and 400µg/ml) 
and amphotericin B (5µg/ml) (Figure 2.6). The explants were incubated in a 
humidified atmosphere of 5% CO2 in air at 37ºC.  Within a few days cells were 
observed growing out from the tissue fragments.  Once a monolayer of cells had 
partially covered the flask (Figure 2.7), cells were lifted from the flask by 
trypsinisation as described in Chapter 2.3.3.  Tissue fragments were removed by 
aspiration. 
 
In the bovine and rat model the main branch of the pulmonary artery was used to 
acquire pulmonary artery fibroblasts. To study fibroblasts from the systemic 
circulation, the mesenteric artery was dissected from the cow and the aorta dissected 
from the rat with primary cell culture as for the pulmonary artery fibroblasts.  
 80
 
 
Figure 2.1 Microflow Laminar Flow Hood 
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Figure 2.2 Location of Pulmonary Artery in Bovine Lung 
Pulmonary Artery 
Main Bronchus 
5cm 
 82
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Longitudinally Dissected Pulmonary Artery in Bovine Lung 
Dissected Main 
Pulmonary Artery 
2.5cm 
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Figure 2.4 Cleaned and Dissected Pulmonary Artery 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Removal of the Intimal and Medial Layers 
Pulmonary  
artery  
Endothelium  scraping 
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Figure 2.6 Explants in 25cm3 Culture Flasks 
 
 
 
Figure 2.7 Pulmonary Artery Fibroblasts Growing From Explants
25cm2 culture flask 
Explant 
 2mm 
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2.3.2 Primary vascular smooth muscle cell culture 
Smooth muscle cells were prepared from bovine pulmonary arteries, using a 
modified explant technique.  Other than the vessel preparation step (when intimal 
and adventitial layers were removed by gentle abrasion, leaving the medial layer) the 
technique was identical to that used to obtain adventitial fibroblasts (Chapter 2.3.1). 
 
2.3.3 Routine cell maintenance 
Cells were grown routinely in 75cm3 culture flasks in Dulbecco’s modification of 
Eagle’s medium (DMEM), supplemented with penicillin (200 units/ml), 
streptomycin (200 ug/ml), L-glutamine (27 mg/ml) and 10% foetal calf serum (FCS). 
The cultures were kept in a humidified atmosphere of 5% CO2 in air at 37oC. Culture 
medium was changed every 2 days and cells were passaged just prior to confluency.  
 
For cell passage, culture medium was removed and 2ml of trypsin solution (0.05% 
trypsin / EDTA 0.02%) was added to the layer of cells and then aspirated. A further 
2ml of trypsin solution was then added and left on the surface of the cells for 
approximately 10s before aspiration. The cells were then incubated at 37oC and 
observed at 2 minute intervals using a light microscope (Olympus CK2) until they 
were seen to have partially dislodged from the flask.  Gentle tapping of the dish was 
used to completely dislodge the cells and 10ml of DMEM containing 10% FCS was 
then added to the flask to re-suspend them.   A portion of this cell suspension (1ml) 
was then aliquoted into new flasks containing another 9mls of fresh medium.  At this 
stage cells could be also be aliquoted into 6, 12 or 24 well plates, as required for 
experimentation. Cells were used for experimentation between passage 3-10. 
 
2.3.4 Cell freezing / thawing 
Confluent cells at passage 2 or 3 were trypsinised as above, resuspended in 10ml of 
10% FCS culture medium and centrifuged at 1000g for 10 minutes.  Medium was 
removed and the cell pellet was resuspended in 1ml of cryopreservation medium 
(DMEM containing 10% FCS and 10% dimethyl sulphoxide).  This was transferred 
to a 2ml cryotubes and cooled for 1 hour each at +4°C and -20°C, then at -80°C 
overnight.  Cryotubes were then maintained in the liquid phase of liquid nitrogen. 
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When required, frozen cells were removed from liquid nitrogen and thawed rapidly 
in a water bath at 37C.  Cryotubes were swabbed with 70% v/v ethanol and the cell 
suspension was transferred to a 75cm2 culture flask containing 9ml of culture 
medium with 10% FCS.  After 4-6 hours the cells were seen to have attached to the 
flask and the medium was replaced with 10ml of fresh 10% FCS culture medium. 
 
2.4 Acute hypoxia 
Maintenance of cells in a nitrogen-supplemented, humidified, temperature-controlled 
incubator (Galaxy R, Wolf Laboratories, York, UK) allowed control of internal 
oxygen levels at 0-21%, whilst CO2 level was maintained at 5% (Figure 2.8).  Due to 
the large volume of nitrogen required to sustain a suitable degree of hypoxia, 
nitrogen cylinders were linked using a Pneuchange automatic gas cylinder change 
over unit (NTC, Woulton, Liverpool, UK) which activated a fresh supply of nitrogen 
as required.   
 
Cells were routinely maintained for the acute hypoxic phase of experiments in an 
atmosphere of 5% O2 and 5%CO2.  Previous assessment of the tissue culture 
supernatant with oxygen and pH probes has confirmed that these conditions PO2 of 
35mmHg for the hypoxic conditions, with pH stable over the 24 hour experimental 
period233.   Experimental controls were achieved with the use of a second incubator 
which could simultaneously maintain control cells in normoxic experimental 
conditions.   
 
2.5 Preparation of statin drugs and other reagents 
Statins, cholesterol pathway intermediates and inhibitors were prepared in stock 
solution (0.04M and/or 200µM, depending on experimental concentrations required) 
with appropriate diluent, as summarised in table 2.1.  All reagents had manufacturer 
or supplier data indicating stability, in appropriate storage, for >2 months.   
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Figure 2.8 Galaxy-R Hypoxic Chamber: Humidity, O2 and CO2 Regulated
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Reagent Supplied as 
Molecular 
Weight 
Diluent Storage 
Atorvastatin Solid powder 1209.42 DMSO 
-20°C 
Bosentan Solid powder 573.6 dH2O @ 50°C N/A* 
Fluvastatin Solid powder 433.46 DMSO 
-20°C 
FPP 200µg in 200µL methanol 433.4 Ethanol 
-20°C 
FTAse inhibitor I Solid powder 470.7 DMSO 
-20°C 
GGPP 200µg in 200µL methanol 450.44 Ethanol 
-20°C 
GGTI-2133 Solid powder 456.5 DMSO 
-20°C 
Hydroxyfasudil 10mM solution in water 343.8 SFM 
-20°C** 
Methyl-β-cyclodextrin Solid powder 1320 SFM +4°C 
Mevalonate Solid powder 130.15 SFM 
-20°C 
NSC-23766 Dry powder 531 SFM 
-20°C 
PDGF-BB Lyophilised Powder 28-31kDa 
HCL 
solution*** -20°C 
Pravastatin Solid powder 446.5 SFM 
-20°C 
SB 203580 Solid powder 377.4 DMSO 
-20°C** 
Sildenafil Solid powder 666.7 Ethanol +4°C 
Simvastatin Solid powder 458.6 DMSO -20°C 
Squalene Liquid (98%) 410.73 DMSO 
-20°C 
Treprostinil 
diethanolamine 
Solid powder 495.66 SFM +4°C 
Zaragozic acid Solid powder 756.7 SFM 
-20°C 
 
Table 2.1 Preparation and Storage of Reagent Stock Solutions 
SFM: Serum free medium DMSO: Dimethyl sulphoxide   
PDGF: Platelet derived growth factor 
*Bosentan is unstable (precipitates) in solution for >24 hours 
**Light sensitive 
***HCL solution for preparing PDGF-BB comprises 0.4M hydrochloric acid with 
1mg/ml bovine serum albumin 
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2.6 Determination of cell proliferation and viability 
2.6.1 [3H] thymidine assay 
Cell proliferation was measured by determining the uptake of [3H]thymidine into 
DNA. 
Cells were seeded at a density of 5x103 cells / well into 24-well plates in 500µl of 
culture medium and grown to 60% confluency.   Cells were then quiesced for 24 
hours by replacing the medium with 500µl serum-free DMEM. Cells were then 
stimulated with appropriate agonists and incubated for 24 hours, either in a normal 
CO2 incubator (5% CO2) or in the hypoxic incubator to obtain an acute hypoxic 
exposure (Chapter 2.4). In the latter case, the O2 content of the atmosphere was 
reduced from 21% to 5% by flooding with N2.  
 
Dilute [methyl-3H]thymidine solution was prepared by adding 10uL of 
[methyl3H]thymidine (1.0mCi/ml)  to 2.5ml serum-free DMEM.  For the final 4h of 
agonist stimulation, 25uL of dilute [methyl-3H]thymidine solution was added to each 
well of the 24 well plate, achieving a radiation concentration of 0.1µCi/well.   
 
At 24 hours, the reaction was stopped by washing the cells twice in ice-cold 
phosphate buffered saline (PBS, 500µl/well). Proteins were precipitated by washing 
three times with 500µl/well 5% trichloroacetic acid (TCA) and lipid fractions were 
solubilised by washing twice with 100% ethanol (500µl/well) for 30mins. The acid / 
alcohol insoluble material was dissolved in 0.3M sodium hydroxide (500µl/well) for 
30mins. The contents of each well were transferred to 1ml eppendorf tubes, to each 
of which was added 0.9mls of Ecoscint A (Ecoscint, Atlanta, Georgia, USA) 
scintillation fluid. Vials were vortexed for 1min and allowed to settle in darkness 
overnight.  Radioactivity was measured by scintillation counting using a Wallac 
1409 scintillation counter.  Results are expressed as disintegrations per minute 
(DPM). 
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2.6.2 Cell counting and trypan blue staining 
Cells were seeded into 12 well plates, grown to 60% confluency, quiesced and then 
stimulated in normoxic or hypoxic conditions with appropriate agonists, as above.  
At the end of the experiment cells were trypsinised with 2 brief exposures to 400µL 
of trypsin solution (0.05% trypsin / EDTA 0.02%) and, once detached, resuspended 
in 1ml PBS.  100µL of cell suspension was mixed with 100µL 0.4% w/v trypan blue 
solution.  20µL of the resulting solution was transferred to a Neubauer 
haemocytometer.  Total cells and non-viable cells (blue-stained) lying in 4 corner 
squares of 1 chamber in the haemocytometer were counted under low power with the 
light microscope.  Total number of cells in the original solution was then calculated 
as standard ie:- 
 
 
  
2.7 Co-culture and conditioned media 
2.7.1 Preparation of pulmonary artery fibroblast conditioned media 
PAFs were grown to approximately 60% confluency in 24-well plates and quiesced 
in serum free medium for 24 hours.  PAF conditioned media was then prepared by 
removing the current medium and adding 0.5ml of fresh serum-free media to each 
well. Drugs or other investigational compounds were added, as required for the 
specific experiment.   
 
Plates were then maintained for 24 hours in either normoxic (21%) or hypoxic (5%) 
conditions, as required.  This process provided conditioned media containing any 
growth promoting or inhibiting mediators secreted from PAFs.  The differential use 
of untreated / drug-treated and normoxic / hypoxic PAFs allows a comparison of the 
effects of these condtions on PAF mediator release. 
 
2.7.2 Application of conditioned media to pulmonary artery smooth muscle  
 cells 
PASMCs were separately grown to approximately 60% confluency in 24 well plates 
and serum starved for 24 hours.  This 24 hour quiescence period coincided with the 
24 hours when PAF media was being conditioned. 
Number of cells in original solution= X 10000  2 X 
Total number of cells counted in 4 squares 
4 
 91
 
At the end of the 24 hour media conditioning / PASMC quiescing period, serum-free 
media was removed from the PASMCs and replaced by the 0.5ml of experimental 
PAF conditioned media.  Experimental mediators were added, as required, and plates 
were maintained for 24 hours in normoxic (21%) or hypoxic (5%) conditions.  [3H] 
thymidine assay was then performed, as before (Chapter 2.6.1) to determine PASMC 
proliferation. 
 
2.7.3 Co-culture of PAFs and PASMCs 
The use of 24 well plate co-culture cell inserts allows 2 different cell types to be 
maintained in direct contact – sharing the same media – for an experimental period.  
The base of the cell inserts comprises a semi-permeable membrane (Figure 2.9).  We 
selected inserts with a membrane pore size of 1µM, which allows free diffusion of 
macromolecules within the shared cell culture media, but not cell migration.  For 
these experiments we were interested in the effects of PAFs on PASMC 
proliferation.  Accordingly, we grew the PASMCs on the 24 well plate, and the PAFs 
on the cell inserts (Figure 2.10).   
 
PAFs were grown to 90% confluency on individual 24 well plate cell inserts; for this 
initial phase the cell inserts were maintained in the wells of a ‘blank’ 24 well plate, 
containing standard 10% supplemented DMEM.  PASMCs were grown 
simultaneously to 60% confluency, on separate 24 well plates.  Both cells types were 
then quiesced for 24-48 hours (variable period to ‘synchronise’ the two cell types at 
appropriate confluency) in serum free media.   
 
Cell inserts containing PAFs were then placed within the wells of the 24 well plate 
containing the PASMCs.  0.5ml of serum free media +/- required experimental 
mediators were applied to the wells of the 24 well plates, containing the PASMC and 
the PAFs (on the cell inserts).  These co-culture experimental plates were then 
maintained for 24 hours in normoxic (21%) or hypoxic (5%) conditions.  The PAFs 
on cell inserts were discarded and PASMC proliferation was determined (chapter 
2.6).   
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2.8 Detection and analysis of proteins 
2.8.1 Preparation of samples for protein analysis 
Cells were seeded at a density of 15x103 cells/well into 6-well plates, grown to 90% 
confluency and then growth-arrested in serum-free DMEM for a period of 24 hours.  
Cells were then stimulated with agonist and maintained in normoxic or hypoxic 
conditions for an appropriate time period (determined by protein in question).  
Culture plates were thereafter maintained on ice.  Culture medium was removed and 
the cell monolayer was washed x2 with 2ml of ice-cold PBS.  The cells were then 
lysed with 50µl radioimmunoprecipitation assay buffer (RIPA buffer; comprises 
Tris-HCl 50mM pH 7.4, NP-40 1%, C24H39O4Na 0.25%, NaCl 150mM, EGTA 
1mM, PMSF 1mM, Na3VO4 1mM, NaF 1mM, CLAP 1/1000, pH 7.4).  Cells were 
mechanically disrupted using a cell scraper.  The contents of each well were 
transferred to 1ml eppendorf tubes on ice and stored at -80°C.   
 
2.8.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples were analysed using SDS-PAGE using precast 10% SDS-PAGE 
gels.   
 
Protein samples to be analysed by SDS-PAGE were first diluted to 50µg in SDS 
Sample Buffer, (93mM Tris-HCl pH 6.8 and 20mM dithiothreitol (DTT), 1mM 
sodium-EDTA, 10% glycerol (v/v), 2% SDS (w/v) and 0.002% bromophenol blue 
(w/v)).  Samples were boiled for 5 min to denature proteins and disrupt disulphide 
bonds. The required volume was loaded into the individual wells of the stacking gel 
using loading tips. Pre-stained SDS protein molecular weight markers (Biorad) of 
known size were also placed in one lane of the gel. After loading samples, 
polyacrylamide gels were assembled into a Bio-Rad electrophoresis unit. The two 
chambers of the unit were filled with Electrophoresis Buffer and the polyacrylamide 
gel subjected to electrophoresis for approximately 1 hour at a constant current of 
240mA. 
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Figure 2.9 24 Well Plate Co-culture Cell Insert.   
 
 
Figure 2.10 Co-culture Cell Insert in a 24 Well Plate. 
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The molecular weight of proteins was estimated by comparing their mobility to that 
of pre-stained SDS-PAGE standards. The standards used were myosin (205kDa), β-
galactosidase (120kDa), bovine serum albumin (87kDa) and ovalbumin (48kDa). 
 
2.8.3 Western blot analysis 
2.8.3.1 Transfer to nitrocellulose membrane 
Following completion of electrophoresis, polyacrylamide gels were removed from 
the apparatus and washed once in Blotting Buffer (20% methanol (v/v), 25mM Tris-
base, 192mM glycine). Proteins were transferred from the polyacrylamide gel to the 
nitrocellulose by assembling a transfer cassette with the nitrocellulose 
juxtapositioned between the polyacrylamide gel and the cathode. By this method 
negatively charged proteins were transferred to nitrocellulose for 1.5-2h at a constant 
1 amp current. 
 
2.8.3.2 Immunoblotting 
The nitrocellulose blots were washed in PBS/T (PBS containing 0.02% Tween-20 
(v/v)) and blocked for non-specific binding for 3h on a rocking platform at room 
temperature in PBS/T supplemented with 10% non-fat milk (Marvel) (w/v). Blots 
were incubated for 1h in PBS/T supplemented with 5% Marvel (w/v) containing a 
1:1000 dilution of primary antibody: either rabbit anti-dual phosphorylated MAPK 
antibody (to assess MAPK activation) or rabbit anti-MAPK antibody (to assess total 
MAPK and ensure equal protein loading).   The blots were rinsed and washed 4 
times over an hour with PBS/T and then incubated for a further 60 mins in PBS/T + 
5% Marvel (w/v) + secondary donkey anti-rabbit IgG antibody conjugated to HRP 
(1:15,000).  The blots were then washed as before. 
 
2.8.3.3 Secondary antibody detection 
Following completion of washing procedures proteins were detected using a method 
of enhanced chemilumenescence (ECL). Blots were incubated in ECL solution 
(Amersham) for 30s and sandwiched between acetate film. Care was taken to ensure 
all air bubbles were removed. Blots were then placed in an X-ray cassette and light 
emission from the horseradish peroxidase enzymatic action on its substrate contained 
 95
within the ECL solution was detected following exposure (1-10mins) of 
nitrocellulose blots to a piece of X-ray film using a KODAK M35-M X-OMAT 
processor. 
 
2.8.3.4 Re-probing nitrocellulose membranes 
In instances where the same membrane was used to probe for different proteins, 
primary and secondary antibodies were stripped from the nitrocellulose by 
incubating in Stripping Buffer (100mM B-mercaptoethanol, 2% SDS and 62.5mM 
Tris-HCl, pH 6.7) for 30 minutes at 50oC with agitation. Blots were then rinsed with 
PBS/T 4x over 40 mins before the immunodetection protocol was repeated. 
 
2.9 Data analysis 
For cell counting and DNA synthesis experiments, data are expressed as mean ± S.D. 
for 4 replicate plates from the same experiment. Experiments were repeated in cells 
from a minimum of 4 different animals. The statistical significance of differences 
between mean values from control and treated groups were determined by Student’s 
t-tests and all graph preparation and data analysis was conducted using GraphPad 
(Prism) software. Two-tailed probability values of less than 0.05 (P<0.05) were 
considered to be significant. 
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Chapter 3 
 
 
Effects of Statins on Rat Pulmonary and Systemic 
Artery Fibroblast Proliferation 
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3.1 Introduction 
As discussed in the general introduction (Chapter 1), regardless of the aetiology, 
pulmonary hypertension is characterised by vascular remodelling affecting the 
intimal, medial and adventitial layers of the pulmonary artery25.  In hypoxic 
pulmonary hypertension, in animals and humans, the earliest changes are seen in the 
adventitial compartment of the pulmonary arteries, with fibroblast proliferation and 
adventitial thickening48.  There is now a substantial body of work characterising 
cellular and molecular changes in pulmonary vascular remodelling.  In particular, the 
available data supports a concept of the pulmonary artery fibroblast (PAF) as a 
“concert leader” of the remodelling in hypoxic pulmonary hypertension3, indicating 
that this may be a valuable target for further research into therapeutic agents which 
may attenuate hypoxic pulmonary hypertension.    
 
Previous work in the SPVU laboratory has characterised aspects of hypoxic PAF 
behaviour.  In particular, PAFs have been shown to proliferate in acute hypoxia178.  
This response is selective for the pulmonary circulation (systemic adventitial 
fibroblasts shown no change in proliferation in hypoxia), is preserved across animal 
species180 and is dependant on the phosphorylation of the stress responsive protein 
p38 MAP kinase150, 155, 171.  Also, proliferative and signalling mechanisms in acute 
hypoxic PAFs have been shown to mirror those in PAFs from chronic hypoxic 
animals177.  Firstly, this body of work provides a basis for further investigation of 
cellular and molecular pathways in hypoxic pulmonary vascular remodelling.  
Secondly, it demonstrates the utility of an acute hypoxic rat PAF model.  In 
particular, the identical proliferative and cell signalling phenotype of acute hypoxic 
PAFs, when compared with either human PAFs and pulmonary hypertensive animal 
PAFs demonstrates the relevance of this cell model, for preliminary experiments 
exploring potential hypoxia-selective antiproliferative agents.  As this cell model is 
robust and readily available it was selected for the initial ‘battery’ of experiments 
with statin drugs, proposed for this thesis. 
 
Observations regarding the demonstrated pleiotropic effects of the HMG-CoA 
reductase inhibitors (statins) led to the suggestion that these drus may be effective in 
pulmonary hypertension.  Various groups have now shown positive effects of statins 
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on experimental pulmonary hypertension, in different animal models, though there 
has been one recent contradictory report (see Chapter 1.10.6 for more details).  Based 
on this, clinical trials of statins for pulmonary arterial hypertension have commenced 
but, as also previously discussed, there is still a substantial gap in the pre-clinical 
knowledge base in relation to statins and pulmonary hypertension.  
 
We considered the possibility of further statin treatment of animals models, in 
particular the chronic hypoxic rat model.  We discounted this as an approach to 
address the aims of this thesis at an early stage.  Firstly, whole animal studies do not 
allow the assessment of the primary molecular mechanism of action of the statin.  
Secondly, dose-ranging and individual statin-comparison experiments would require 
a prohibitive number of animals.  Also, it is not clear how well dosing studies in 
animals translate to human use.   
 
As statins have been shown to have antiproliferative effects on diverse cell types - 
including fibroblasts234 - we suspected that they may have useful anti-proliferative 
effects on PAFs.  When the known effects of statins on cell signalling pathways (see 
chapter 1.10.5) are considered alongside hypoxic signalling pathways (eg RhoA-Rho 
kinase or Rac1-NADPH oxidase) it was considered possible that statins may 
specifically have effects on hypoxic proliferation in PAFs. 
 
If statins were shown to have an effect on acute hypoxia-induced proliferation in rat 
pulmonary artery fibroblasts (RPAFs), this would provide a basis to further explore 
the therapeutic potential of statins, using our established cell models.  Also, the 
known effects of statins on cell signalling could then be exploited to further 
interrogate hypoxic signalling in these cells.  We hypothesised that statins would 
have an inhibitory effect on acute hypoxia-induced proliferation in RPAFs and the 
experiments in this chapter were conceived to clarify this. 
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3.2 Methods 
As outlined in the general methods (Chapter 2) rat pulmonary artery fibroblast 
(RPAF) and rat aortic fibroblast (RAF) cell lines were established from normal adult 
male Sprague-Dawley rats.  Cell lines were characterised (by negative smooth 
muscle α-actin staining) and morphology reviewed at each experimental stage to 
exclude cell transformation or infection.  Proliferation and viability of RPAF and 
RAF cells was determined in experimental conditions - normoxia vs acute hypoxia 
(5%) +/- serum, statin or other mediator - by cell counting, thymidine assay and 
trypan blue staining.  Results are expressed in the figures as mean +/- 1 standard 
deviation.   
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3.3 Results 
3.3.1 Confirmation of the Fibroblast Cell Type 
Initial cultures of individual cell lines were stained at the time of initial passage, after 
explant, for α-smooth muscle actin.  Positively stained cells would indicate smooth 
muscle contamination and this cell line would not be used for experimentation.   
 
Visual assessment of cell morphology undertaken at each passage and daily in cells 
undergoing experimentation confirmed the stability of the cell lines.  Figure 3.1 
shows fibroblasts derived from the pulmonary artery, confluent in a cell culture plate.  
In particular, the shape of the cell provided identification of the cell type.   
Fibroblasts appeared multipolar or bipolar and well spaced when subconfluent but, 
when confluent, typically appeared bipolar and less well spread233. 
 
3.3.2 Effect of Fluvastatin on Serum-induced DNA Synthesis And  
 Proliferation of Rat Adventitial Fibroblasts  
To determine the effects of fluvastatin on serum-induced proliferation of pulmonary 
and systemic adventitial fibroblasts, incremental doses of serum (1, 3 and 5%) and 
fluvastatin (0.1, 0.5, 1, 2.5, 5, 10, 20 and 50µM) were variously added to serum-
starved semi-confluent cells during 24 hour proliferation assay.  [3H] thymidine 
uptake and total cell counts were determined, and cell viability was assessed using 
trypan blue staining.   
 
Figure 3.2 illustrates the effect of fluvastatin on serum-induced DNA synthesis, 
measured by [3H] thymidine uptake, in RPAFs (panel A) and RAFs (panel B).  
Figure 3.3 similarly outlines the effects of fluvastatin on serum-induced proliferation, 
as measured by total cell counts. 
 
Increased DNA synthesis and proliferation of RPAFs and RAFs was seen with 
increasing concentrations of serum.  Fluvastatin at doses ≤1µM had no effect on 
serum-induced proliferation.  Doses of fluvastatin of 10µM or greater completely 
inhibited serum-induced proliferation (p<0.001) with [3H] thymidine uptake and total 
cell numbers similar to serum-starved control cells.  Fluvastatin 5µM had an 
intermediate effect on RPAF and RAF proliferation.   
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Figure 3.1 Confluent Pulmonary Adventitial Fibroblasts 
Fibroblasts from the pulmonary artery were visualised by light microscopy. 
 
 
 
 
 
 
 
 
 
 
  
2.5mm 
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Figure 3.2 Effects of Fluvastatin on Serum-induced [3H] Thymidine Uptake  
  by Adventitial Fibroblast Cells 
Growth arrested rat pulmonary artery fibroblasts (Panel A) and rat aortic fibroblasts 
(Panel B) were stimulated with graded doses of serum and fluvastatin, for 24 hours.  
DNA synthesis, as an index of cell proliferation, was measured by [3H] thymidine 
uptake.  Experiments with other doses of fluvastatin (0.1, 2.5, 20 and 50µM) were 
also undertaken but these are omitted from the graphs for clarity.   Values shown are 
mean +/-SD from 4 replicate experiments on cells from the same animal; 
experiments were repeated on cells from >4 animals and representative graphs are 
shown here.   
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Figure 3.3 Effects of Fluvastatin on Serum-induced Proliferation of  
  Adventitial Fibroblast Cells. 
Growth arrested rat pulmonary artery fibroblasts (Panel A) and rat aortic fibroblasts 
(Panel B) were stimulated with graded doses of serum +/- fluvastatin 1µM (F1) or 
fluvastatin 10µM (F10), for 24 hours.  Cells were stained with trypan blue and 
counted.  Experiments with other doses of fluvastatin (0.1, 2.5, 20 and 50µM) were 
also undertaken but these are omitted from the graphs for clarity.  Values shown are 
mean +/- 1SD from 4 replicate experiments on cells from the same animal; 
experiments were repeated on cells from >4 animals and representative graphs are 
shown here.  (*value significantly greater than control p<0.01). 
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Proliferation responses of pulmonary and systemic adventitial fibroblasts to serum 
were similar.  Also, no significant differences were seen when comparing the effects 
of fluvastastin on serum-induced proliferation of pulmonary vs systemic adventitial 
fibroblasts.   
 
3.3.3 Effects of Fluvastatin on Rat Adventitial Fibroblast Viability 
Cell viability (as assessed by morphology and failure to stain with trypan blue) was 
unaffected by fluvastatin at doses up to and including 10µM: <5% of cells stained 
with trypan blue for all experimental conditions.   
 
Fluvastatin 20 and 50µM were seen to induce cell death by the end of the 24 hour 
experiment with minimal residual cells seen at light microscopy (figure 3.4).  These 
residual cells stained with trypan blue, indicating loss of plasma membrane integrity / 
non-viable cells. 
 
3.3.4 Effect of Fluvastatin on Platelet-Derived Growth Factor-induced  
 Proliferation of Rat Pulmonary Adventitial Fibroblasts 
To determine if the effects of fluvastatin on adventitial fibroblast proliferation were 
mitogen-specific, selected experiments were repeated, using PDGF-BB in place of 
serum.  Given similar results obtained in the preceding experiments with serum in 
both [3H] thymidine uptake vs cell culture and with RPAFs vs RAFs only [3H] 
thymidine uptake in RPAFs was undertaken for this comparison. 
 
PDGF-BB stimulated DNA synthesis in RPAFs, with a dose response seen, as 
previously shown.  As with serum-stimulation, dose of fluvastatin <10µM had no 
effect in DNA synthesis.  10µM fluvastatin reduced DNA synthesis, but less so than 
in the serum stimulation experiments.  As with the serum-stimulated cells, 20µM 
fluvastatin induced cell death, regardless of PDGF-BB concentration. 
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Figure 3.4 Effect of  20µM Fluvastatin on Rat Pulmonary Adventitial  
  Fibroblast Cell Viability  
Rat pulmonary adventitial fibroblasts were visualised by light microscopy, following 
a 24 hour proliferation experiment. Quiescent cells had been maintained in cell 
culture media supplemented with 5% serum and fluvastatin 20µM, in normoxic 
conditions for 24 hours.   
2.5mm 
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Figure 3.5 Effect of Fluvastatin on Platelet-Derived Growth Factor-Induced 
  [3H] Thymidine Uptake by Pulmonary Adventitial Fibroblast  
  Cells. 
Growth arrested rat pulmonary artery fibroblasts were stimulated with graded doses 
of serum for 24 hours +/- fluvastatin 1µM or 10µM.  DNA synthesis, as an index of 
cell proliferation, was measured by [3H] thymidine uptake.  Values shown are mean 
+/- 1SD from 4 replicate experiments on cells from the same animal; experiments 
were repeated on cells from >4 animals and representative graphs are shown here.  
(*value significantly reduced vs control, p<0.01). 
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3.3.5 Effects of Acute Hypoxia and Fluvastatin on Adventitial Fibroblast  
 Proliferation    
The effects of acute hypoxia on RPAF proliferation was confirmed by thymidine 
experiments, with incremental serum concentrations, with [3H] thymidine uptake 
compared in cells which had been maintained in normoxic (21%) and hypoxic (5%) 
conditions for the 24 hour experimental period (Figure 3.6).  As had been previously 
shown, acute hypoxia had no effect on quiescent (control) cells but caused a 
significant increase in cellular DNA synthesis, in the presence of serum.   
 
This effect – increased proliferation in acute hypoxia – was seen across all serum 
concentrations.  The magnitude of the effect, however, appeared less with higher 
serum concentrations as the cells proliferated to the extent that they had become 
confluent in the wells before the end of the 24 hour period.  Contact inhibition results 
and a relative reduction in DNA synthesis at the end of the experiment occurs.  This 
artefact is seen to be most marked with 10% serum where early proliferation is so 
high even in normoxic conditions that the thymidine assay falsely suggests reduced 
proliferation. 
 
Fluvastatin 1µM – a dose shown not to affect mitogen-induced proliferation of 
RPAFs in preceding experiments – completely blocked the acute hypoxia-induced 
increase in [3H] thymidine uptake in RPAFs.  Again, this was seen across the range 
of serum concentrations (Figure 3.6).   
 
The effect of acute hypoxia on DNA synthesis and cell proliferation was found (as 
previously) to be pulmonary-selective: RAFs exhibited no increase in thymidine 
uptake (Figure 3.7) or cell numbers (Figure 3.8) in acute hypoxia.  Also the anti-
proliferative effect of fluvastatin 1µM was confirmed to be circulation and stimulus 
selective.  Acute hypoxia-induced DNA synthesis and proliferation in RPAFs was 
completely inhibited by fluvastatin 1µM.  Serum-induced proliferation in RPAFs and 
all proliferation in RAFs was again unaffected by fluvastatin at this dose.  This is 
compared to the non-selective effect of fluvastatin at doses ≥10µM (significantly 
inhibited serum-induced proliferation in both cell types).   
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Figure 3.6    Effects of Incremental Serum Concentrations, Acute Hypoxia and  
  1µM Fluvastastin on [3H] Thymidine Uptake by Rat Pulmonary  
  Adventitial Fibroblast Cells.  
Growth arrested rat pulmonary artery fibroblasts were stimulated in normoxia (21%) 
or hypoxia (5%, 35mmHg) for 24 hours +/- serum (1%, 3%, 5% or 10%) and 
fluvastatin 1µM.  DNA synthesis, as an index of cell proliferation, was measured by 
[3H] thymidine uptake.  Values shown are mean +/- 1SD from 4 replicate 
experiments on cells from the same animal; experiments were repeated on cells from 
>4 animals and representative graphs are shown here.  (*value significantly greater 
than serum-normoxia, p<0.01). 
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Figure 3.7    Effects of Acute Hypoxia and Fluvastatin on [3H] Thymidine  
  Uptake by Adventitial Fibroblast Cells. 
Growth arrested rat pulmonary artery fibroblasts (Panel A) and rat aortic fibroblasts 
(Panel B) were stimulated in normoxia (21%) or hypoxia (5%, 35mmHg) for 24 
hours +/- 1% serum and fluvastatin 0.1, 1 or 10µM (F0.1, F1 or F10).  DNA 
synthesis, as an index of cell proliferation, was measured by [3H] thymidine uptake.  
Values shown are mean +/- 1SD from 4 replicate experiments on cells from the same 
animal; experiments were repeated on cells from >4 animals and representative 
graphs are shown here.  (* value significantly greater than normoxia-1%serum, 
p<0.05; ** value significantly less than normoxia-1% serum, p<0.05).     
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Figure 3.8    Effects of Acute Hypoxia and Fluvastatin on Proliferation of  
  Adventitial Fibroblast Cells. 
Growth arrested rat pulmonary artery fibroblasts (Panel A) and rat aortic fibroblasts 
(Panel B) were stimulated in normoxia (21%) or hypoxia (5%, 35mmHg) for 24 
hours +/- 1% serum and fluvastatin 0.1, 1 or 10µM (F0.1, F1 or F10).  Cells were 
stained with trypan blue and counted.  Values shown are mean +/- 1SD from 4 
replicate experiments on cells from the same animal; experiments were repeated on 
cells from >4 animals and representative graphs are shown here. (* value 
significantly greater than normoxia-1%serum, p<0.05; ** value significantly less 
than normoxia-1% serum, p<0.05).     
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3.3.6 Comparison of the Anti-Proliferative Potency of Different Statins 
The effects of 3 lipophilic statins (atorvastatin, fluvastatin, simvastastin) and 1 
hydrophilic statin (pravastatin) on serum and hypoxia-induced proliferation of 
RPAFs and RAFs were compared.  As before, serum +/- incremental doses of statin 
was added to quiescent fibroblasts at the start of a 24 hour experiment.  Cells were 
transferred to the normoxic or hypoxic incubator and [3H] thymidine uptake was 
measured.  Rigorous attention was taken to ensure accuracy of the concentration of 
the statin stock solutions and the doses added to the experimental wells.  The number 
of wells for each experimental condition was also doubled for these experiments (to 
8), so that any small differences in potency could be resolved. 
 
No difference in the potency of the lipophilic statins was identified.  In particular, 
hypoxia-induced proliferation of RPAFs was completely and selectively inhibited by 
1µM fluvastatin, simvastatin and atorvastatin (Figure 3.9).  These 3 statins exhibited 
similar anti-proliferative potency across a narrow dose range around this (0.5– 
2.5µM). 
 
The hydrophilic statin pravastatin had no effect on cell viability, serum-induced 
proliferation of RPAFs or RAFs or hypoxia-induced proliferation of RPAFs, at doses 
up to 50µM.   
 
3.3.7 Effects of Established Pulmonary Hypertension Therapeutic Agents on  
 Adventitial Fibroblast Proliferation 
The effects of a prostacyclin analogue (treprostinil diethanolamine, UT15c), a 
phosphodiesterase-5 inhibitor (sildenafil) and an endothelin antagonist (bosentan) on 
serum and acute hypoxia-induced proliferation of RPAFs was determined.  As 
before, graded concentrations of serum and experimental mediators were added to 
quiescent cells and thymidine uptake was measured after 24 hours in either normoxic 
or hypoxic conditions. 
 
50µM of UT15c, sildenafil and bosentan had a non-specific inhibitory effect on 
serum-induced proliferation (Figure 3.10) and also on cell viability as visualised by 
light microscopy. With sildenafil and bosentan 50µM, precipitated material (most 
likely drug) was visualised in the wells at 24 hours. 
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Figure 3.9 Comparison of the Effects of 4 Different Statins on Hypoxia- 
  Induced [3H] Thymidine Uptake by Pulmonary Adventitial  
  Fibroblast Cells.   
The effect of a range of doses of lipophilic statins (fluvastatin, atorvastatin, 
simvastatin) and a hydrophilic statin (pravastatin) on [3H] thymidine uptake in 
quiescent RPAFs, stimulated with 1% serum and 24 hours of hypoxia (5%, 
35mmHg), was determined.  Results are plotted as ratios of measured thymidine 
uptake vs thymidine uptake in control cells (mean of 8 experiments on cells from the 
same animal; respresentative results from experiments on 4 different animals are 
shown).  The mean +/- 1SD [3H] thymidine uptakes of RPAFs stimulated with 1% 
serum in normoxia or hypoxia without statin are shown as shaded areas.  (p<0.05 for 
fluvastatin, simvastatin, atorvastatin 1 & 2.5µM treated cells, vs serum-hypoxia 
treated cells) 
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Figure 3.10 Effects of a Prostacyclin Analogue, PDE-5 Inhibitor and ET-1  
  Receptor Antagonist on Serum and Acute Hypoxia-Induced [3H]  
  Thymidine Uptake by Pulmonary Adventitial Fibroblasts.   
The effect of a range of doses of treprostinil diethanolamine (UT-15c), sildenafil and 
bosentan on [3H] thymidine uptake in quiescent RPAFs, stimulated with 1% serum 
and 24 hours of hypoxia (5%, 35mmHg), was determined.  Values shown are mean 
+/- 1SD from 4 replicate experiments on cells from the same animal.  Experiments 
were repeated once in cells from a different animal and respresentative results are 
shown.  (* value significantly greater than normoxia-1%serum, p<0.05; ** value 
significantly less than normoxia-1% serum, p<0.05). 
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 10µM of UT-15c partially inhibited serum-induced proliferation, with no effect on 
cell viability.  1µM of UT-15c and 1-10µM of sildenafil and bosentan had no effect 
on serum-induced RPAF proliferation.  None of these drugs, across the range of cell 
culture concentrations, exhibited any definite hypoxia-selective effect.  The error 
bars in the experiments with serum-normoxia and serum-normoxia+10µM UT-15c 
overlap – accordingly 10uM of UT-15c may be considered to possibly have partially, 
non-specifically inhibited proliferation or alternatively to have had no effect on 
serum-induced proliferation and a specific effect on hypoxia-induced proliferation.   
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3.4 Discussion 
In this chapter, the ability to establish and maintain a previously characterised cell 
model (pulmonary and systemic adventitial fibroblasts from normal rats, in normoxia 
and acute hypoxia) was demonstrated.  Techniques to assess cell proliferation were 
undertaken and the effects of statin drugs on adventitial fibroblast proliferation were 
determined. 
 
For the initial experiments of this project, cell proliferation was estimated by both 
[3H] thymidine uptake and cell counting.  [3H] thymidine uptake is widely used as a 
proxy measure of DNA synthesis and cell proliferation.  Though there are potential 
sources of error with this (some of the [3H] thymidine may be incorporated into 
macromolecules other than DNA; some of the DNA into which it is incorporated 
may be for cell repair rather than cell proliferation), using [3H] thymidine uptake to 
determine cell proliferation has previously proven robust in our laboratory.  In 
particular, the optimal timing of [3H] thymidine addition (at 4 hours prior to 
experiment completion in a 24 hour experiment) had been previously verified233.   
 
For further clarification, [3H] thymidine and cell counting experiments were initially 
used in tandem.  As the tandem experiments in this chapter using these two 
techniques mirrored one another completely, [3H] thymidine was used as a lone 
assessment tool for cell proliferation hereafter. 
 
Fluvastatin was the statin initially available to us for experimental work.  The effects 
of fluvastatin on serum and PDGF-BB induced proliferation and viability of PAF and 
SAFs are in line with numerous previous investigators findings with other (normal or 
tumor) cell types200, 233-4.  A cell culture dose of 5µM caused partial inhibition of 
proliferation and doses of 10µM or greater caused complete inhibition of 
proliferation and cell death.  This effect (inhibition of mitogen-induced adventitial 
fibroblast proliferation +/- cell death) was not specific to the mitogens studied, 
though effects mediated by PDGF-BB may be slightly more resistant to statin 
inhibition.   
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Based on previous investigators findings, it is speculated that this non-specific 
antiproliferative effect of fluvastatin, at doses >5µM, was a consequence of  HMG-
CoA reductase inhibition with consequent disruption of prenylated G-protein 
signalling and/or cell membrane lipid raft integrity.  This contention was not pursued 
further in this project, firstly as hypoxic proliferation (rather than mitogen-induced 
proliferation) was the focus and secondly, as the cell culture dose required for these 
effects (5-10µM) is very much higher than that achieved in the circulation, in vivo, in 
humans, after standard oral dosing of this drug192.  Accordingly, it was not 
considered likely that this effect is of major relevance to pulmonary vascular disease 
in humans, or potential treatment.   
 
Acute hypoxia has been previously shown to stimulate significant increase in rat 
PAF cell proliferation, with no effect on systemic adventitial fibroblast 
proliferation155.  This was confirmed again in this chapter’s experiments.  We also 
established that statins have a selective inhibitory effect on hypoxic proliferation, at a 
lower cell culture dose than is required for inhibition of mitogen-induced 
proliferation.  Fluvastatin, at a dose of 1µM, demonstrated striking inhibition of acute 
hypoxia-induced proliferation.  At this dose, the effect of fluvastatin was selective 
for hypoxia (fluvastatin 1µM had no effect on serum or PDGF-BB induced 
proliferation) and this cell type (fluvastatin 1µM had no effect on systemic 
adventitial fibroblasts proliferation).  This result – selective inhibition of hypoxic 
PAF proliferation by fluvastatin 1µM - is the foundation for the other chapters in this 
thesis.   
 
Inhibition of pulmonary vascular cell proliferation by statins has previously been 
reported, but effects were only recognised with high cell culture doses of statins (30–
80 mM)218, which are much higher than those achieved with standard dosage of 
statins, in vivo, in humans. Furthermore, in these previous studies, the pulmonary 
specificity of this antiproliferative effect was not studied: at these cell culture doses 
statins have nonspecific antiproliferative effects on virtually any cell studied, 
including systemic vascular cells235, possibly via disruption of centromere 
assembly234.   
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A dose dependant / stimulus specific / cell type specific in vitro effect of statin has 
been noted previously.  A suggested explanation is that the cell signalling 
mechanisms unique to the stimulus or cell under study may be very reliant on ready 
supply of individual compounds produced by the HMG-CoA reductase pathway, 
accordingly rendering them very sensitive to statin inhibition.  It seemed likely that 
acute hypoxia-induced proliferation of RPAFs was dependant on a HMG-CoA 
reductase product, but other mechanisms of action of the statin were considered 
possible.  Experiments to fully address this were proposed and these are considered 
in detail in the following chapter. 
 
There are 5 statins currently in mainstream clinical use in the UK (pravastatin, 
simvastastin, atorvastatin, fluvastatin and rosuvastatin) and the effects of some of 
these on cell proliferation have been compared237.   Simvastatin, atorvastatin and 
fluvastastin are typically equipotent in in vitro proliferation studies, whilst 
pravastatin has much less, or no antiproliferative effect.  To clarify this in our cell 
model, the acute hypoxia-selective antiproliferative effect in RPAFs was compared 
across a range of statin doses, with 3 different lipophilic statins (fluvastatin, 
atorvastatin and simvastatin).  No difference in either the nature of the effect, or in 
statin dose-response was seen: we found the lipophilic statins to be equipotent.  This 
result is compatible with the statin effect on acute hypoxic proliferation being 
mediated by HMG-CoA reducatase inhibition (for which these statins would be 
expected to be equipotent at a cellular level) rather than an HMG-CoA reductase 
independent effect (which depends on the specific statin’s molecular structure)215.  
Our findings -equipotency of fluvastatin, atorvastatin and simvastatin in 
antiproliferative cell culture experiments - are in line with most of the literature.  For 
our experiments, preparation and dilution of stock solutions of these statins was 
minimised and meticulous attention was taken, in order to minimise any cumulative 
error from repeated pipetting etc. 
 
Lipophilic statins diffuse freely across cell membranes and have been shown to have 
effects on cellular processes in diverse cell types.  In contrast, water soluble statins 
(eg pravastatin, rosuvastatin) do not diffuse across cell membranes and are expected 
only to have an effect on cells with specific membrane receptor mechanism to 
internalise them (eg hepatocytes).  There have, however, been occasional reports of 
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positive effects of pravastatin on cell lines other than hepatocytes.  To clarify 
whether there was an effect of hydrophilic statins on this cell model, pravastatin was 
studied.  No effect on hypoxic or serum mediated PAF proliferation or cell viability 
was seen, at doses up to 50µM.  This data suggests adventitial fibroblasts lack a 
cellular mechanism to internalise pravastatin.  This result is typical for non-
hepatocyte cell culture studies238.  
 
Combined with the previous results of other groups (statin-mediated inhibition / 
reversal of experimental pulmonary hypertension), it was considered that the 
observed cellular effects of statin - selective inhibition of acute hypoxia-induced PAF 
proliferation by low dose fluvastatin, atorvastatin and simvastatin - may be 
theoretically beneficial in clinical application in pulmonary hypertension.  It was 
therefore felt relevant to determine if this cellular effect was novel, or simply 
duplicates an effect achieved by drugs already established in clinical use in 
pulmonary hypertension.  To address this, an agent from each of the 3 established 
drug classes (prostacyclin analogue, phosphodiesterase-5 inhibitor, endothelin-1 
antagonist) in PAH was obtained and evaluated.  Prostacyclin acts via cell membrane 
receptors stimulating cAMP production and via PPAR-receptors, with direct effects 
on intracellular processes.  Phosphodiesterase 5 (PDE-5) inhibitors inhibit the 
breakdown of cGMP (thereby increasing the intracellular concentration of cGMP).  
Endothelin-1 (ET-1) antagonists reversibly block cell membrane ET-1a +/- ET-1b 
receptors.  All of these mediator pathways have been implicated in hypoxic signaling 
and pulmonary vascular cell proliferation (see Chapter 1.5.2).  The manufacturing 
drug companies provided treprostinil diethanolamine (UT-15c, a prostacyclin 
analogue), sildenafil (a PDE-5 inhibitor) and bosentan (a dual ET-1 A/B receptor 
antagonist). 
 
UT-15c, sildenafil and bosentan had non-specific inhibitory / cytotoxic effects, on 
serum-induced RPAF proliferation, at high cell culture doses.  We found no definite 
specific effect of these drugs on hypoxia-induced proliferation which argues against 
a role for prostacyclin, cGMP or ET-1 signalling pathways in acute hypoxic 
proliferative signaling pathways in this cell type.  The inconclusive results with 
10µM UT-15c are, however, as acknowledged in section 3.3.7.  The results with 
these agents should not be overinterpreted, particularly as time constraints limited the 
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number of experimental repeats undertaken for this section, in comparison with all of 
the other experiments presented in this chapter.  Temporary issues with cell-culture 
infection interrupted experiments at this time and the decision was made to focus on 
the most relevant results (with the low dose statin) rather than the equivocal result 
with a cell-culture dose of UT-15c which is of doubtful clinical relevance.  With 
caveats about less experimental repetition, however, the result with bosentan is 
notable.  Stenmark’s group have previously shown endothelin-1 release by PAFs in 
acute hypoxia and implicated autocrine/paracrine release of mediators (ET-1 and 
adenosine triphosphate) in hypoxia-induced PAF proliferation105, 239.  The results we 
obtained with bosentan are not incompatible with those findings, but they do indicate 
that autocrine and/or fibroblast-fibroblast paracrine pro-proliferative effects of ET-1 
do not significantly contribute to hypoxic proliferation of rat PAFs, over a 24 hour 
period. 
 
Hypoxia-induced proliferation of pulmonary adventitial fibroblasts is likely to be a 
key process in pulmonary vascular remodelling in pulmonary hypertension.  In 
previous work, and in the current series of experiments, the only agents which have 
been identified as selective inhibitors of hypoxia-induced proliferation of PAFs are 
p38 MAP kinase inhibitors155 and low-dose statins240.  Though these findings suggest 
therapeutic potential for statins in hypoxia-associated pulmonary hypertension, we 
also considered that there was a more immediate experimental application.  The 
effects of statins on cellular processes have previously been shown to be mediated by 
a restricted panel of effects on intracellular proteins and signalling, and specific 
inhibitors and mediators for each of these individual mechanisms is available.  
Combining an awareness of the HMG-CoA reducatase signalling pathway with the 
key results from this chapter (selective inihibition of acute hypoxic PAF proliferation 
by 1µM fluvastatin) offered the possibility to further interrogate hypoxic proliferative 
signalling in this important pulmonary vascular cell.  The experiments conceived in 
order to achieve this interrogation are the focus of the following chapter. 
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Chapter 4 
 
 
 
Characterisation of Acute Hypoxic Signalling Pathways 
in Pulmonary Adventitial Fibroblasts: Mechanism of the 
Antiproliferative Effect of Fluvastastin 
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4.1 Introduction 
In the previous chapter competencies with routine cell culture, an acute hypoxic cell 
model and standard proliferation assays were established.  Results from that chapter 
showed the effects of statins on proliferation of adventitial fibroblasts.  In particular, 
acute hypoxia-induced proliferation of rat pulmonary adventitial fibroblasts was 
selectively inhibited by 1µM of fluvastastin, atorvastastin or simvastastin.  We 
sought to determine the mechanism of this inhibitory effect of statin, in order to 
characterise hypoxic signalling pathways in rat pulmonary adventitial fibroblasts. 
 
The general mechanisms of action of statins have been previously outlined (see 
Chapter 1.10.5 and figure 4.1).  Notably, intermediates of the cholesterol 
biosynthesis pathway and inhibitors of specific downstream steps related to this 
pathway are now available for experimental use.  Based on this, a sequence of 
experiments to determine the effects of these inhibitors and intermediates (alone and 
in combination with fluvastatin), on acute hypoxia-induced RPAF proliferation were 
conceived, in order to clarify the mode of action of the statin. 
 
Phosphorylation of p38 MAP kinase α and γ has been shown to be an obligatory step 
responsible for the differential response of pulmonary and systemic adventitial 
fibroblasts to acute hypoxia, mediating acute hypoxic proliferation155.  p38 MAP 
kinase inhibitors selectively inhibit hypoxia-induced PAF proliferation (ie identical 
effect to 1µM fluvastatin) whereas inhibitors of other MAP kinase proteins have no 
effect233.  This hypoxia-p38 MAPK-proliferation signalling pathway has been 
confirmed in acute and chronic hypoxia177, and in rat, bovine and human cells180.  
There is, however, some contradictory data from a neonatal calf acute hypoxia PAF 
model.  In these cells, there is also biphasic p38 MAP kinase phosphorylation.  Acute 
hypoxic proliferation, however, of these PAFs is dependant on phosphorylation of 
ERK, rather than p38 MAPK241.  Accordingly, given the similar effect of 1µM statin 
and p38 MAPK inhibitor on acute hypoxic RPAF proliferation and this controversy 
about MAP kinase signalling in hypoxic adventitial fibroblasts, we also elected to 
determine the effects of acute hypoxia, statins and the other inhibitors and mediators 
on MAP kinase phosphorylation. 
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Considering the known effects of statins, we considered it likely that the positive 
effect (ie inhibition of acute hypoxic RPAF proliferation) identified in Chapter 3 
might be mediated via effects on a prenylated GTPase protein.  Based on 
observations about acute hypoxic signalling in general (see Chapters 1.6.5 and 1.7.2), 
we additionally speculated that this GTPases may be RhoA or Rac1, acting upstream 
of p38 MAP kinase.  Based on this, we proposed to evaluate the effects of specific 
inhibitors of Rho kinase and Rac1 activation on hypoxia-induced MAP kinase 
phosphorylation and proliferation or RPAFs, if the results with the HMG-CoA 
reductase pathway compounds were suggestive of a role for a geranylgeranylated 
signalling protein. 
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Figure 4.1 Cholesterol Biosynthesis Pathway: Intermediates and Related Inhibitors   
The cholesterol biosynthesis pathway with its related cell signalling systems (see chapter 1.10.5 for further description) is shown annotated with 
available inhibitors (green boxes).  Statins inhibit the synthesis of mevalonate (the rate limiting step in this pathway) and accordingly have the 
potential to interfere with the indicated cell signalling pathways (blue boxes).  Statins have also been shown to have effects on cell activity 
independent of this pathway, via direct interaction with cell receptors (eg the LFA-1 receptor on T lymphocytes). 
 
Prenyltransferase enzymes (farnesyl transferase or geranylgeranyl transferase I and II) facilitate the post-translational modification of selected 
target GTPase proteins, attaching the specific isoprenoid molecule (FPP or GGPP) onto the protein.  Specific inhibitors are available for farnseyl 
transferase (FTase I) and geranylgeranyl transferase I (GGTase I).  Zaragozic acid A (squalestatin) is a squalene synthase inhibitor, blocking the 
conversion of sqalene to cholesterol.  There is, however, some crossover inhibition of farnesyltransferase with this compound242 and an 
additional agent was sought to comprehensively assess this ‘lipid raft arm’ of the cholesterol pathway.  Methyl-β-cyclodextrin doesn’t affect the 
cholesterol biosynthesis pathway directly but it is an avid binding molecule of cholesterol, retaining it within its molecular ring structure.  When 
added to cell medium for a short period (30mins to 1 hour) methyl-β-cyclodextrin disrupts lipid raft structures by leaching cholesterol from the 
plasma membrane and sequestering it in the water soluble culture media243. 
 
Where statins are shown to have an inhibitory effect in cell culture (as with acute hypoxic proliferation of RPAFs, Chapter 3) the mechanism of 
this effect, and the cell signalling system implicated can be clarified with reference to this pathway.  In particular, the cell signalling events can 
be interrogated by a sequence of experiments using statin inhibition and sequential repletion with each of the pathway intermediates, with 
concurrent experiments utilising each of the indicated downstream inhibitors. 
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4.2 Methods 
As outlined in the general methods (Chapter 2), rat pulmonary artery fibroblast 
(RPAF) cells were studied in experimental conditions - normoxia vs acute hypoxia 
(5%) +/- serum, statin or other mediator.  Under these experimental conditions, cell 
proliferation was assessed by thymidine assay and phosphorylation of mitogen-
activated protein kinases was determined by the application of relevant antibodies to 
nitrocellulose membranes containing proteins separated from cell extracts using an 
SDS-PAGE / western blot technique.  Results are expressed in the figures as mean 
+/- 1 standard deviation.   
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4.3 Results 
4.3.1 Effects of Hypoxia and Fluvastatin on MAP Kinase Phosphorylation 
Previous experimental work in the SPVU laboratory had demonstrated the effects of 
serum and acute hypoxia, at various timepoints over a 24 hour period, on MAP 
kinase phosphorylation in rat PAFs.  There is constitutive phosphorylation of 
ERK1/2 in normoxic or hypoxic RPAFs.  There are peaks of p38 MAP kinase 
phosphorylation at 4 and 16 hours and inhibitor experiments confirm that hypoxic 
proliferation is dependant on these.  JNK is not phosphorylated in these cells in 
normoxia or hypoxia180. 
 
In order to establish competency in protein analysis techniques and as a precursor to 
experiments with statin, phosphorylated MAP kinase and total MAP kinase in cells 
maintained in normoxia or hypoxia for 16 hours were determined by Western Blot 
analysis (Figure 4.2).  Subsequent experiments demonstrated complete inhibition of 
p38 MAP kinase phosphorylation after 16 hours of acute hypoxia, by 1µM 
fluvastatin.  There was no effect of fluvastatin 1µM on phosphorylated ERK or JNK, 
or total MAP kinase, at this time point.  
 
4.3.2 Inhibition of Hypoxic Proliferation and p38 MAP Kinase  
 Phosphorylation by  Low Dose Fluvastatin: Effects of Mevalonate  
 Replacement 
The first question regarding the statin’s mechanism of action on hypoxic signalling 
in RPAFs was whether this was a consequence of HMG-CoA reductase inhibition, or 
whether there was an HMG-CoA reductase independent statin effect.  To answer 
this, we added supplemented statin-inhibited cells simultaneously with mevalonate, 
‘bypassing’ the effects of statin-mediated HMG-CoA reductase inhibition (figure 
4.3A). 
 
Mevalonate, at doses up to 1mM had no effect on serum or hypoxia-induced RPAF 
proliferation.  Mevalonate repletion completely negated the inhibitory effect of 1µM 
fluvastatin on acute hypoxia-induced RPAF proliferation after 24 hours and p38 
MAP kinase phosphorylation at 16 hours (Figures 4.3B & 4.3C). 
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Figure 4.2 Effects of Acute Hypoxia and Fluvastastin 1µM on MAP Kinase 
  Phosphorylation in RPAF cells 
Quiescent RPAFs were maintained in normoxia (21%) or hypoxia (5%) for 16 hours.  
Cell extracts were subjected to SDS-PAGE and western blot analysis of 
phosphorylated (p) and total (t) JNK, ERK and p38 MAP kinase was conducted.  
Each blot is representative of at least 3 independent experiments on cells from 
different animals. 
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Figure 4.3 Assessment of the HMG-CoA Reductase Pathway in Acute  
  Hypoxic Proliferative Signalling in RPAFs 
Panel A shows the cholesterol biosynthesis pathway annotated to indicate the 
assessment of statin mechanism (via HMG-CoA-reductase inhibition or cholesterol 
pathway independent effect) achieved by mevalonate repletion. 
 
Growth arrested rat pulmonary artery fibroblasts were stimulated with serum +/- 
fluvastatin 1µM (F1) or mevalonate 1mM (M) for 24 hours in normoxic (21%) or 
hypoxic (5%) conditions.  DNA synthesis, as an index of cell proliferation, was 
assessed by [3H] thymidine uptake at 24 hours (Panel B).  Values shown are mean 
+/-SD from 4 replicate experiments on cells from the same animal (*value 
significantly greater than 1% serum-normoxia, p<0.01).   
 
p38 MAP kinase phosphorylation was assessed by western blot analysis after 16 
hours (Panel C).  Data in panel B and C is representative of >3 repeat experiments on 
cells from different animals. 
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4.3.3 Effects of Cholesterol Pathway Intermediates on Rat Pulmonary 
 Adventitial Fibroblast Proliferation 
Having confirmed that fluvastatin’s effects on acute hypoxic RPAFs was mediated 
by HMG-CoA reductase, we sought to determine which intermediate compound 
from the HMG-CoA pathway was required for acute hypoxia-induced p38MAPK 
phopshorylation and RPAF proliferation. 
 
We initially repeated the statin/acute hypoxia proliferation experiments with 
repletion of squalene, FPP and GGPP, using 0.1-1mM of these compounds (these 
cell culture doses were based on previous reports and experience with mevalonate in 
the preceding experiments).  After 24 hours of exposure to these cholesterol pathway 
intermediates, at these concentrations, RPAF proliferation was completely inhibited 
and distortion of cell architecture / cell lysis was seen under light microscopy 
(photomicrographs not retained). 
 
A direct toxic effect of these HMG-CoA reductase pathway compounds on the RPAF 
cells was suspected.  In order to determine a safe concentration of these for future 
experiments, the individual effects of a graded series of concentrations of squalene, 
FPP and GGPP on serum and hypoxia-induced proliferation of RPAFs was 
determined. 
 
Threshold concentrations of squalene (25µM), FPP (1µM) and GGPP (0.5µM) 
(which had no effects on cell architecture or on serum or acute hypoxia-induced 
proliferation of RPAFs) were identified (Figure 4.4).  At higher concentrations of 
squalene, FPP and GGPP, non-specific antiproliferative and toxic effects on RPAFs 
were seen. 
 
4.3.4 Lipid Raft Disruption as a Potential Mechanism for the Fluvastastin  
 Effect on Hypoxia-induced RPAF proliferation and p38 MAP Kinase  
 Phosphorylation 
Lipid raft integrity has been implicated in abnormal proliferation of pulmonary 
vascular cells.  Statins disrupt lipid raft integrity by interrupting the supply of 
intracellular cholesterol necessary for lipid raft maintenance.  To determine if an 
effect of fluvastatin 1µM on lipid rafts was mediating the inhibitory effect on acute  
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Figure 4.4 Effects of Cholesterol Pathway Intermediates on Serum and  
  Hypoxia-Induced [3H] Thymidine Uptake by RPAFs 
RPAF cells were grown to 60% confluence and quiesced.  The cholesterol 
biosynthesis intermediates - squalene (Sq) 25, 100 and 250µM, farnesyl 
pyrophosphate (FPP) 0.5, 1 and 2.5µM or geranylgeranyl pyrophosphate (GGPP) 
0.5, 1 and 2.5µM - were added as indicated, with 1% serum.  Cells were maintained 
in normoxic (21%) or hypoxic (5%) conditions for 24 hours with cell proliferation 
assessed by [3H] thymidine uptake.  Values shown are mean +/-SD from 4 replicate 
experiments on cells from the same animal and are representative of experiments 
from cells from >3 animals.  (*values significantly greater than control, ** values 
significantly less the 1% serum-normoxia, p<0.01). 
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hypoxic proliferation and p38 MAPK phosphorylation the effect of squalene 
repletion on the statin effect (ie did it negate it) was established.  Also, the effects of 
direct intracellular cholesterol synthesis disruption via squalene synthase inhibition 
(zaragozic acid) or membrane cholesterol depletion (methyl-β-cyclodextrin) – 
specifically to enquire if these agents mimicked the effect of fluvastatin 1µM – were 
studied (Figure 4.5A). 
 
Co-administration of squalene 25µM with fluvastatin 1µM had no influence on the 
statin effect (ie inhibition of hypoxic proliferation and p38 MAPK phosphorylation 
in RPAFs; Figures 4.5B & 4.5C).  Zaragozic acid (60µM) had no effect on serum or 
hypoxia-induced RPAF proliferation, or on hypoxia-induced p38 MAP kinase 
phosphorylation.  Pre-incubation of cells with methyl-b-cyclodextrin 1mM (a 
concentration previously shown to disrupt lipid raft integrity) had visible effects on 
cell architecture on light microscopy (not shown) but no effect on proliferation or 
p38 MAPK status in RPAFs in either normoxia or hypoxia. 
 
4.3.5 Disruption of Protein Prenylation as a Potential Mechanism for the  
 Fluvastastin Effect on Hypoxia-induced RPAF Proliferation and p38  
 MAP Kinase Phosphorylation 
As discussed above (chapter 4.1), we suspected a prenylated protein, possibly one of 
the Rho GTPase family, as a cell signalling intermediate in acute hypoxic signalling, 
upstream of p38 MAPK.  To clarify this, and in order to focus the search, we 
investigated the effect of FPP and GGPP repletion on the statin/acute hypoxia RPAF 
proliferation and p38 MAPK protein experiments.  The prenyltransferase inhibitors 
FTAseI and GGTI-276 were selected based on their potency and selectivity, in 
comparison to other available prenyltransferase inhibitors.  The effect of these 
prenyltrasferase inhibitiors on acute hypoxia-induced proliferation and p38 MAPK 
phosphorylation in RPAFs was studied in conjunction with acute hypoxia / statin / 
FPP & GGPP repletion experiments (figures 4.6A and 4.7A). 
 
Co-administration of FPP (0.5µM) with fluvastatin (1µM) restored hypoxia-induced 
p38 MAPK phosphorylation and proliferation in RPAFs.  FTAseI 5µM had, 
however, no effect on acute hypoxic proliferation (figure 4.6B).   Considering the 
effect of FTAseI on p38 MAPK phosphorylation in these RPAFs (figure 4.6C) there 
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Figure 4.5 Effects of Cholesterol Deprivation on Acutely Hypoxic RPAFs 
Panel A shows the cholesterol biosynthesis pathway annotated to indicate the 
assessment of the cholesterol biosynthesis pathway and lipid raft integrity achieved 
by fluvastatin / squalene co-administration, squalene synthase inhibition (by 
zaragozic acid, ZA) and membrane cholesterol depletion (by methyl-β-cycoldextrin, 
MBCD). 
 
Fluvastastin 1µM, squalene 25µM, zaragozic acid 60µM and 1% serum were added 
as indicated to quiescent RPAFs, prior to 24 hour incubation in normoxic (21%) or 
hypoxic (5%) conditions.  Selected cells were pre-treated with MBCD 1mM for 30 
mins prior to the start of the 24 hour experiment.  DNA synthesis, as an index of cell 
proliferation, was assessed by [3H] thymidine uptake at 24 hours (Panel B).  Values 
shown are mean +/-SD from 4 replicate experiments on cells from the same animal.  
p38 MAP kinase phosphorylation was assessed by western blot analysis after 16 
hours (Panel C).  Data shown is representative of >3 repeat experiments on cells 
from different animals.  (*values significantly greater than 1% serum-normoxia, 
p<0.01). 
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Figure 4.6 Farnesyl Pyrophosphate Dependant Pathways in Acutely Hypoxic 
  RPAFs 
Panel A shows the cholesterol biosynthesis pathway annotated to indicate the 
assessment of this achieved by fluvastatin / FPP repletion and a farnesyl transferase 
inhibitor. 
 
Fluvastastin 0.5µM, the farnesyl transferase inhibitor FTaseI (FTI 5µM) and 1% 
serum were added as indicated to quiescent RPAFs, prior to 24 hour incubation in 
normoxic (21%) or hypoxic (5%) conditions.  DNA synthesis, as an index of cell 
proliferation, was assessed by [3H] thymidine uptake at 24 hours (Panel B).  Values 
shown are mean +/-SD from 4 replicate experiments on cells from the same animal.  
p38 MAP kinase phosphorylation was assessed by western blot analysis after 16 
hours (Panel C).  Data shown is representative of >3 repeat experiments on cells 
from different animals.  (*values significantly greater than 1% serum-normoxia, 
p<0.01). 
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is an apparent slight reduction in the pp38 blot in hypoxia, with this inhibitor.  This is 
considered equivocal, particularly when considered in comparison to the abrogation 
of hypoxic p38 phosphorylation seen with fluvastatin and other the inhibitors 
investigated subsequently, and as it was not consistent with other results.   
 
GGPP repletion (0.5µM) also completely negated the inhibitory effect of fluvastatin 
effect.  GGTI-276 (5µM) selectively inhibited acute hypoxia-induced proliferation 
and p38 MAP kinase phosphorylation in RPAFs, mimicking the effects of fluvastatin 
1µM (figure 4.7B & 4.7C). 
 
4.3.6 Effects of a Rho Kinase and a Rac1-specific Guanine Exchange Factor 
 Inhibitor on Hypoxia-induced RPAF Proliferation and p38 MAP Kinase  
 Phosphorylation 
The preceding experiments implicated a geranylgeranylated protein (ie from the Rho 
superfamily) in acute hypoxic prolfierative signalling, upstream of p38 MAP kinase 
phosphorylation, in RPAFs.   We had previously suspected a RhoA-Rho kinase or 
Rac1-NADPH oxidase pathway in hypoxic signalling in RPAFs (chapter 1.7.2).   As 
a further (preliminary) assessment of these possibilities we obtained a selective Rho 
kinase inhibitor (hydroxyfasudil).  Guanine exchange factor (GEF) proteins, when 
activated, convert GTPase proteins from the inactive GDP-bound state to an active 
GTP-bound state.  NSC-23766 is a recently described compound which selectively 
inhibits the interaction between Rac1 and its specific GEFs (Trio and Tiam1)244.  We 
also obtained this and repeated normoxia/hypoxia RPAF proliferation and p38 MAP 
kinase phosphorylation experiments with these 2 inhibitors. 
 
Hydroxyfasudil had no effect on serum or hypoxia-induced RPAF proliferation or 
hypoxia-induced p38 MAPK phosphorylation, even at high cell culture dose (20µM.  
In contrast, NSC-23766 (100µM) selectively inhibited hypoxia-induced p38 MAPK 
phosphorylation and proliferation in RPAFs (figure 4.8). 
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Figure 4.7 Geranylgeranylpyrophosphate Dependant Pathways in Acutely 
  Hypoxic RPAFs 
Panel A shows the cholesterol biosynthesis pathway annotated to indicate the 
assessment of this achieved by fluvastatin /  GGPP repletion and a geranylgeranyl 
transferase inhibitor. 
 
Fluvastastin 0.5µM, the geranylgeranyl transferase inhibitor GGTI-276 (GGTI 5µM) 
and 1% serum were added as indicated to quiescent RPAFs, prior to 24 hour 
incubation in normoxic (21%) or hypoxic (5%) conditions.  DNA synthesis, as an 
index of cell proliferation, was assessed by [3H] thymidine uptake at 24 hours (Panel 
B).  Values shown are mean +/-SD from 4 replicate experiments on cells from the 
same animal.  p38 MAP kinase phosphorylation was assessed by western blot 
analysis after 16 hours (Panel C).  Data shown is representative of >3 repeat 
experiments on cells from different animals.  (*values significantly greater than 
1%serum-normoxia, p<0.01). 
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Figure 4.8 Effects of a Rho Kinase and a Rac1-GEF Exchange Inhibitor on 
  Acutely Hypoxic RPAFs 
The Rho kinase inhibitor hydroxyfasudil (HF, 20 µM), the selective Rac1 GEF-
exchange factor inhibitor NSC-23766 (NSC 100µM) and 1% serum were added as 
indicated to quiescent RPAFs, prior to 24 hour incubation in normoxic (21%) or 
hypoxic (5%) conditions.  DNA synthesis, as an index of cell proliferation, was 
assessed by [3H] thymidine uptake at 24 hours (Panel A).  Values shown are mean 
+/-SD from 4 replicate experiments on cells from the same animal.  p38 MAP kinase 
phosphorylation was assessed by western blot analysis after 16 hours (Panel B).  
Data shown is representative of >3 repeat experiments on cells from different 
animals.  (*values significantly greater the 1% serum-normoxia, p<0.01). 
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4.4 Discussion 
In this chapter, the mechanism of the inhibitory effect of fluvastatin on acute-hypoxia 
induced proliferation of RPAFs (as identified in Chapter 3) was studied. 
 
An obligatory role for p38 MAP kinase phosphorylation in acute-hypoxia induced 
PAF proliferation has been shown previously150, 155, 171.  Statins have been shown to 
indirectly inhibit MAP kinase phosphorylation in other cell types and it was notable 
that the effect of fluvastatin 1µM on acute hypoxic RPAF proliferation (Chapter 
3.3.5) duplicated those previously seen with the p38 MAP kinase inhibitor 
SB203580233.  We considered it likely that the inhibitory effect of 1µM fluvastatin 
seen in the experiments in Chapter 3 would be via inhibition (directly or indirectly) 
of a signalling component upstream of p38 MAP kinase.  It was also considered 
possible that fluvastatin may have a ‘bystander’ effect on the other MAP kinases and 
also that the effect of fluvastatin may be on a parallel signalling pathway, 
independent of p38 MAP kinase.  These contentions were, however, refuted by the 
initial data in this chapter where we found that fluvastatin 1µM completely inhibited 
acute hypoxia-induced p38 MAP kinase phosphorylation, with no effect on total or 
phosphorylated ERK1/2 or JNK, either in normoxia or hypoxia. 
 
Having confirmed that the inhibitory effect of fluvastatin was mediated upstream of 
p38 MAPK, it was considered that exploitation of this effect, in conjunction with 
available cholesterol biosynthesis pathway intermediates, offered the possibility of 
clarifying the nature of the  upstream signalling pathway in the acute hypoxia-p38 
MAP kinase–HIF-1a–proliferation pathway (previously identified in RPAF cells, in 
this laboratory). 
 
When an antiproliferative effect of statin on a cell has been identified, co-
administration of mevalonate, in order to clarify if the effect of statin is via HMG-
CoA reductase inhibition, is a long established experimental modality245.  
Mevalonate, however, has been reported in other cell types to have independent 
effects on cell activity 246.  In our experiments, mevalonate had no effect on RPAF 
proliferation, even at high dose.  Repletion with mevalonate negated the effect of 
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fluvastatin 1µM, implicating a cholesterol biosynthesis pathway component as an 
obligate compound for acute hypoxic proliferative signalling in RPAFs. 
 
Other investigators have variously used FPP and GGPP to further study statin effects 
on proliferative cell signalling pathways, in other cell types and with other mediators.  
However, there is no known report where all 3 ‘arms’ of this pathway have been 
assessed together, as completely as was undertaken here.  Based on observations 
from other cell types, each of the individual cell signalling systems in question (lipid 
rafts, farnesylated and geranylgeranylated proteins) could conceivably be implicated 
in hypoxic signalling and/or MAP kinase pathways in RPAFs.  As overlap or 
redundancy between these different systems was considered a possibility (eg a cell 
membrane based signalling protein may require both prenylation and lipid raft 
association for normal function), it was considered that, even if positive or negative 
results were found on early experiments with one or other ‘arm’, that a 
comprehensive experimental interrogation of this pathway was required. 
 
The observation that standard experimental concentrations of squalene, FPP and 
GGPP could disrupt normal RPAF cell status (see section 4.3.3) provided some 
challenges.   We were able to identify ‘safe’ concentrations of each of these 
compounds which did not disrupt RPAF cell status or serum/hypoxia-induced 
proliferation.  This left us, however, with uncertainty as to how to interpret a partial 
or negative proliferation result.  For example, if the effect of fluvastatin was 
unchanged when co-administered with the ‘safe’ concentration of a cholesterol 
pathway intermediate, would this be a true negative result or a function of inadequate 
repletion at the concentration of the intermediate used?  Also, if a lack of effect was 
seen with a downstream inhibitor from the cholesterol pathway, it would be unclear 
if this were a true negative, or due to inadequate dosing or other experimental 
problem with the inhibitor under study. 
 
To counter these concerns, we conceived and performed complementary experiments 
for each arm of the pathway: statin/cholesterol pathway intermediate repletion 
experiment + specific inhibitor experiments combined, for each arm.  Moreover, 
when we considered the lipid raft arm, we noted the potential for crossover inhibition 
of farnesyltransferase with zaragozic acid.  The negative result with this compound 
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implied that products of squlaene synthase and farnesyltransferase were not required 
for acute hypoxic RPAF proliferation.  However, as we also obtained negative results 
the fluvastatin/squalene repletion experiment, we sought a third experiment to ensure 
that these results were ‘true’ negatives, rather than a function of a problem with these 
compounds or their cell culture dosing.  Pre-incubation of RPAFs with methyl-β-
cyclodextrin - to deplete membrane cholesterol and directly disrupt lipid rafts - was 
therefore also done.  Though we haven’t determined whether fluvastatin 1µM and/or 
MBCD had any effect or not on lipid raft integrity, the negative results with 
fluvastatin/squalene repletion, zaragozic acid and MBCD strongly suggest that the 
inhibitory effect of fluvastatin 1µM, on acute hypoxic proliferation and p38 MAPK 
phosphorylation, is not mediated via lipid raft disruption.  These results also argue 
against a requirement for lipid raft integrity for normal acute hypoxic proliferative 
signalling in these cells. 
 
Repletion of RPAFs with FPP negated the inhibitory effect of fluvastatin 1uM on 
acute hypoxic RPAF proliferation and p38 MAPK phosphorylation.   With review of 
the cholesterol pathway, it can however be seen that this effect does not help to 
discriminate the statin’s mechanism: FPP is a direct precursor of farnesylated 
proteins and other compounds involved in the cell cycle, and an indirect precursor 
(via GGPP) or geranylgeranylated proteins.  The data on acute hypoxic RPAF 
proliferation and p38 MAPK phosphorylation which follow this - no effect with the 
farnesyl transferase inhibitor, negation of the effect of fluvastatin with GGPP 
repletion and duplication of the fluvastatin effect by the geranylgeranyl transferase 
inhibitor – led us to conclude, however, that the statin effect is mediated via 
inhibition of GPP synthesis.  This conclusion does have a minor caveat in relation to 
the slight reduction in pp38 intensity in the acute hypoxia blot with the FTase 
inhibitor (chapter 4.3.5): this may have been a spillover effect of this inhibitor to 
GGTase at the experimental concentration explored but further study of this at 
different concentrations was not considered necessary, given the clear cut result with 
the GGPP compound and the geranylgeranyl transferase inhibitor. 
 
These results also allow us to conclude that a geranylgeranylated protein is involved 
in acute hypoxic proliferation in RPAFs, upstream in the signalling pathway from 
p38 MAP kinase.  Specifically, we considered the possibility that either RhoA or 
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Rac1 may be the geranylgeranylated protein in this pathway.  The negative results 
with the Rho kinase inhibitor and positive results with the Rac1-GEF inhibitor 
(mimicking the effects of fluvastatin ie selective inihibition of acute hypoxic RPAF 
proliferation and p38 MAPK phosphorylation) provide circumstantial evidence for 
an acute hypoxia-Rac1-p38 MAPK pathway in these cells.  Lack of time and 
resources meant that it was not possible to conduct experiments to determine Rac1-
GDP vs Rac1-GTP (activated) status in normoxic, hypoxic and statin-treated RPAFs 
directly.  The positive results with NSC-23766, however, do provide strong 
circumstantial evidence for the signalling pathway that is proposed in Figure 4.9.  
 
Data from other researchers supports this proposed pathway.  Rac1 has been 
identified as an upstream activator of p38 MAP kinase in other cell types248.  Small 
inhibitory RNAs to NADPH oxidase 4 (NOX4) have been shown to inhibit acute 
hypoxia-induced increase in ROS production and proliferation in PAFs247.  Function 
of NOXs and their transduction of external signals via intracellular ROS generation 
is known to be dependant on association of the complex with intracellular 
membranes249. Activated Rac1 is known to be a constituent of NADPH oxidase 
protein complexes, stabilising the interaction between inactive membrane-bound 
components of the complex, and intracellular activator components of the complex.  
Based on the findings in this chapter, it seems appropriate to speculate that, in 
RPAFs, acute hypoxia results in geranylgeranyl pyrophosphate dependant 
translocation of Rac1-NOX to the (plasma or endoplasmic reticular) membrane, 
leading to a localised increase ROS production which triggers a signalling cascade 
which results in phophorylation of p38 MAPK, stabilisation and phosphorylation of 
HIF-1α155 and increased cellular proliferation.  The previous findings that 
atorvastatin can inhibit intracellular ROS production via inhibition of Rac1 
geranylgeranylation in vascular smooth muscle cells250 and that enhancement of 
Rac1 function leads to increased membrane associated NADPH oxidase complex and 
ROS production, support this contention251.   
 
Even if the identity of the geranylgeranylated protein inhibited by fluvastatin in 
hypoxic RPAFs is considered to be incompletely clarified, the results in this chapter 
provide insights into the intracellular processes which may be involved in the activity 
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Figure 4.9 Proposed Model of Acute Hypoxic Proliferative Signalling in Rat  
  Pulmonary Adventitial Fibroblast Cells 
The results presented in this chapter, supplemented by previous work (on p38 MAPK 
inhibition and HIF-1α stabilisation) in the SPVU laboratory155, suggest the above cell 
signalling pathway.   
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of this protein.  Specifically, acute hypoxic signalling in RPAFs is blocked by a very 
small cell culture dose of statin (10-50 fold less than is typical for other inhibitory 
effects seen with statins).  This finding - complemented by the results in this chapter 
- indicates a signalling process which is extremely dependant on ready ‘supply’ of 
GGPP.  Differential sensitivity of individual cell signalling processes within a single 
cell type, to statin inhibition, has been documented in other cell types252.  The 
observations in this chapter are also consistent with previous observations that – 
when activated - Rho-family proteins circulate from the cytosol to the plasma 
membrane253.  The previous suggested explanation for this – which is supported by 
the results in this chapter – is that this intracellular circulation is dependant on 
dynamic prenylation of the protein.   
 
In summary, a detailed interrogation of the HMG-CoA reductase pathway and the 
mechanism of fluvastatin’s inhibitor effect on acute hypoxia-induced proliferation of 
RPAFs was conducted in this chapter.  The results obtained provide significant new 
information on acute hypoxic signalling in this cell type and this is an important 
outcome of itself.  That fluvastatin 1µM had a stimulus (hypoxia), circulatation 
(pulmonary) and MAP kinase (p38) specific inhibitory effect on this cell type, which 
is important in pulmonary vascular remodelling, seems highly notable. When we 
consider, however, potential application of these results to the pathogenesis or 
treatment of human hypoxia-induced pulmonary hypertension, acute hypoxia has 
problems as a model.  In this human condition, by the time treatment is sought, 
hypoxia has been chronic.  It therefore seemed relevant to consider whether statins 
have a positive effect on chronic hypoxic PAF behaviour, and whether 
geranylgeranylpyrophosphate, Rac1 and p38 MAP kinase have a role in chronic 
hypoxia-induced PAF proliferation.  This is considered further in the following 
chapter. 
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Chapter 5 
 
 
Effects of Fluvastatin on the Hyperproliferative 
Phenotype of Pulmonary Artery Fibroblasts from 
Chronic Hypoxic Rats 
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5.1 Introduction 
In the preceding two chapters the ability of low dose fluvastatin to selectively inhibit 
acute hypoxia-induced RPAF proliferation, via inhibition of a geranylgeranylated 
protein-p38 MAPK pathway, was established.  Though a drug which can selectively 
inhibit acute hypoxic proliferation may be considered to have therapeutic potential, 
more impressive would be the ability to reverse the hyperproliferative PAF 
phenotype seen after exposure to chronic hypoxia. 
 
The important contributions of changes in pulmonary artery fibroblast behaviour in 
chronic hypoxia-induced pulmonary vascular remodelling have been discussed (see 
chapter 1.8).  Following chronic hypoxia, pulmonary artery fibroblasts exhibit 
increased proliferative capacity and this effect persists on cell culture passage, 
regardless of whether the cells are maintained in normoxic or hypoxic conditions.  
This sustained, excessive proliferation of PAFs from chronic hypoxic rats (CH-
RPAF) has been previously shown to be dependant on constitutive phosphorylation 
of p38 MAP kinase and reversed by p38 MAPK inhibition177.  Also, as with acute 
hypoxia, this p38 MAPK response and increased proliferation is circulation specific: 
systemic adventitial fibroblasts (SAFs) from chronic hypoxic rats behave identically 
to SAFs from normal rats.   
 
Based on all of this, we considered it possible that low dose fluvastastin (which had 
acted as an indirect p38 MAPK inhibitor on acute hypoxic RPAFs) might also 
influence CH-RPAF proliferation, if the geranylgeranylated protein (speculated to be 
Rac1), which acted upstream of p38 in acute hypoxic RPAFs, was also constitutively 
activated in CH-RPAFs.  To explore these possibilities we proposed proliferation and 
Western Blot analysis experiments, comparing PAFs and SAFs from normal and 
chronic hypoxic rats, with assessment of the effects of fluvastatin, cholesterol 
intermediates and related inhibitors.  We did not assess MAPKs other than p38, 
given the results obtained in Chapters 4.3.1. 
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5.2 Methods 
For the chronic hypoxic model, rats were maintained in hypobaric hypoxia for 2 
weeks (see general methods, chapter 2).  Following this, pulmonary and aortic 
fibroblast cell lines were established and scrutinised for cell transformation and 
infection regularly.  Quiescent cells were studied in experimental conditions – 
normoxia +/- serum, statin or other mediator- and cell proliferation was assessed by 
thymidine assay and phosphorylation of mitogen-activated protein kinases was 
determined by the application of relevant antibodies to nitrocellulose membranes 
containing proteins separated from cell extracts using an SDS-PAGE / western blot 
technique.  Results are expressed in the figures as mean +/- 1 standard deviation.   
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5.3 Results  
5.3.1 [3H] Thymidine Uptake and p38 MAP Kinase Phosphorylation in  
 Pulmonary and Aortic Adventitial Fibroblasts from Normal and Chronic  
 Hypoxic Rats 
Previous work in the SPVU laboratory on CH rats has confirmed the proliferation 
and p38 MAPK status in vascular fibroblasts of normal and chronic hypoxic rats.  To 
clarify competency with the chronic hypoxic rat model and establish controls for the 
following work, these experiments were repeated.  As 24 hours of acute hypoxia had 
previously been shown to have no additional effect on CH rat proliferation or p38 
MAPK phosphorylation233, all experiments in this chapter were conducted in 
normoxic (21%) conditions. 
 
Increased proliferation of adventitial fibroblasts with increasing concentrations of 
serum was confirmed (figure 5.1A).  Serum-treated PAFs from chronic hypoxic rats 
demonstrated increased [3H] thymidine uptake at a given concentration of serum, in 
comparison with PAFs from normal animals.  This hyperproliferative phenotype of 
CH-RPAFs was independent of cell passage (data not shown) and circulation 
specific: SAFs from normal and chronic hypoxic rats proliferated at similar rates 
with serum stimulation.   
 
In CH-RPAFs, p38 MAP kinase was phosphorylated at all times points studied (16 
hours is shown, to maintain consistency with previous experiments, figure 5.1B).  No 
p38 MAP kinase phosphorylation was seen in PAFs or SAFs from normal rats or in 
SAFs from hypoxic rats.   
 
The phenotype of CH rat systemic artery fibroblasts - normal proliferation to serum 
and absence of p38 MAPK phosphorylation - in comparison to pulmonary artery 
fibroblasts allowed the use of CH-RSAFs as control cells for the following 
experiments. 
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Figure 5.1 [3H] Thymidine Uptake and p38 MAP Kinase Phosphorylation in  
  Pulmonary and Systemic Artery Fibroblasts from Normal and  
  Chronic Hypoxic Rats 
Growth arrested pulmonary (PAF) and systemic artery fibroblasts (SAF) from 
normal and chronic hypoxic rats were stimulated with serum for 24 hours in 
normoxic (21%) conditions.  DNA synthesis, as an index of cell proliferation, was 
assessed by [3H] thymidine uptake at 24 hours (Panel A).  Values shown are mean 
+/-SD from 4 replicate experiments on cells from different animals.  p38 MAP 
kinase phosphorylation was assessed by western blot analysis after 16 hours (Panel 
B).  Data shown is representative of >3 repeat experiments on cells from different 
animals.  (*value significantly greater than that in normal rat PAF or CH-rat SAF, at 
equivalent serum dose, p<0.05). 
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5.3.2 Effects of Fluvastatin on the Chronic Hypoxic Rat Pulmonary  
 Adventitial Fibroblast Phenotype 
The effects of fluvastastin on serum-induced proliferation of CH rat PAFs and SAFs 
were determined, using doses (1µM and 10µM), based on experiments in Chapters 
3.3.2 and 3.3.5. 
   
Fluvastastin 1µM had no effect on CH-RSAF proliferation but it reduced serum-
induced proliferation of CH-RPAF, such that 3[H] thymidine uptake was at a similar 
level to the control (SAF) cells (Figure 5.2A).  Fluvastatin 1µM did not otherwise 
interefere with the proliferative response of CH-RPAFs or SAFs to incremental doses 
of serum.  Fluvastatin 10µM had a complete / non-specific anti-proliferative effect on 
CH-RPAFs and SAFs, similar to that seen with PAFs and SAFs from normal 
animals.   
 
Phosphorylated p38 MAP kinase was not detected (ie constitutive phophorylation 
was reversed) in CH-RPAF cells which had been incubated with fluvastatin 1µM for 
16 hours (Figure 5.2B).   
 
5.3.3 Effects of Cholesterol Pathway Intermediates and Related Inhibitors on  
 the Chronic Hypoxic Rat Pulmonary Adventitial Fibroblast Phenotype 
We next explored the mechanism of the selective pp38 MAPK inhibitory / anti-
proliferative effect of fluvastatin 1µM on CH-RPAF cells.  We duplicated a selected 
panel of experiments used on the acute hypoxic RPAF model (chapter 4.3).  In 
particular, we used only the specific cholesterol intermediates and inhibitors (at the 
previously established appropriate dose) which had yielded positive results in the 
acute hypoxia model.  This allowed an interrogation of the HMG-CoA reductase 
pathway in these chronic hypoxic rat cells, with a significantly reduced experimental 
workload. 
 
As before, fluvastatin 1µM attenuated CH-RPAF [3H] thymidine uptake to a level 
similar to control (SAF) cells, and inhibited/reversed constitutive p38 MAPK 
phosphorylation (Figure 5.3A and 5.3B). 
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Figure 5.2 Effects of Fluvastastin on [3H] Thymidine Uptake and p38 MAPK  
  Phosphorylation in Chronic Hypoxic Rat PAFs 
Growth arrested pulmonary (PAF) and systemic artery fibroblasts (SAF) from 
chronic hypoxic rats were stimulated with serum +/- fluvastatin (F) 1 or 10µM for 24 
hours in normoxic (21%) conditions.  DNA synthesis, as an index of cell 
proliferation, was assessed by [3H] thymidine uptake at 24 hours (Panel A).  Values 
shown are mean +/-SD from 4 replicate experiments on cells from different animals.  
p38 MAP kinase phosphorylation was assessed by western blot analysis after 16 
hours (Panel B).  Data shown is representative of >3 repeat experiments on cells 
from different animals.  (*value significantly less than control cells, p<0.05; **value 
significantly greater than control cells, p<0.05) 
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Repletion of fluvastatin treated CH-RPAFs with mevalonate 1mM and GGPP 0.5µM 
negated the statin effect.  Treatment of CH-RPAFs with the geranylgeranyl 
transferase inhibitor GGTI-276 (5µM), or the Rac1 GEF inhibitor NSC-23766 
(100µM), attenuated [3H] thymidine uptake to control cell levels.  p38 MAPK 
phosphorylation was also inhbited/reversed by these inhibitors.  These reagents had 
no effect on [3H] thymidine uptake by chronic hypoxic rat systemic artery fibroblasts 
(data not shown). 
 
5.3.4 Effects of Established Pulmonary Hypertension Therapeutics on [3H]  
 Thymidine Uptake in Chronic Hypoxic Rat Pulmonary Adventitial  
 Fibroblasts 
Having demonstrated a positive and selective effect of fluvastatin on CH-RPAFs, we 
sought to determine if this effect simply duplicated an effect seen with established 
pulmonary hypertension therapeutics. 
 
Cell culture concentrations of treprostinil diethanolamine (UT-15c), sildenafil and 
bosentan which did not have an effect on normal rat PAF proliferation had been 
previously identified (chapter 3.3.6).  These doses (1µM of UT-15c and 10µM of 
sildenafil and bosentan) were applied to CH-RPAFs and the effect on [3H] thymidine 
uptake was determined.   
 
The prostacyclin analogue, PDE-5 inhibitor and ET-1 receptor antagonist had no 
effect on CH-RPAF proliferation (figure 5.4), nor on systemic artery fibroblast 
proliferation (data not shown), at these doses.  Given this negative result, the effect 
of these agents on p38 MAPK phosphorylation in CH-RPAFs was not studied. 
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Figure 5.3 Effects of Fluvastastin, Cholesterol Pathway Intermediates and  
  Related Inhibitors on [3H] Thymidine Uptake and p38 MAPK  
  Phosphorylation in Chronic Hypoxic Rat PAFs 
Growth arrested pulmonary (PAF) and systemic artery fibroblasts (SAF) from chronic 
hypoxic rats were stimulated with serum for 24 hours in normoxic (21%) conditions.  
Fluvastatin (F1, 1µM), mevalonate (M, 1mM), geranylgeranyl pyrophosphate (GGPP, 
0.5µM), GGTI-276 (GGTI, 5µM) or NSC-23766 (NSC, 100µM) were added, at the start 
of the experiment, as indicated.   
  
DNA synthesis, as an index of cell proliferation, was assessed by [3H] thymidine uptake 
at 24 hours (Panel A).  Values shown are mean +/-SD from 4 replicate experiments on 
cells from different animals.  p38 MAP kinase phosphorylation was assessed by western 
blot analysis after 16 hours (Panel B).  Data shown is representative of >3 repeat 
experiments on cells from different animals.  (*value significantly greater than CH-
RSAF control cells, p<0.01).  
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Figure 5.4 Effects of Fluvastastin and Established PH Therapeutic Agents on  
  [3H] Thymidine Uptake in Chronic Hypoxic Rat PAFs 
Growth arrested pulmonary and systemic artery fibroblasts from chronic hypoxic rats 
were stimulated with serum for 24 hours in normoxic (21%) conditions.  Fluvastatin, 
prostacyclin analogue (UT15c), phosphodiesterase-5 inhibitor (sildenafil) and 
endothelin A/B receptor antagonist (bosentan) were added along with serum, as 
indicated. 
 
DNA synthesis, as an index of cell proliferation, was assessed by [3H] thymidine 
uptake at 24 hours.  Values shown are mean +/-SD from 4 replicate experiments on 
cells from different animals.  (*values significantly greater than CH-RSAF control 
cells, p<0.01). 
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5.4 Discussion 
In this chapter, we sought to determine whether fluvastatin had a selective anti-
proliferative effect on chronic hypoxic rat PAFs and, if this effect was present, if this 
was indicative of constitutive activation of a geranylgeranylated protein-p38 MAP 
kinase pathway in CH-RPAFs, similar to pathway proposed for acute hypoxic RPAF 
proliferation, in Chapter 4.4.   
 
The results in this chapter with CH-RPAFs mirrored those seen with acute hypoxia 
applied to RPAFs from normal animals.  The selective inhibitory effect of fluvastatin 
1µM on CH-RPAF proliferation and p38 MAPK phosphorylation, negation of this 
effect by mevalonate and GGPP and duplication of this effect with geranylgeranyl 
transferase and Rac1 inhibitors strongly suggests that the hyperproliferative 
phenotype of CH-RPAFs is dependant on constitutive activation of the same 
signalling pathway as is activated by acute hypoxia in normal rat PAFs.   
 
A phenotypic switch in PAF behaviour after exposure to chronic hypoxia, whereby 
explanted PAFs from chronic hypoxic rats exhibit enhanced proliferation, dependant 
on constitutive p38 MAPK phosphorylation,  even once exposed to normoxic 
conditions / multiple cell passage, has been previously proposed and suggested as an 
important mechanism in chronic hypoxic pulmonary vascular remodelling48.  In the 
experiments conducted in this chapter, this phenotypic switch has again been 
confirmed and linked to p38 MAPK status.  The experiments with fluvastatin, 
cholesterol pathway intermediates, related inhibitors and PH therapeutics further 
characterise the molecular basis for this phenotypic switch and provide an indication 
of the potential of statin therapy to positively influence cellular mechanisms 
important in hypoxia-related pulmonary hypertension. 
 
As with the acute hypoxic RPAF work in chapter 4, the data in this chapter 
implicates a Rac1-NADPH oxidase signalling complex in proliferative signalling, 
upstream of p38 MAPK, in chronic hypoxic PAFs.  Moreover, the abrogation of 
excessive CH-RPAF proliferation by 1µM fluvastatin suggests that the molecular 
location of the phenotypic 
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proliferative switch in these cells lies at an upstream location, prior to Rac1.  The 
sensitivity of this to statin inhibition is again notable, and combined with the 
repletion / complementary inhibitor experiments indicates again that the activated 
signalling pathway here is very dependant on a ready supply of GGPP.  This suggests 
a dynamic process is continuing in these cells – eg Rac1 is continually cycling 
through a prenylated / unprenylated state – rather than a static, irreversible change in 
this signalling protein’s status.   
 
Lipophilic statins have been previously shown to attenuate and reverse chronic 
hypoxic pulmonary hypertension in rats4, 220.  The results presented here complement 
and extend these, in several ways.  The animal model experiments reported suggest 
that the positive effects of statins are mediated via HMG-CoA reductase (agreeing 
with our results) and exploratory work from the animal models suggested that 
modification of eNOS by statins is not involved in their mechanism of action, but 
that inhibition of Rho-kinase activity may be.  Medial thickening in the pulmonary 
arteries of the CH-rats is also attenuated / regressed by statin therapy, suggesting a 
direct or indirect benficial effect of statins on smooth muscle cells.  Our data 
suggests that the positive effects of statins on CH rat pulmonary hypertension in vivo 
may be mediated, at least partly, via positive effects on adventitial fibroblasts, and 
via a Rac1-p38 MAP kinase pathway.  A particular difficulty with all experiments of 
potential new therapeutics on experimental PH models is that the effects of many 
drugs on these models (eg sildenafil, simvastatin, VIP, adrenomedullin) are, broadly 
speaking, similar, and typically out of proportion to the more modest effects seen 
when translating findings (so far) to human clinical disease.  The similarity of the 
effects of these drugs on the animal models makes the identification of whether a 
new drug has a novel effect or simply duplicates the effect(s) of an established agent 
difficult.  The results in this chapter and in chapter 3.3.6 – obtained in a cell-based 
model rather than an animal model - indicate that statins have a potentially beneficial 
effect on a disease-related cellular mechanism which does not simply duplicate an 
effect of a drug from each of the three established PH therapeutic drug classes.   
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An unanswered question in relation to statins (and many other drugs with 
demonstrated positive effects on chronic hypoxic rat PH) is how essential they are: 
do they simply duplicate the effects of re-oxygenation (ie the condition could as 
easily be treated by oxygen, as by other drugs) or do they enhance the effects of re-
oxygenation?  Our finding of a phenotypic switch in CH-RPAFs, persisting in 
normoxic cell culture could be interpreted as evidence that simple re-oxygenation 
would be inadequate to restore normal pulmonary vascular cell physiology.  
However, if the interpretation of the sensitivity of this phenotypic switch to low dose 
fluvastatin is correct (ie that the activation of the Rac1-p38 MAPK pathway is 
dynamic) this raises the possibility that the phenotypic switch may itself be dynamic, 
and potentially subject to reversal by re-oxygenation, in vivo where cell-cell and cell-
matrix interactions may modify the effects of hypoxia then subsequent normoxia, in 
contrast to the explant cell situation.   
 
When considering human hypoxia-related PH and its treatment, it is notable that the 
characteristics of the underlying lung problem often prohibit complete correction of 
hypoxia, even with supplemental oxygen.  Also, patients may exhibit persistent or 
progressive pulmonary hypertension, even if hypoxia and the underlying condition is 
treated.  Therefore, drugs which can duplicate or enhance the effects of re-
oxygenation on the pulmonary vasculature seem relevant.  The experimental data 
previously reported and presented in this chapter would suggest that statins may have 
the potential to complement re-oxygenation (whether achieved with oxygen 
supplementation or treatment of the lung disorder).  The ability of fluvastatin to 
selectively normalise CH-RPAF proliferation at a cell culture dosage potentially 
relevant to human pharmacology is notable.  Further work to extend this observation 
and assess re-oxygenation formally (in vitro or in vivo) was outwith the scope of this 
project.  It would, however, seem relevant in future to assess the effects of re-
oxygenation +/- statin therapy, in the chronic hypoxic rat model, in particular 
considering the differential effects of these on regression of pulmonary vascular 
remodelling and normalisation of the PAF phenotype.   
 
In addition to general concerns about the applicability of cell culture experiments on 
animal tissue to human disease, there are specific drawbacks when considering the 
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clinical application of the results in this chapter.  Experiments were only conducted 
on cells from Wistar rats.  Different strains of rats are known to exhibit different 
pulmonary vascular cell responses to hypoxia254, and it may be that the CH-RPAF 
proliferative phenotype, the Rac1-p38 MAPK signalling pathway, and the effects of 
fluvastatin on these, are unique to this rat strain.  Future work should extend these 
observations to PAFs from other rat strains (eg Sprague-Dawley or high altitude 
susceptible rats) and to human cells, ideally from lung tissue from normal patients 
and patients with hypoxic lung disease related pulmonary hypertension.  Access to 
human tissue from patients with hypoxic PH is very limited, and potentially 
confounded by the effects of the underlying primary lung disease.  Some reassurance 
can, however, be taken from the previous observations indicating the identical 
proliferative and MAPK responses to acute hypoxia seen when comparing human 
PAFs with Wistar rat PAFs180.  Overall, it is considered that the experiments 
conducted here provide important insights into molecular and cellular processes 
potentially involved in hypoxic pulmonary hypertension and reflect a reasonable 
compromise between expediency and applicability.   
 
When we consider pulmonary vascular remodelling in animals or humans, although 
significant changes are seen in the adventitia, the most notable changes in established 
disease are in the media, where the smooth muscle cells reside.  In the chronic 
hypoxic simvastatin experimental work, prevention / regression of medial 
hypertrophy was the notable histological finding (though the reports available 
provide no information on the status of the adventitia or the fibroblasts).  Interactions 
between adventitial fibroblasts and medial smooth muscle cells are thought likely to 
be important in hypoxic pulmonary vascular remodelling and we considered it 
possible that the positive effects of simvastatin on medial hypertrophy in the chronic 
hypoxic rat model might be mediated via an initial positive effect on adventitial 
fibroblasts, with consequent favourable modification of fibroblast-smooth muscle 
cell interactions.  Experimental work to better characterise PAF-PASMC interactions 
in hypoxia was ongoing in our laboratory at this time.  Having identified and 
characterised a positive effect of fluvastatin on CH-RPAF proliferation in the 
experiments in this chapter, it seemed logical to progress to characterise the effects 
of fluvastatin on hypoxic PAF-PASMC interactions.  This proposition led to the 
work which comprises the following chapter. 
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Chapter 6 
 
 
Effects of Hypoxia and Fluvastatin on Bovine 
Pulmonary Adventitial Fibroblast – Pulmonary Artery 
Smooth Muscle Cell Interactions  
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6.1 Introduction 
In the preceding chapters, the focus has been on hypoxia-induced adventitial 
fibroblast proliferation and the signalling systems involved.  Although it is 
considered likely that this proliferation is an important contributor to pulmonary 
vascular remodelling in pulmonary hypertension (as discussed in Chapter 1.8) it is 
also acknowledged that the most profound changes (medial hypertrophy, sustained 
vasoconstriction, muscularisation of distal arteries, neointimal formation) involve the 
media of the vessel.  It may be that migration and transdifferentiation of adventitial 
fibroblasts is important to the expansion in numbers of smooth muscle/myofibroblast 
cells in remodelled vessels but it seems likely that proliferation/phenotypic changes 
in medial SMCs contributes significantly. 
 
Much of this work on pulmonary vascular remodelling has focused on the 
endothelial and smooth muscle cells, and their interactions.  Notably, endothelial-
derived vasodilators (eg prostacyclin, nitric oxide) and vasoconstrictors (eg 
endothelin-1, thromboxane) have been implicated in smooth muscle cell proliferation 
and consequent vascular remodelling: the processes of vasoconstriction and 
remodelling seem to be connected.  In hypoxic pulmonary vasoconstriction, 
however, endothelial-independent constriction dominates and the signalling 
pathways involved (eg inhibition of membrane potassium channels, RhoA-Rho 
kinase activation) are intrinsic to the pulmonary artery smooth muscle cells 
(PASMC).  These cell signalling pathways are also implicated in PASMC 
proliferation, supporting the concept of vasomotor coupling (see Chapter 1.6.3).  As 
a counterpoint, however, many investigators (with caveats about definitions of 
hypoxia, Chapter 1.6.5) have been unable to demonstrate that the isolated PASMCs 
proliferate to hypoxia, in vitro137.  Possible explanations are that the medial 
hypertrophy seen is due to an expansion of a subpopulation of hypoxia-responsive 
PASMCs (not represented in the PASMC population routinely cultured), or that the 
medial hypertrophy/distal muscularisation is caused by an influx of 
transdifferentiated cells originating from the adventitia, or the circulation.  The 
explanation with the most experimental support, however, is that the presence of a 
paracrine co-factor (either intrinsic or hypoxia-dependant), released from other the 
other cells in the vessel wall, in the in vivo hypoxic pulmonary artery, is necessary 
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for PASMC proliferation.  This mitogenic co-factor may facilitate PASMC 
proliferation in response to hypoxia, or may be a direct PASMC mitogen which is 
only released by adjacent cells or from the circulation, in response to hypoxia.  Given 
that the earliest vascular changes in hypoxia are seen in the adventitia, it seems 
appropriate to speculate that the fibroblast may be the source of this PASMC 
mitogen or co-mitogen.  Mitogens (including endothelin-1 and hypoxia-inducible 
mitogenic factor, HIMF) have been shown to be released by hypoxic pulmonary 
adventitial fibroblasts and these are known to stimulate PASMC proliferation, 
supporting this speculation105, 255. 
 
We considered the possibility that the cell signalling pathways responsible for 
proliferation of PAFs might also be responsible for secretion by hypoxic PAFs of a 
PASMC mitogen.  Work on hypoxic PAF-PASMC interactions is ongoing in the 
SPVU laboratory and, based on the results in the preceding chapters, we proposed 
experiments with statins, cholesterol pathway mediators, related inhibitors and PH 
therapeutics in order to better characterise hypoxia-induced cell signalling events 
which lead to mitogen release by PAFs. 
 
Cell-cell interactions in vivo can be modelled in the cell culture laboratory.  Two 
complementary techniques were used here:-  
• Co-culture. This involves the use of basket-like cell culture plate 
inserts with a permeable membrane.  The 2 cells types of interest are 
grown separately, one in standard cell culture wells and the other on 
the cell culture inserts.  During the experimental period the inserts 
(containing cell type 1) are placed in the cell culture wells (containing 
cell type 2).  The permeable membrane allows any secreted paracrine 
factors(s) from the cells in the inserts to pass freely and interact with 
the other cell type.   Inserts with different membrane pore sizes are 
available.  Here we used pore sizes which freely allow transfer of 
large molecules (including any experimental reagents and secreted 
factors) but not cell migration. 
• Conditioned media.  Cell culture media which has been in contact 
with one cell type (in this situation, PAFs) for a period (under  
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experimental conditions) can be aspirated and applied to cells of 
another type (in this situation PASMCs).  The effects of this 
conditioned media on proliferation can be compared with control 
media, allowing assessment of any mitogenic factors released. 
 
Both of these have drawbacks.   Co-culture cell culture inserts are expensive.  Any 
experimental drug or inhibitor applied during co-culture experiments can diffuse 
freely and affect either cell type in the experiment.  In conditioned media 
experiments, any drug or inhibitor applied to the initial cell type will remain in the 
conditioned media and can affect the second cell type also.  These 2 experimental 
techniques are, however, complementary.  In addition, any experiments which yield 
positive findings can be duplicated such that the experimental condition is applied to 
cell type 1 for the period where media is conditioned and separately after 
conditioning but before application to cell type 2.  With these approaches, which cell 
type the experimental reagent is affecting can be deduced. 
 
Rat PAFs are problematic for these experiments as they only respond to hypoxia in 
the presence of serum180.  Any serum applied to the PAFs (in conditioned media or 
co-culture) would also affect PASMC proliferation and this would require an entire 
extra set of experimental control conditions.  Also, the serum might confound / 
overwhelm the effect of any secreted mitogen.  Human and bovine PAFs do not 
require a serum-cofactor to respond to hypoxia and, accordingly, bovine cells were 
selected for the work in this chapter.   
 
Previous work has reassured that there are no differences in proliferative or MAP 
kinase responses to hypoxia with PAFs derived from different species.  It was, 
however, considered relevant to exclude any difference (in comparison to rat PAFs) 
in terms of the effects of statins and other mediators on hypoxia-induced bovine PAF 
proliferation.  Also, it was necessary to clarify the effects of acute hypoxia and 
statins on bovine PASMC proliferation, to characterise the isolated cell type.  We 
therefore proposed proliferation experiments – with fluvastastin and other mediators 
- on bovine PAFs and PASMCs separately, as a prelude to studying the effects of 
acute hypoxia, fluvastatin and other reagents on BPAF-BPASMC interactions using 
conditioned media and co-culture experiments. 
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6.2 Methods 
Bovine pulmonary artery fibroblast (BPAF) and bovine pulmonary artery smooth 
muscle cell (BPASMC) lines were established and characterised (Figure 6.1). 
Interactions between these cells were studied by conditioned media and co-culture 
techniques (see general methods, Chapter 2.7).  The influence of experimental 
mediators on these cellular interactions, and the overall effect on BPASMC 
proliferation was determined by thymidine assay.  Results are expressed in the 
figures as mean +/- 1 standard deviation.  
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Figure 6.1 Bovine Pulmonary Artery Fibroblasts (A) and Pulmonary Artery  
  Smooth Muscle Cells (B) 
Cells were visualised by light microscopy.  Characteristic morphology was noted and 
verified at each cell passage. 
1.5mm 
1.5mm 
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6.3 Results 
6.3.1 Effects of Hypoxia, Serum and Fluvastatin on Bovine Pulmonary  
 Adventitial Fibroblast Proliferation 
Bovine PAFs have previously been shown to proliferate to acute hypoxia in the 
absence of serum233.  In the presence of serum, the proliferative effects of acute 
hypoxia are augmented significantly.   
 
The effects of fluvastatin on acute hypoxic and serum-augmented acute hypoxic 
proliferation of bovine PAFs were studied using [3H] thymidine assay.  24 hours of 
acute hypoxia (5%) again resulted in increased proliferation of BPAFs, both in the 
absence or presence of serum (Figure 6.2).  Fluvastatin 1µM selectively attenuated 
BPAF proliferation in acute hypoxia, restoring it to a level similar to normoxic cells, 
both with and without serum.   
 
6.3.2 Effects of Choleterol Pathway Intermediates and Related Inhibitors on  
 Bovine Pulmonary Adventitial Fibroblast Proliferation 
We next sought to determine if the effects of cholesterol pathway intermediates and 
related inhibitors on acute hypoxia-induced bovine PAF proliferation were similar to 
those seen with rat PAFs (Chapter 4).   
 
The effects of fluvastatin 1µM on acute hypoxia-induced BPAF proliferation were 
negated by mevalonate and GGPP (figure 6.3).  The p38 MAP kinase inhibitor 
SB203580 (5µM), geranylgeranyl transferase inibitor (GGTI-276, 5µM) and the 
selective Rac1-GEF inhibitor (NSC-23766, 100µM) selectively inhibited serum-
augmented, acute hypoxia-induced BPAF proliferation. 
 
6.3.2 Effects of Hypoxia, Serum and Fluvastatin on Bovine Pulmonary Artery  
 Smooth Muscle Cell Proliferation 
Effects of acute hypoxia on bovine PASMCs, under our standard experimental 
conditions, had not previously been reported.  The effects of serum, 24 hours of acute 
hypoxia (5%) and fluvastatin on DNA synthesis by bovine PASMCs were 
determined. 
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Figure 6.2 Effects of Acute Hypoxia and Fluvastatin on [3H] Thymidine  
  Uptake by Bovine Pulmonary Artery Fibroblasts. 
Growth arrested bovine PAFs were stimulated in normoxia (21%) or hypoxia (5%) 
for 24 hours +/- 1% serum +/- fluvastatin (F) 1µM.  DNA synthesis, as an index of 
cell proliferation, was assessed by [3H] thymidine uptake at 24 hours.  Values shown 
are mean +/-SD from 4 replicate experiments.  (*value significantly greater than 
normoxic cells, p<0.01).   
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Figure 6.3 Effects of Acute Hypoxia, Fluvastatin, Cholesterol Pathway 
  Intermediates and Related Inhibitors on [3H] Thymidine Uptake 
  by Bovine Pulmonary Artery Fibroblasts. 
Growth arrested BPAFs were stimulated in normoxia (21%) or hypoxia (5%) for 24 
hours.  1% serum, fluvastatin (F) 1µM, mevalonate (M, 1mM), GGPP (0.5µM), 
SB203580 (SB, 5µM), GGTI-276 (GGTI, 5µM) or NSC-23766 (NSC, 100µM) were 
added to selected wells on the cell culture plate.  DNA synthesis, as an index of cell 
proliferation, was assessed by [3H] thymidine uptake at 24 hours.  Values shown are 
mean +/-SD from 4 replicate experiments.  (*value significantly greater than 
normoxic cells, p<0.01).   
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Acute hypoxia had no effect on BPASMC [3H] thymidine uptake, either in the 
presence or absence of serum (figure 6.4).  Fluvastatin 1µM had no effect but 
fluvastatin 10µM significantly reduced serum-induced [3H] thymidine uptake, similar 
to that previously seen with fluvastatin 10µM applied to serum-treated pulmonary 
and systemic artery fibroblasts (chapter 3.2).   
 
6.3.3 Effects of Fibroblast Conditioned Media, Fibroblast Co- culture and  
 Hypoxia on Pulmonary Artery Smooth Muscle Cell Proliferation 
We considered two possibilities:- either that acute hypoxia caused PAFs to release a 
BPASMC mitogen or that PAFs secrete a mitogen (either constitutively or only in 
hypoxia) which facilitates a proliferative effect of acute hypoxia on PASMCs.  To 
clarify this, we first studied the effects, on BPASMC proliferation, of different doses 
of conditioned media derived from normoxic and hypoxic BPAFs.  Also, we 
determined the effects of BPAF-BPASMC co-culture, in normoxia and hypoxia, on 
BPASMC proliferation.   
 
Conditioned media from normoxic BPAFs had no effect on BPASMC DNA 
synthesis over 24 hours, either in normoxia or hypoxia (figure 6.5).  Conditioned 
media from hypoxic BPAFs led to increased BPASMC [3H] thymidine uptake, and a 
dose response was seen.  Maintaining the BPASMCs in normoxia or hypoxia had no 
effect on the proliferative response to conditioned media.  Co-culture of BPAF-
BPASMCs in normoxia had no effect on BPASMC DNA synthesis.  Co-culture in 
hypoxia, however, led to an increase in [3H] thymidine uptake by BPASMCs. 
 
6.3.4 Effects of Fluvastatin, p38 MAP Kinase Inhibitor and Other  
 Therapeutics  on Fibroblast Conditioned Media-Induced Pulmonary  
 Artery Smooth Muscle Cell Proliferation 
Results from the preceding experiment were in keeping with previous reports, 
indicating that acute hypoxia induces PAFs to release (directly acting) PASMC 
mitogens66.  The effects of fluvastatin, cholesterol pathway intermediates and related 
inhibitors on hypoxia-induced PAF proliferation had been established (Chapters 4.3, 
6.3.1 and 6.3.2).   
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Figure 6.4 Effects of Acute Hypoxia and Fluvastatin on [3H] Thymidine  
  Uptake by Bovine Pulmonary Artery Smooth Muscle Cells. 
Growth arrested bovine PASMCs were stimulated in normoxia (21%) or hypoxia 
(5%) for 24 hours.  1% serum and fluvastatin (F) 1 or 10µM were added to selected 
wells in the cell culture plate.  DNA synthesis, as an index of cell proliferation, was 
assessed by [3H] thymidine uptake at 24 hours.  Values shown are mean +/-SD from 
4 replicate experiments.  (*values significantly greater than 0%-normoxia, p<0.01). 
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Figure 6.5 Effects of Application of Fibroblast Conditioned Media, Co- 
  Culture with PAFs and Acute Hypoxia on [3H] Thymidine Uptake 
  by Bovine PASMCs 
Bovine PASMCs were quiesced for 24 hours in serum free media.  In selected cell 
wells, serum free media was then replaced by 0.1ml or 0.5ml of conditioned media 
taken from bovine PAFs which had been previously maintained for 24 hours in 
normoxia (21%) or hypoxia (5%).  In other wells, co-culture cell inserts containing 
confluent bovine PAFs were placed.  BPASMCs maintained in serum free media, 
and in media supplemented with 1% serum served as controls. 
 
BPASMC plates were maintained for 24 hours in normoxia (21%) or hypoxia (5%) 
and DNA synthesis, as an index of cell proliferation, was assessed by [3H] thymidine 
uptake.  Values shown are mean +/-SD from 4 replicate experiments.  (*values 
significantly increased vs 0% serum-normoxia, p<0.01).   
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We therefore sought to determine if similar effects were seen on hypoxia-induced 
PAF mitogen release, using these drugs at previously established experimental 
concentrations.   
 
In the previous experiment, the effects of conditioned media from hypoxic PAFs, on 
PASMC proliferation, were found to be identical, regardless of whether PASMCs 
were in normoxia or hypoxia.  Given this finding, all of the following experiments 
were conducted with the PASMCs in normoxia. 
 
Conditioned media from hypoxic BPAFs again stimulated BPASMC proliferation 
(figure 6.6).  Conditioned media from BPAFs treated with fluvastatin 1µM had no 
mitogenic effect on BPASMCs but co-treatment of the BPAFs with 
fluvastation/mevalonate and fluvastatin/GGPP resulted in conditioned media which 
stimulated BPASMC proliferation.   
 
Conditioned media from BPAFs treated with fluvastatin 10µM had an inhibitory 
effect on BPASMC proliliferation: this may have been a ‘spillover’ effect of the 
fluvastatin still present in the conditioned media, or it may reflect release of growth 
inhibitory substances from BPAFs damaged by this large dose of statin.   
 
Treatment of the hypoxic BPAFs during the media-conditioning phase with p38 
MAP kinase inhibitor (SB203580, 5 µM), geranylgeranyl transferase inhibitor 
(GGTI-276, 5 µM) or Rac1 inhibitor (NSC-23766, 100 µM) resulted in conditioned 
media which did not stimulate BPASMC proliferation.  In contrast, treatment of the 
hypoxic BPAFs during media conditioning with a prostacyclin analogue (UT-15c, 
1µM), phosphodiesterase-5 inhibitor (sildenafil, 10µM) or endothelin A/B receptor 
antagonist (bosentan, 10µM) had no effect on the conditioned media stimulated 
BPASMC proliferation.  
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Figure 6.6 Effects of Application of Fibroblast Conditioned Media from  
  Drug-Treated Hypoxic PAFs on Bovine PASMC Proliferation. 
Bovine PASMCs were quiesced for 24 hours in serum free media.  Serum free media 
was then replaced by 0.5ml of conditioned media taken from bovine PAFs which had 
been previously maintained for 24 hours in hypoxia (5%) +/- fluvastatin (F, 1 or 
10µM),  mevalonate (M, 1mM), GGPP (0.5µM), SB203580 (SB, 10µM), GGTI-276 
(GGTI, 5µM), NSC-23766 (NSC, 100µM), treprostinil dethanolamine (UT-15c, 
1µM), sildenafil (sil, 10µM) or bosentan (bos, 10µM).   
 
BPASMC plates were then maintained for 24 hours in normoxia (21%) and DNA 
synthesis, as an index of cell proliferation, was assessed by [3H] thymidine uptake.  
Values shown are mean +/-SD from 4 replicate experiments.  (*values significantly 
greater than 0% serum control cells, ** value significantly less than 0% serum 
control cells, p<0.05).   
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The lack of effect of fluvastatin 1µM on BPASMC proliferation (figure 6.4) offered 
some reassurance that the observed inhibitory effects of fluvastatin in these 
conditioned media experiments were a result of action of the drug on the BPAFs 
during the media conditioning, rather than a direct inhibitory effect of residual drug 
in the conditioned media, on the BPASMCs.  To clarify this for fluvastatin and all of 
the other inhibitors, the conditioned media experiments were repeated, but on this 
occasion drugs were applied to the BPASMCs at the time of addition of conditioned 
media (from fibroblasts not treated with drugs). 
 
Fluvastatin 1µM, SB203580 5µM, GGTI-276 5µM and NSC-23766 100µM had no 
effect on BPAF conditioned media stimulated proliferation of BPASMCs (figure 
6.7).  Fluvastatin 10µM inhibited BPASMC proliferation induced by serum or BPAF 
conditioned media, consistent with the non-specific effects of this dose of fluvastatin, 
identified throughout this thesis.  UT-15c and sildenafil again had no effect but 
bosentan partially attenuated the stimulatory effect of hypoxic BPAF derived 
conditioned media on BPASMC proliferation. 
 
6.3.5 Effects of Fluvastatin and Bosentan on Bovine Pulmonary Artery  
 Fibroblast - Smooth Muscle Cell Coculture  
Only a small number of co-culture inserts were available at this time and 
consequently only a very limited repertoire of inhibitor experiments could be 
undertaken.  Effects of statins were the focus of these experiments but the results in 
the preceding experiment with bosentan were intriguing (endothelin-1 release by 
hypoxic PAFs has previously been shown).  Accordingly, the effects of bosentan and 
low dose fluvastation on BPAF-BPASMC co-culture in normoxia and hypoxia were 
studied. 
 
Co-culture with BPAFs in acute hypoxia led to increase in [3H] thymidine uptake by 
BPASMCs.  This increased DNA synthesis was prevented by fluvastatin 1µM and 
bosentan 10µM (figure 6.8). 
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Figure 6.7 Effects of Simultaneous Application of Fibroblast Conditioned  
  Media  from Hypoxic PAFs and Investigational Drugs on Bovine  
  PASMC Proliferation. 
Bovine PASMCs were quiesced for 24 hours in serum free media.  Serum free media 
was then replaced by 0.5ml of conditioned media taken from bovine PAFs which had 
been previously maintained for 24 hours in hypoxia (5%).   Fluvastatin (F, 1 or 
10µM),  mevalonate (M, 1mM), GGPP (0.5µM), SB203580 (SB, 10µM), GGTI-276 
(GGTI, 5µM), NSC-23766 (NSC, 100µM), treprostinil dethanolamine (UT-15c, 
1µM), sildenafil (sil, 10µM) or bosentan (bos, 10µM) was added to the PASMC, 
along with the conditioned media.    
 
BPASMC plates were then maintained for 24 hours in normoxia (21%) and DNA 
synthesis, as an index of cell proliferation, was assessed by [3H] thymidine uptake.  
Values shown are mean +/-SD from 4 replicate experiments.  (*values significantly 
greater than 0% serum, **value significantly less than 0% serum, ***value 
significantly greater than 0% serum and significanlty less than 1% serum, p<0.05) 
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Figure 6.8 Effects of Fluvastatin and Bosentan on Bovine PASMC  
  Proliferation  in PAF-PASMC Co-culture. 
Cell culture inserts containing confluent, quiescent bovine PAFs were applied to cell 
culture wells on plates containing growth arrested bovine PASMCs.   Fluvastatin and 
bosentan were added to selected wells and the co-culture plates were maintained in 
normoxia (21%) or hypoxia (5%) for 24 hours, as indicated.  [3H] thymidine uptake 
by the PASMCs was then assessed at 24 hours and results are expressed as mean +/-
SD from 4 replicate experiments.  (*value significantly greater than 0% serum-
normoxia, p<0.01).    
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6.4 Discussion 
This chapter focused on the interaction between pulmonary artery fibroblasts and 
pulmonary artery smooth muscle cells in hypoxia: specifically studying whether 
acute hypoxia causes PAFs to release a PASMC mitogen, whether this is amenable 
to low dose statin inhibition and if the cell signalling pathway responsible for this is 
similar to that in hypoxia-induced proliferation.   
 
As a prelude to addressing these questions about BPAF-BPASMC interactions, the 
effects of hypoxia and fluvastatin on BPAF and BPASMC proliferation were 
individually characterised.  As previously seen with rat PAFs, the effects of acute 
hypoxia on BPAF proliferation were selectively and completely inhibited by 
fluvastatin.  The results with mevalonate/GGPP repletion and p38 MAPK, 
geranylgeranyl transferase and Rac1 inhibitors indicate that the speculative Rac1-
p38-proliferation signalling pathway identified in rat PAFs is also activated by acute 
hypoxia in bovine PAFs.   
 
Bovine PASMCs showed no proliferative response to 24 hours exposure to 5% 
normobaric hypoxia.  This result may be a function of the cell population obtained 
(explant from proximal pulmonary arteries and no specific single clone isolated) or 
the level of hypoxia used (5% may be relative ‘hypoxia’ to PAFs but relative 
‘normoxia’ to medial PASMCs which typically reside distant from the PA lumen or 
the vasa vasorum).  This result is, however, consistent with the majority of the 
literature and does support the contention that a substantial component of PASMC 
proliferation in hypoxic pulmonary vascular remodelling may be a consequence of 
indirect effects of hypoxia on other pulmonary vascular cells, rather than a direct 
effect of hypoxia on PASMCs.  If we assume that the level of hypoxia (5%) studied 
here is appropriate, given that PASMCs are hypoxia sensitive in general (ie in acute 
hypoxic pulmonary vasoconstriction), why they should not exhibit a proliferative 
response to hypoxia is unknown.  The Rac1-p38 MAPK pathway, present in PAFs, 
may be absent or insensitive to hypoxia, it may be activated but ineffective, or there 
may be additional hypoxia signalling pathways activated in PASMCs which 
counteract its effects.  Further exploration of these possibilities was outwith the 
scope of this thesis. 
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Considering BPASMC proliferation further, fluvastatin 10µM again had a non-
specific antiproliferative effect but fluvastatin 1µM had no effect on BPASMC 
proliferation.  This result again supports the interpretations made previously (chapter 
3.4): that 1µM dose of statin has a selective effect on hypoxia-activated proliferative 
signalling pathways.   
 
Having characterised the effects of fluvastatin on BPAF and BPASMC proliferation 
individually, we proceeded to study the effects on BPAF-BPASMC interactions.  
The effects of hypoxic BPAFs on BPASMC proliferation have been previously 
reported by others66 but results with our experimental conditions have not been 
described.  We found an increase in BPASMC proliferation with BPAF in acute 
hypoxia, but not in normoxia.  Conditioned media derived from hypoxic BPAFs 
caused a dose dependant increase in BPASMC proliferation but conditioned media 
from normoxic BPAFs had no effect.  Also, proliferation of conditioned media 
treated BPASMCs were similar in normoxia and hypoxia.  Taken together, these 
results suggest acute hypoxia causes secretion of soluble mitogen(s) by BPAFs, 
which have a direct pro-proliferative effect on BPASMCs, rather than facilitating a 
BPASMC proliferative response to hypoxia.  These results are consistent with all 
previous data reported in this field. 
 
We considered it possible that hypoxia-induced mitogen release by PAFs may be 
mediated by the same signalling pathway as is responsible for hypoxia-induced PAF 
proliferation.  The results with fluvastatin 1µM in the conditioned media and co-
culture experiments (where the fibroblasts were drug-treated) were indicative of 
complete inhibition of acute hypoxic BPAF mitogen release, supporting this 
contention.  Negation of the effect of fluvastatin by mevalonate and GGPP again 
implicated a geranylgeranylated signalling protein.  Moreover, inhibition of 
BPASMC proliferation, in the conditioned media experiments, by treatment of the 
BPAFs with the p38 MAP kinase inhibitor and Rac1-GEF interaction inhibitor 
strongly support a cell signalling model for acute hypoxia-induced PAF mitogen 
release (figure 6.9), similar to that  
 183
 
Figure 6.9 Proposed Model of Acute Hypoxic Signalling Leading to PASMC  
  Mitogen-Release by Bovine PAFs 
The results presented in this chapter, supplemented by results from Rose et al66, 
suggest the above cell signalling pathway 
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proposed for PAF proliferation (figure 4.9).  This model is also supported by the 
work of Rose et al66.  They confirmed mitogen-release by hypoxic PAFs and 
confirmed that this was dependant on hypoxia-induced stabilisation of HIF-1α: 
previous SPVU research has linked acute hypoxic PAF proliferation to p38 MAPK 
dependant HIF-1α stabilisation.  Considering these 2 reports alongside the results in 
this chapter adds further weight to the contention that proliferation and mitogen-
release by acutely hypoxic PAFs occur as a consequence of activation of the same 
signalling pathway. 
 
With these conditioned media experiments, the possibility that ‘spillover’ of drug 
still present in the conditioned media had a direct inhibitory effect on the BPASMCs, 
rather than on BPAF mitogen release, was considered.  Fluvastatin 1µM and p38 
MAPK, GGTI and Rac1-GEF inhibitors, when added to BPASMCs along with 
conditioned media derived from hypoxic BPAFs, had no effect on (conditioned 
media stimulated) BPASMC proliferation, excluding the possibility of a spillover 
effect. 
 
We found the prostacyclin analogue UT-15c and the phosphodiesterase-5 inhibitor 
sildenafil to have no effect on BPAF-BPASMC interactions in these experiments.  
These findings argue against either a prostacyclin or a GTP / PDE-5 influenced 
signalling pathway mediating either hypoxia-induced BPAF mitogen release or the 
proliferative response of BPASMC to this mitogen(s).  Prostacyclin is known to have 
inhibitory effects on BPASMC proliferation, in general.  We did not explore this 
further but the lack of inhibitory effect of UT-15c on BPAF-induced BPASMC 
proliferation may have therapeutic implications: prostacyclin therapy may be 
ineffective or less effective as an anti-remodelling therapy in situations where an 
important pathophysiological mechanism is BPASMC proliferation driven by 
mitogen(s) derived from BPAFs (ie a mechanism thought to be important in chronic 
hypoxic pulmonary hypertension). 
 
Hypoxic pulmonary artery fibroblasts have been shown to release a variety of 
mitogens, including ATP239, HIMF255 and ET-1105.  These previous reports have 
identified an autocrine effect of these compounds on PAFs and a paracrine effect on 
vasa vasorum endothelial cells and smooth muscle cells.  A comprehensive study of 
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compound(s) released by hypoxic PAFs with characterisation of the individual 
effects of each on PASMCs would seem very relevant but time constraints prevented 
inclusion of this work in this project.  As a preliminary observation, however, the 
results with bosentan in the conditioned media and co-culture experiments suggest an 
important role for PAF-derived ET-1. In these experiments, co-treatment of 
BPASMCs with bosentan 10µM along with hypoxic PAF-derived conditioned media 
partly attenuated PASMC proliferation and application of bosentan to co-cultured 
BPAF-BPASMCs blocked the increase in BPASMC proliferation.  Treatment of 
BPAFs with bosentan during the media conditioning period had no subsequent effect 
on BPASMC proliferation.  This result could initially be considered contradictory: 
should residual endothelin antagonist in the conditioned media not block interaction 
of BPAF-derived ET-1 with ETA/B receptors on BPASMCs?  It is known, however, 
that bosentan is only stable in solution for periods of less than 24 hours (personal 
communication, Dr J Jepf, Actelion).  Consequently, by the time conditioned media 
was added to the BPASMCs, there would be no active bosentan present, and this 
result is therefore compatible.   It is also considered notable that angiotensin-II 
induced ET-1 release by systemic vascular fibroblasts has been shown to be 
regulated by NADPH oxidases256: there are common themes in these cellular 
signalling pathways. 
 
It was considered notable that the effects of hypoxic PAF-derived conditioned media 
were consistent, regardless of whether the PASMCs were maintained in normoxia 
and hypoxia.  It seems appropriate to speculate that this – along with the previously 
discussed proliferative phenotypic switch in chronically hypoxic PAFs (Chapter 5.4) 
– is a cellular mechanism which could account for persistent/progressive pulmonary 
vascular remodelling and pulmonary hypertension in hypoxic lung disease, even if 
hypoxia is corrected therapeutically.  If the proliferative phenotypic switch in PAFs 
also led to persistent release of PASMC mitogens - which seems likely, given the 
identical intracellular signalling pathways which have been identified here - whose 
effect is independent of oxygen tension, then this maladaptive proliferative cell-cell 
interaction would require drug treatment which could specifically block it (eg statin), 
if it were confirmed in humans, in vivo.  Future work to characterise PASMC 
mitogen release by chronic hypoxic PAFs is proposed. 
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These results were obtained at the end of the experimental program comprising this 
thesis and time did not permit even experiments to directly confirm ET-1 release by 
these hypoxic PAFs (though ET-1 release by BPAFs has already been shown by 
others).  As a result of these findings, however, experiments to fully characterise 
endothelin-1 (and other possible mitogen) release by hypoxic PAFs and further study 
receptor interactions and proliferative mechanisms on the PASMC are in progress in 
the SPVU laboratory. 
 
In conclusion, the results in this chapter indicate that acute hypoxia causes release of 
BPASMC mitogens from BPAFs.  This is likely to be mediated by a Rac1-p38 MAP 
kinase pathway in the PAFs and inhibition of this by a dual A/B endothelin 
antagonist suggests endothelin-1 is likely to be one of the mitogens responsible 
(figure 6.10).  This BPAF-BPASMC hypoxic interaction is likely to be an important 
pathophysiological mechanism in the initiation and persistence of chronic hypoxic 
pulmonary vascular remodelling and the observation that this was completely and 
selectively inhibited by fluvastatin, at cell culture concentrations which are 
potentially clinically relevant, may have important therapeutic applications. 
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Figure 6.10 Schematic of Suspected Acute Hypoxic Signalling Pathways PAF-PASMC Cellular Interactions in Hypoxic  
  Pulmonary Vascular Remodelling 
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Chapter 7 
 
 
General Discussion 
 189
7.1  Summary of Results 
The data presented in this thesis show that statins, at low cell culture dose (1µM), 
have a marked, but selective, inhibitory effect on hypoxia-induced pulmonary artery 
fibroblast cell proliferation.  Using established acute and chronic hypoxic cell 
models, this effect of statin drugs has been characterised.  We have shown that:- 
 
• Large doses of statin (>5µM) have a non-specific antiproliferative effect on 
mitogen induced proliferation of all cell types studied (pulmonary and 
systemic artery fibroblasts from normal and chronic hypoxic rats and bovine 
pulmonary artery fibroblasts and smooth muscle cells).   
• Low doses of statin (1µM) inhibit the augmented proliferation of pulmonary 
artery fibroblasts in acute hypoxia, or in cells derived from chronic hypoxic 
rats, via selective inhibition of hypoxia-induced p38 MAP kinase 
phosphorylation.  This dose of statin has no effect on serum-induced 
proliferation of pulmonary artery fibroblasts or smooth muscle cells, or on 
proliferation of systemic artery fibroblasts.  1µM statin also had no effect on 
ERK or JNK MAP kinase status in normoxic or acutely hypoxic rat 
pulmonary artery fibroblasts. 
• The lipophilic statins fluvastatin, simvastatin and atorvastatin were equipotent 
when the effects of these on acute hypoxic pulmonary artery fibroblast 
proliferation were compared. 
• A geranylgeranylated protein, probably Rac1, is an obligatory component 
upstream of p38 mitogen-activated protein kinase, in the acute hypoxia-
proliferative signalling pathway in pulmonary artery fibroblasts. 
• This geranylgeranylated protein–p38 MAP kinase pathway appears to be 
constitutively activated in chronic hypoxic rat pulmonary artery fibroblasts 
and this is likely responsible for the ‘phenotypic switch’ in these cells which 
results in sustained increases in proliferative capacity, even when they are 
restored to normoxia.  Despite this phenotypic switch low dose fluvastatin is 
able to attenuate the proliferation of these cells, such that their proliferation is 
at a rate similar to fibroblast cells from the systemic circualation.. 
• The hypoxia-selective antiproliferative effect of low dose statin on pulmonary 
artery fibroblasts is not duplicated by a drug from each of the established 
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pulmonary hypertension therapeutic classes (prostacyclin analogue, 
phosphodiesterase-5 inhibitor and endothelin-1 antagonist).   
• Though human cells were not available for this project, we were able to show 
that the statin effect and hypoxic signalling pathways implicated were 
identical in pulmonary artery fibroblasts from 2 different species (rat and 
cow).  This is consistent with previous reports on conservation of this p38 
MAP kinase-proliferative hypoxic signalling pathways between species180. 
 
We also studied the potential for smooth muscle cell mitogen release by hypoxic 
pulmonary artery fibroblasts and were able to show that:- 
• Acute hypoxia causes bovine pulmonary artery fibroblasts to release soluble 
mediator(s) which act directly to cause smooth muscle cell proliferation.  
• This hypoxia-induced mediator release by PAFs again appeared related to 
activation of a Rac1-p38 MAP kinase signalling pathway, and was sensitive 
to inhibition by low dose fluvastation.  This suggests that fluvastatin may 
have broad spectrum effects on pathophysiological mechanisms implicated in 
hypoxic pulmonary vascular remodelling. 
• The effect of the hypoxic pulmonary artery fibroblast derived mediators on 
smooth muscle cells is not influenced by subsequent hypoxia.  
• Bosentan attenuated the effects of hypoxic PAF-derived conditioned media 
on PASMC proliferation, implicating endothelin-1 as a principle PASMC 
mitogen released by the hypoxic pulmonary artery fibroblasts. 
 
7.2 Cell Signalling in Hypoxic Pulmonary Artery Fibroblasts 
The initial results with fluvastatin – selective inhibition of acute-hypoxic induced 
PAF proliferation – offered the potential to exploit the known effects of statins to 
interrogate PAF cell signalling events.  A number of other investigators have 
reported on a limited panel of experiments using repletion of cholesterol 
intermediates along with statins.  The experimental protocol that we devised and 
successfully employed involved a comprehensive sequence of experiments (more 
extensive than any previous reports that have been identified) in order to completely 
characterise the effects of the statin.  The rationale for this protocol has been 
previously discussed (Chapter 4.4).   
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Four novel observations in relation to hypoxic signalling in pulmonary artery 
fibroblasts have been made:- 
•  A protein which requires a ready supply of geranylgeranyl pyrophosphate is 
an obligatory signalling molecule upstream of p38 MAP kinase.  Though 
time did not permit direct demonstration of hypoxia-induced Rac1 activation, 
the consistent observation that a Rac1 inhibitor duplicated the effects of low 
dose statin and p38 MAP kinase inhibitor provides strong circumstantial 
evidence the Rac1 is this signalling protein. 
• The sensitivity of this hypoxic signalling pathway to statin inhibition is 
relatively novel.  The majority of reported beneficial effects of statins in cell 
culture experiments have required doses around 10µM.   Our findings of 
inhibitory effects on hypoxic PAF proliferation and mitogen release with a 
statin dose of 1uM indicate a signalling system which requires a consistent 
supply of GGPP,.  This suggests that the protein involved is not prenylated 
prior to hypoxic stimulation.  Possibilities are that activation of the protein by 
hypoxia facilitates prenylation, that there are no intracellular stores of GGPP 
to draw on and that ongoing de novo synthesis of GGPP is required.  
Alternatively prenylation of this protein could be a dynamic / unstable 
situation where GGPP is required for constant replenishment of the modified 
protein.  Recognition of this has implications for our understanding of 
hypoxic signalling and Rho family protein function.  It is considered 
relatively likely that hypoxia-induced activation of the protein involved (Rac1 
or GTPase?) involves an prenylation-facilitated alteration of cellular 
localisation from the cytosol to an intracellular membrane.  Also, the fact that 
we have found that some cell signalling systems are more sensitive to statin 
inhibition than others may be a mechanism explaining the successful 
translation of statin therapy in some clinical fields, but lack of effect at 
standard dosage in other clinical trials (despite preceding observations about 
disease pathophysiology and pre-clinical cell biology studies suggesting 
statins would be beneficial).   
• We have shown that the proposed hypoxia-Rac1-p38 MAP kinase pathway is 
responsible not only for PAF proliferation but also for mitogen release.   
Though mitogen release by acutely hypoxic PAFs had been shown to be 
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dependant on HIF-1α stabilisation, this is the first study to directly 
demonstrate a common molecular mechanism for these cellular processes 
(proliferation and mitogen release) which likely contribute significantly to 
hypoxic pulmonary vascular remodelling.  Also, the identical patterns of 
inhibition on these separate cellular process with low dose statin, Rac1 
inhibitor, geranylgeranyl transferase inhibitor and p38 MAP kinase inhibitor 
suggest that these compounds may have a broad spectrum inhibitory effect on 
hypoxic PAFs, which may be therapeutically more useful in comparison to an 
agent which only possess anti-proliferative properties. 
• Previous observations about the “phenotypic switch” (persistent 
hyperproliferation of PAFs from chronic hypoxic rats despite re-oxygenation, 
with constitutive phophorylation of p38 MAPK) had been considered to 
reflect a potentially irreversible change in these cells.  Positive effects with 
low dose statin and the other inhibitors utilised not only demonstrate that the 
phenotypic switch is reversible; they also imply that the signalling pathway 
involved is dynamic.  The requirement for a ready supply of GGPP suggests 
an aspect of this signalling pathway must be continuously in flux, rather than 
constitutively altered.   
 
Our results are consistent with the majority of the literature in this field, as noted in 
the relevant chapter discussions.  One notable contradiction - with the data in this 
thesis and our previous results - is with the work of Stenmark’s group in Denver, 
Colorado.  As previously briefly discussed (Chapter 1.8), rather than attributing 
hypoxia-induced proliferation of PAFs to p38 MAP kinase phosphrylation, they find 
hypoxia-induced proliferation to be dependant on activation of both a 
phosphatidylinositol-3-kinase - AKT – mTOR signalling pathway (which we have 
not assessed in our cell model) and ERK1/2 (which we also find to be 
phosphorylated in our cells, but not required for proliferation).  These results are not 
completely inconsistent: the Stenmark group also show hypoxia-induced biphasic 
p38 MAP kinase phosphorylation in hypoxic PAFs (but find it not to be required for 
hypoxic proliferation).  Also, Rac1 – which we are implicating upstream of p38 
MAPK in our hypothetical cell signalling model in PAFs – has been shown in other 
cell types to associate with AKT248: we may be looking at different aspects of the 
same pathway, or parallel signalling pathways.  That both our group and the 
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Stenmark group find complete / selective inhibition of hypoxic PAF proliferation 
with inhibition of our competing pathways is, however, confounding.  The most 
likely explanation for these discrepancies lies in the nature of the cell types studied.  
We experiment on PAFs from of adult rats, cows and (in previous work but not in 
this thesis) humans whilst Stenmark’s group report on PAFs from neonatal or fetal 
calves67.  The neonatal pulmonary circulation in all species studied is known to 
respond more briskly to hypoxia than the mature circulation, with a tendency to 
increased constriction and more rapid remodelling.  The differences in hypoxic PAF 
cell signalling shown by our group and Stenmark’s group may reflect maturation and 
may explain the different responses of the pulmonary circulation, at different ages. 
 
7.3 Acute and Chronic Hypoxic Cell Models: Strengths and  
 Weaknesses 
The results obtained (effects of statins on PAFs and hypoxic cell signalling pathways 
illustrated) are only directly related to the cells on which they have been obtained.  
Problems with the definition of hypoxia, animal cell origin and different 
subpopulations of resident cells within different territories of the pulmonary artery 
have been commented on previously.   
 
5% hypoxia, used in the acute hypoxia experiments has been previously shown to 
achieve a supernatant PO2 of 35mmHg, which approximates typical alveolar PO2 in 
chronic hypoxic disorders.  Also, previous work has reassured that changes in pH in 
acute hypoxia for this time period are insignificant233.  Perhaps most important is the 
observation that maintenance of PAFs for 24 hours in 5% normobaric hypoxia leads 
to proliferative and cell signalling responses which mimic exactly those seen in PAFs 
from chronic hypoxic animals.  It is considered a strength of the experimental 
program presented in this thesis that experiments were repeated in the acute and 
chronic hypoxic models, with consistent results.  The consistent results obtained with 
statins, cholesterol intermediates and inhibitors in these models also provides further 
reassurance about the relevance of our acute hypoxic PAF cell model.  An advantage 
of the acute hypoxic model are that it offers the potential to rapidly screen dose 
ranges of a large number of compounds, allowing for future experiments on less 
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readily available cells (eg chronic hypoxic or human) to be rationalised, as was 
achieved in this thesis. 
 
Whether 24 hours of 5% hypoxia is relevant to pulmonary artery smooth muscle cells 
is, as previously discussed, less certain.  Where PASMCs have been previously 
found to proliferate to acute hypoxia, it has been at oxygen fractions of 1-5%.  Our 
results therefore cannot be taken as conclusive that isolated PASMCs do not 
proliferate to hypoxia, however, our observations are consistent with the majority of 
the literature.  Whilst it seems likely that whilst there may be a population of 
PASMCs which proliferate in direct response to hypoxia in the native pulmonary 
artery, proliferation of PASMCs as a consequence of hypoxia-induced mitogen 
release by other cells is likely important in pulmonary vascular remodelling. 
 
We derived both our PAFs and PASMCs from proximal vessels and this may be a 
weakness when considering the application of our results to in vivo pulmonary 
vascular remodelling, where the dominant changes are in the distal vessels.  We also 
did not distinguish between different subpopulations of fibroblasts or SMCs:  PAFs 
and PASMCs with differing hypoxia / proliferative responses have been previously 
demonstrated to reside in both proximal and distal vessels61, 176.  Again, similar 
results in this thesis with the acute and chronic hypoxic PAFs offer some reassurance 
that the population of PAFs obtained for the acute hypoxic studies is of relevance.  It 
is, however, possible that subpopulations of PAFs and PASMCs, whose hypoxic 
proliferative and cell signalling responses differ from those that were cultured in this 
project are important in vivo but this is not being appreciated in our experiments.   
 
An important limitiation of this project is that the majority of work was carried out 
on rat cells.  The applicability of any of these findings to human disease is uncertain.  
As previously outlined it has, however, previously been shown that rat and human 
PAFs have a number of shared responses to acute hypoxia (increased proliferation 
and p38 MAP kinase phosphorylation).  Some additional reassurance can be taken 
from the fact that results with acutely hypoxic bovine PAFs duplicated those 
obtained with statins and other mediators on the rat cells: bovine PAF proliferative 
and MAPK responses have previously shown the greatest homology to human cell 
responses.  There is difficulty in obtaining and interpreting results on PAFs derived 
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from human tissue.  PAFs from “normal” patients are typically acquired from 
elective lung resections, usually carried out for lung cancer surgery.  These patients 
will typically have been exposed to tobacco smoke – which has direct effects on the 
pulmonary circulation - and it is therefore difficult to regard these PAFs as “normal”.  
Pulmonary arteries are occasionally available from unused lungs acquired from 
organ donors but there will usually have been a significant pre-morbid injury and a 
period of invasive ventilation and, again, it is difficult to regard these cells as truly 
“normal”.   PAFs from hypertensive pulmonary arteries are typically sourced from 
explanted lungs at the time of transplant surgery.   Again there are problems with 
these: there is considerable heterogeneity in the underlying primary lung disease, the 
cells will have been exposed to various pulmonary vascular therapeutics prior to 
explant and the pulmonary arteries are at the end stage of the disease (rather than at 
the early stage, when we would be hoping to treat the condition).  The relevance of 
any results obtained solely on PAFs from either normal patients or pulmonary 
hypertensive patients is therefore considered to be as questionable as those obtained 
on animal cells.  Taking all of this together, it is considered that human and animal 
cell models are complementary.  The results from this project provide a necessary 
foundation for performing a limited profile of complementary statin experiments on 
human PAFs and this is proposed as future work arising from this thesis.   
 
7.4 Relevance of Observed Effects of Statins on PAF Behaviour to  
 Hypoxia-Induced Pulmonary Vascular Remodelling 
The initial premise to this research project was the observed reversal of experimental 
PH with statin drugs.  Determining the mechanism of action of the statins in these 
animal models is difficult: differentiating cellular and molecular events which are a 
direct consequence of statin therapy from those which are simply a secondary 
consequence of reduced remodelling is not possible.  Observed effects of statins in 
these experimental models include a reduction in vessel wall thickness, reduction in 
medial hypertrophy, smooth muscle cell apoptosis, reduced Rho kinase activity and 
upregulation of eNOS and BMPR1a transcription (see chapter 1.10.6).  All of these 
observations, however, were based on experiments on the animals at the end of a 
period of statin treatment.  Early effects of statins were not studied and, notably, any 
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effects of either experimental conditions (chronic hypoxia, monocrotaline etc) or 
statin on the vessel adventitia or the adventitial fibroblasts have not been reported.   
 
Given that the earliest changes – possibly the initiating changes - in chronic hypoxic 
pulmonary vascular remodelling occur in the adventitia, it may be that the efficacy of 
statin drugs at preventing CH rat PH are a consequence of the inhibition of hypoxia-
induced PAF proliferation and mitogen release that we have demonstrated here.  
Also, the demonstration that low doses of statins can completely reverse the 
proliferative phenotypic switch in PAFs may be a mechanism responsible for the 
reversal of CH rat PH achieved by statins: restoration of normal fibroblast behaviour 
may allow normal pulmonary vascular homeostasis to re-establish.  Alternatively, 
there may be additional cellular effects of statins in the remodelled pulmonary 
circulation (eg pro-apoptotic, anti-inflammatory) which contribute.  We have not yet 
studied the effects of statins on other fibroblast behaviours influenced by hypoxia (eg 
migration, transdifferentation, collagen, elastin and matrix synthesis): these may be 
under control of the same hypoxic signalling pathway as proliferation and mitogen 
release, and they may be additionally important cellular targets for any potential 
pulmonary vascular remodelling therapy.   
 
Based on previous observations about the role of the resident pulmonary adventitial 
fibroblasts to hypoxia-induced pulmonary vascular remodelling and all of the data 
presented in this thesis, Figure 7.1 illustrates a hypothetical model of this aspect of 
pulmonary vascular remodelling and indicates the likely effects of fluvastatin and the 
other drugs used in this project on this. 
 
The relevance of any experiments conducted on isolated cell culture to the in vivo 
situation (where cells are in contact with one another, with the extracellar matrix, the 
extracellular fluid, vascular mediators etc) is uncertain.  For all of the reasons 
previously noted experiments to elucidate basic mechanisms or compare different 
therapies in whole animal experiments are difficult and cell culture models offer the 
only available compromise.  The work described here with PAF-PASMC co-culture 
is an early aspect of a proposed future major research direction, whereby we hope to 
better model the in vivo pulmonary artery with cell culture techniques.  Statins look 
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likely to remain a useful experimental tool to interrogate the different cell-cell and 
cell-matrix interactions that we hope to explore. 
 
7.5 Potential Clinical Applications 
A major obstacle in the treatment of pulmonary hypertension in the past has been an 
inability to selectively affect the pulmonary circulation: this was a particular problem 
with vasodilator therapies.  The results obtained in this thesis once again underscore 
the fundamental differences between the pulmonary and systemic circulations and 
suggest that—with appropriate dosing— statins may have a stimulus (hypoxia) and 
circulation (pulmonary) selective anti-fibroproliferative effect. 
 
There are substantial limitations in applying any of the results obtained here to 
pulmonary hypertension in humans, or its treatment.  These were experiments on 
animal cells, in artificial conditions, with drugs dosed directly onto cells.  Failure of 
results obtained at the bench to translate to benefits at the bedside is, in general, more 
common than success.  With all of these provisos, however, some speculation does 
seem appropriate, particularly as clinical trials of statins for pulmonary hypertension 
have already been commenced, with only the limited animal experiments previously 
commented on (chapter 1.10.6) as their foundation. 
 
The observations that low doses of statins can inhibit PAF proliferation and mitogen 
release in acute hypoxia, and reverse the proliferative phenotypic switch in chronic 
hypoxic PAFs, suggest that statins may have broad spectrum inhibitory effects on a 
cell type which is likely to be an important contributor to the initiation, maintenance 
and progression of chronic hypoxic pulmonary vascular remodelling.  The 
proliferative PAF phenotypic switch, which persists despite cellular re-oxygenation, 
may be a factor in the failure of chronic hypoxic pulmonary hypertension to 
consistently improve with oxygen therapy and the experimental results presented 
here may indicate a potential for statin therapy to augment the beneficial effects of 
oxygen therapy in patients with chronic hypoxic lung disease and related pulmonary 
hypertension. 
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In the cell models, we found positive effects on hypoxic PAFs identical to those 
achieved with fluvastatin, with a geranylgeranyl transferase inhbitor, a Rac1 inhibitor 
and a p38 MAP kinase inhibitor.  Geranylgeranyl transferase inhibitors and the Rac1 
inhibitor are recently described compounds and use of these in animals or humans 
has not yet been described.   p38 MAP kinase inhibitors are in a more advanced state 
of drug development but there are concerns about toxicity and progression of these 
beyond phase II clinical trials appears to have stalled.  Whilst alternative strategies to 
achieve p38 inhibition may come to fruition (eg siRNA, inhalation of drug rather 
than systemic treatment), the ready availability, low cost and established safety 
profile of statins makes them more attractive than these inhibitors for any proposed 
clinical study.  Also, statins have theoretical beneficial effects in the pulmonary 
circulation (eg anti-inflammatory, enhance eNOS) which exceed those of these other 
inhibitors.   
 
With the exception of inhibiton of hypoxic PAF-conditioned media induced PASMC 
proliferation by bosentan, the identified beneficial effects of statins on hypoxic PAFs 
were not duplicated by a drug from each class established in pulmonary hypertension 
therapy.  This is an important observation as the majority of patients with severe 
pulmonary hypertension (in resourced parts of the world) are currently treated with 
one or more of these drugs.  The beneficial effects of statins on PAF behaviours may 
therefore complement the mechanisms of action of these established drugs, rather 
than simply duplicate it.   
 
When we consider the current therapeutic scenario for PAH in general, the PH 
community is moving towards combination therapy, and currently treating all forms 
of PH similarly (on a relatively empirical basis).  Given patient heterogeneity and the 
difficulties of comparative clinical trials, establishing the most appropriate drug 
treatment(s) for the different forms of severe PH and establishing the most rational 
combinations (with complementary rather than duplicate or contradictory 
mechanisms) requires basic science work.  This approach has been successfully 
employed in oncology, where laboratory research has established the most rational 
combinations from the large complement of chemotherapeutics and biological agents 
now available, for different tumour types, with notable (though qualified) clinical 
success.  It would seem sensible to duplicate these translational strategies in 
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pulmonary hypertension research, studying the effects of established and 
experimental therapies on different cell types, in experiments aiming to model the 
different forms of pulmonary hypertension.  As combination and comparison 
experiments in animal models are impossible (the effects of a single drug are usually 
too marked to allow any differentiation) we consider the experimental approach 
utilised here – comparing effects of a new drug with established drugs in 
complementary cellular modles – one which should be adopted for future 
experimental programs studying disease pathophysiology and potential therapeutic 
strategies in pulmonary hypertension. 
 
Considering statin therapy for PH more specifically, we compared different 
lipophilic statins, in the acute hypoxic rat PAF model, and found them to be 
equipotent.  Comparisons of different statins in the experimental PH animal models 
are incomplete, but no clear cut differences in efficacy have been shown.  There are 
notable differences in the pharmacokinetics of these statins in humans (see Table 
1.2).  Simvastatin and atorvastatin undergo substantial hepatic first pass metabolism 
and, whilst there may be circulating active metabolites of these drugs, only very 
small peak circulating concentrations of these drugs are achieved in humans.  In 
contrast, fluvastatin undergoes relatively little first pass metabolism and achieves 
much higher concentrations in the post-hepatic (ie systemic and pulmonary) 
circulations) after standard oral dosing.  It is notable that standard oral dosage of 
fluvastatin achieves peak circulating concentrations of ~1µM, a dose that had a 
positive and selective effect in our experiments.  Our study is therefore the first to 
demonstrate that statins - specifically fluvastatin - may have an inhibitory effect on 
pulmonary vascular cell proliferation at cell culture doses that are within the 
concentration range achievable in the human pulmonary circulation, with oral statin 
dosing.   
 
The clinical trials of statins for pulmonary hypertension currently in progress have 
selected simvastatin in their protocols.  Our results and observations suggest that this 
drug may be problematic: it may not achieve adequate concentrations in the human 
pulmonary circulation to achieve the beneficial effects seen in the animal models.  
Also, simvastatin metabolism is enchanced by bosentan (which a substantial number 
of enrolled patients will be taking) which will potentially confuse interpretation of 
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results.  In relation to this, perhaps the most important message which can be derived 
from this thesis is that if these initial clinical trials of simvastatin for PAH are 
negative, we should not dismiss statins as potential agents for selected forms of 
severe PH.  Hypoxia-associated PH may be particularly susceptible to statin therapy 
and fluvastatin may be a more appropriate choice of statin.   It is concluded, 
however, that substantial additional preclinical work – determining the differential 
actions of statins and other drugs in complementary cell and animal PH models - is 
required if we are to avoid potentially confounding and wasteful negative clinical 
trials. 
 
7.6 Future Work 
The work in this thesis has extended our understanding of hypoxic signalling in 
pulmonary artery fibroblasts and identified potentially therapeutically relevant 
effects of fluvastatin on this.  Some of the gaps in our experimental program have 
been acknowledged in the chapter discussions.  Appropriate immediate future 
directions would include clarifying Rac1 prenylation / turnover in acute hypoxia, 
clarifying Rac1 involvement in proliferative hypoxic signalling (eg via siRNA 
studies) and extending the experimental protocol used in Chapters 4 and 5 to human 
cells.   
 
The pattern of experiments conducted here – comparing effects of a potential new 
therapy with established therapies – is considered a relevant template for future work 
on cellular and molecular pulmonary arterial pathophysiology and drug exploration.  
As indicated, the success of this approach in the oncology field suggests this 
template should be more widely adopted and extended.  Specifically, utilisation of 
other proposed PH therapeutics (eg PDGF inhibitors, vasoactive intestinal 
polypeptide) in our hypoxic cell models may facilitate new insights into cellular 
mechanisms, therapeutic potential and allow deduction of rational combination 
therapies for clinical study. 
 
The single cell type cell culture model will always be problematic in translational 
medicine but novel approaches to better model the normal and diseased pulmonary 
vessels in the cell culture lab are proposed.  The fibroblast-smooth muscle cell co-
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culture and conditioned media experiments that we conducted would seem to be a 
small step towards better modelling the complete pulmonary artery in vitro.  
Improving on this, initially by including other cell types (eg endothelial cells and 
distal rather than proximal vascular cells) seems relevant.   
 
Lastly, it is clear that pulmonary vascular remodelling and pulmonary hypertension 
is not a process involving simply a segment of the pulmonary artery: circulating 
cells, pulmonary veins and the right heart are critical in the overall clinical 
manifestation.  Whilst it remains likely (though still contentious) that the primary 
problem is an arteriopathy, the contribution of these other cell and tissue types to the 
disease state, and the effects of experimental stimuli (eg hypoxia) and investigational 
therapies (eg statins) on these need to be characterised. 
 
In conclusion, the data and interpretations presented in this thesis are considered a 
small, but significant aspect of an increasingly active worldwide research program 
into this important group of diseases.  In addition to the ongoing research in the 
SPVU laboratory which this thesis has prompted it is hoped that the conclusions 
made will prove to be interesting and stimulating for the pulmonary vascular 
community in general. 
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